10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[ X ]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

OR

[  ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to __________.

COMMISSION FILE NUMBER: 001-37349

NOBILIS HEALTH CORP.

(Exact name of registrant as specified in its charter)

British Columbia (State or other jurisdiction of incorporation or organization) 98-1188172 (I.R.S. Employer Identification No.)

11700 Katy Freeway, Suite 300, Houston, Texas (Address of principal executive offices) 77079 (Zip Code)

(713)355-8614

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES  [ X ]  NO  [  ]

(Note: As a voluntary filer not subject to the filing requirements of Sections 13 or 15(d) of the Exchange Act, the registrant has filed all reports pursuant to Section 13 or 15(d) of the Exchange Act during the preceding 12 months as if it were subject to such filing requirements.)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES  [ X ]  NO  [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  [  ]	Accelerated filer  [ X ]
Non-accelerated filer  [  ]	Smaller reporting company  [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES  [  ]  NO  [ X ]

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

76,877,014 common shares as of October 28, 2016.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION	3
Item 1. Financial Statements	3
Notes to Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3. Quantitative and Qualitative Disclosures about Market Risk	46
Item 4. Controls and Procedures	47
PART II. OTHER INFORMATION	48
Item 1. Legal Proceedings	48
Item 1A. Risk Factors	48
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	48
Item 3. Defaults Upon Senior Securities	48
Item 4. Mine Safety Disclosures	48
Item 5. Other Information	49
Item 6. Exhibits	50
Signatures	51

In this Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 (“Quarterly Report”), the terms "Nobilis", "we", "us", "our", "ours", or "the Company" refers to Nobilis Health Corp. and all of its subsidiaries.

2

Part I – Financial Information

Part I – Financial Statements

Nobilis Health Corp.

Consolidated Balance Sheets

September 30, 2016 and December 31, 2015

(in thousands, except share amounts)

(unaudited)

	September 30, 2016			December 31, 2015
Assets
Current Assets:
Cash	$	19,614		$	15,666
Trade accounts receivable, net of allowance of $2,144 at September 30, 2016 and $5,165 at December 31, 2015	86,170			92,569
Medical supplies	4,321			4,493
Prepaid expenses and other current assets	3,727			2,789
Total current assets	113,832			115,517
Property and equipment, net	34,638			35,303
Intangible assets, net	18,268			19,619
Goodwill	44,833			44,833
Deferred tax asset	27,470			25,035
Other long-term assets	1,942			1,720
Total Assets	$	240,983		$	242,027
Liabilities and Shareholders' Equity
Current Liabilities:
Trade accounts payable	$	19,702		$	23,381
Accrued expenses	20,661			16,648
Current portion of capital leases	3,484			5,193
Current portion of long-term debt	1,006			1,243
Current portion of warrant and stock option derivative liabilities	380			332
Other current liabilities	6,802			5,025
Total current liabilities	52,035			51,822
Lines of credit	8,135			3,000
Long-term capital leases, net of current portion	12,711			13,654
Long-term debt, net of current portion	22,826			21,469
Warrant and stock option derivative liabilities, net of current portion	1,537			2,619
Other long-term liabilities	3,523			3,386
Total liabilities	100,767			95,950
Commitments and Contingencies
Contingently redeemable noncontrolling interest	10,567			12,225
Shareholders' Equity:
Common shares, no par value, unlimited shares authorized, 76,855,014 and 73,675,979 shares issued and outstanding, respectively	—			—
Additional paid in capital	218,724			211,827
Accumulated deficit	(88,410		)	(85,491		)
Total shareholders’ equity attributable to Nobilis Health Corp.	130,314			126,336
Noncontrolling interests	(665		)	7,516
Total shareholders' equity	129,649			133,852
Total Liabilities and Shareholders' Equity	$	240,983		$	242,027

The accompanying notes are an integral part of the interim unaudited consolidated financial statements.

3

Nobilis Health Corp.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Revenues:
Patient and net professional fees	$	65,666		$	46,237		$	167,199		$	126,661
Contracted marketing revenues	2,604			4,410			10,754			8,059
Factoring revenues	2,413			1,836			5,874			4,481
Total revenues	70,683			52,483			183,827			139,201
Operating expenses:
Salaries and benefits	13,209			10,255			38,377			26,927
Drugs and supplies	15,473			8,405			39,670			22,265
General and administrative	33,195			21,025			85,678			54,625
Bad debt expense	—			929			—			1,129
Depreciation and amortization	1,952			1,522			6,462			3,114
Facility operating expenses	63,829			42,136			170,187			108,060
Corporate expenses:
Salaries and benefits	1,765			1,540			5,077			3,532
General and administrative	4,576			5,192			14,984			17,707
Legal expenses	1,535			521			4,110			1,733
Depreciation	79			43			209			99
Total corporate costs	7,955			7,296			24,380			23,071
(Loss) income from operations	(1,101		)	3,051			(10,740		)	8,070
Other expense (income) :
Change in fair value of warrant and stock option derivative liabilities	133			(6,381		)	(1,566		)	(4,677		)
Interest expense	744			322			2,115			1,106
Bargain purchase gain	—			(4,358		)	—			(4,358		)
Other income, net	(198		)	(106		)	(3,011		)	(1,518		)
Total other expense (income)	679			(10,523		)	(2,462		)	(9,447		)
(Loss) income before income taxes and noncontrolling interests	(1,780		)	13,574			(8,278		)	17,517
Income tax expense (benefit)	483			256			(1,766		)	862
Net (loss) income	(2,263		)	13,318			(6,512		)	16,655
Net income (loss) attributable to noncontrolling interests	496			2,375			(3,594		)	10,617
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943		$	(2,918	)	$	6,038
Net (loss) income per basic common share	$	(0.04	)	$	0.15		$	(0.04	)	$	0.09
Net (loss) income per fully diluted common share	$	(0.04	)	$	0.14		$	(0.04	)	$	0.08
Weighted average shares outstanding (basic)	76,774,967			70,935,587			76,114,538			65,310,610
Weighted average shares outstanding (fully diluted)	76,774,967			77,656,264			76,114,538			75,067,623

The accompanying notes are an integral part of the interim unaudited consolidated financial statements.

4

Nobilis Health Corp.

Consolidated Statements of Cash Flows

(in thousands)

	Nine Months Ended September 30,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$	(6,512	)	$	16,655
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	6,671			3,213
Provision for bad debts	—			1,129
Share-based compensation	5,226			12,469
Change in fair value of warrant and stock option derivative liabilities	(1,566		)	(4,677		)
Recoupment of indemnified expenses	—			(1,700		)
Deferred income taxes	(2,435		)	—
Gain on bargain purchase of a business	—			(4,358		)
Gain on sale of property and equipment	(265		)	—
Earnings from equity method investment	(1,000		)	—
Amortization of deferred financing fees	112			66
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed:
Trade accounts receivable	6,399			(11,962		)
Medical supplies	172			(612		)
Prepaid expenses and other current assets	(938		)	(2,095		)
Other long-term assets	152			(37		)
Trade accounts payable and accrued liabilities	334			(4,372		)
Other current liabilities	1,777			(900		)
Other long-term liabilities	137			19
Distributions from equity method investments	1,079			—
Net cash provided by operating activities	9,343			2,838
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,388		)	(2,533		)
Investment in associate	—			(206		)
Purchase of equity method investment	(609		)	—
Note receivable, net	150			(197		)
Acquisition of Victory	—			(1,436		)
Acquisition of Peak	—			(849		)
Acquisition of Peak, net of cash acquired	—			(1,299		)
Deconsolidation of imaging centers and urgent care clinic	—			(166		)
Net cash used for investing activities	(4,847		)	(6,686		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Distributions to noncontrolling interests	(6,245		)	(9,015		)
Proceeds from exercise of stock options	2,074			521
Proceeds from exercise of stock warrants	130			4,343
Proceeds from private placement	—			28,395
Payments on capital lease obligations	(2,652		)	(719		)
Proceeds (payments) from line of credit	5,135			(5,420		)
Proceeds from debt	6,440			20,000
Payments on debt	(5,026		)	(20,124		)
Deferred financing fees	(404		)	(662		)
Net cash (used for) provided by financing activities	(548		)	17,319
NET INCREASE IN CASH	3,948			13,525
CASH — Beginning of period	15,666			7,568
CASH — End of period	$	19,614		$	21,093

The accompanying notes are an integral part of the interim unaudited consolidated financial statements.

5

Nobilis Health Corp.

Notes to Consolidated Financial Statements

NOTE 1 – COMPANY DESCRIPTION

Nobilis Health Corp. (“Nobilis” or the “Company”) was incorporated on March 16, 2007 under the name "Northstar Healthcare Inc." pursuant to the provisions of the British Columbia Business Corporations Act. On December 5, 2014, Northstar Healthcare Inc. changed its name to Nobilis Health Corp. The Company owns and manages health care facilities in the States of Texas and Arizona, consisting primarily of ambulatory surgery centers and acute-care surgical hospitals. In 2014, through its acquisition of Athas Health, LLC (“Athas”), the Company expanded its service offering within the health care industry to include providing contracted marketing services and accounts receivable factoring.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying interim consolidated financial statements have not been audited by the Company’s independent registered public accounting firm, except that the Consolidated Balance Sheet at December 31, 2015, is derived from previously audited consolidated financial statements. In the opinion of management, all material adjustments, consisting of normal recurring adjustments, necessary for fair presentation have been included. These interim consolidated financial statements include all accounts of the Company. All significant intercompany transactions and accounts have been eliminated upon consolidation.

Certain reclassifications have been made to prior period amounts to conform to current period financial statement classifications. The reclassifications included in these comparative consolidated financial statements are (i) a change in presentation of other comprehensive income and (ii) a reclassification from cost of goods sold to operating expenses. The reclassifications were deemed to be immaterial to the consolidated financial statements both individually and in the aggregate.

These consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. Therefore, these interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Annual Report”) filed with the SEC on March 15, 2016. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

There have been no material changes to the Company’s critical accounting policies or estimates from those disclosed in the 2015 Annual Report.

Recent Accounting Pronouncements

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). This update changes how entities account for and measure the fair value of certain equity investments and updates the presentation and disclosure of certain financial assets and liabilities. This new ASU is effective for annual and interim periods beginning on or after December 15, 2017, and for interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact that ASU 2016-01 will have on the Company’s consolidated financial position and disclosures.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net) (“ASU 2016-08”). The amendments address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The ASU clarifies that an entity should evaluate whether it is the principal or the agent for each specified good or service promised in a contract with a customer. The amendments affect the guidance in ASU 2014-09 which is not yet effective. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company is currently evaluating the new guidance to determine the method of adoption that it will use and the impact it will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU-2016-09"). ASU 2016-09 impacts several aspects of the accounting for share-based

6

payment transactions, including classification of certain items on the Consolidated Statement of Cash Flows and accounting for income taxes. Specifically, the ASU requires that excess tax benefits and tax deficiencies (the difference between the deduction for tax purposes and the compensation cost recognized for financial reporting purposes) be recognized as income tax expense or benefit in the Consolidated Statement of Operations, introducing a new element of volatility to the provision for income taxes. ASU No. 2016-09 is effective on January 1, 2017, with early adoption permitted. The transition method varies for each of the areas in the ASU. The Company is currently evaluating the impact of adopting this new accounting standard on its results of operations and financial position.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies the guidance in ASU 2014-09 regarding assessing whether promises to transfer goods or services are distinct, and whether an entity's promise to grant a license provides a customer with a right to use or right to access the entity's intellectual property. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). This Update provides for amendments to ASU 2014-09, amending the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. Specifically, ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides guidance on how certain cash receipts and cash payments are to be presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.

7

NOTE 3 – SUPPLEMENTAL CASH FLOWS

The supplemental cash flows information for the nine months ended September 30, 2016 and 2015 are comprised of the following (in thousands):

	Nine Months Ended September 30,
	2016		2015
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	2,052	$	1,129
Cash paid for taxes	$	2,279	$	633
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash acquisition of property and equipment	$	—	$	15,345
Non-cash acquisition of goodwill and intangibles	$	—	$	13,532
Non-cash deconsolidation of property and equipment	$	—	$	2,828
Non-cash deconsolidation of goodwill	$	—	$	701
Athas settlement in lieu of contingent shares	$	—	$	5,685

NOTE 4 – ACQUISITIONS

Scottsdale Liberty Hospital (SLH)

In November 2015, the Company acquired a 60% interest in Freedom Pain Hospital (n/k/a SLH) located in Scottsdale, Arizona. The Company acquired management control of the entity which was formed to own and operate the successor hospital. The transaction was treated as a business combination.

8

The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition (in thousands):

	November 1, 2015
Net assets acquired:
Trade accounts receivable	$	82
Prepaid expenses and other current assets	36
Inventory	69
Property and equipment	13,266
Other long-term assets	113
Goodwill	6,932
Tradename	160
Hospital license	12
Net assets acquired	$	20,670
Net liabilities assumed:
Trade accounts payable	$	2,668
Accrued liabilities	419
Current portion of capital leases	658
Long-term portion of capital leases	12,213
Total liabilities assumed	$	15,958
Consideration:
Cash, net of cash acquired	$	3,180
Noncontrolling Interest	1,532
Total consideration	$	4,712

Unaudited Supplemental Pro Forma Information

The following unaudited supplemental pro forma financial information includes the results of operations for SLH, and is presented as if the acquired company had been consolidated as of the beginning of the year immediately preceding the year in which the company was acquired. The unaudited supplemental pro forma financial information has been provided for illustrative purposes only and does not purport to be indicative of the actual results that would have been achieved by combining the companies for the periods presented, or of the results that may be achieved by the combined companies in the future. Further, results may vary significantly from the results reflected in the following unaudited supplemental pro forma financial information because of future events and transactions, as well as other factors.

There were no acquisitions during the period ended September 30, 2016, thus the consolidated financial statements for the period include full financial results of all consolidated subsidiaries. The following table shows our pro forma results for the nine months ended September 30, 2015(in thousands, except per share amounts):

	September 30, 2015
Revenue	$	139,774
Income from operations	$	8,225
Net income attributable to noncontrolling interests	$	10,360
Net income attributable to common stockholders	$	6,282
Net income per basic common share	$	0.10

9

NOTE 5 – TRADE ACCOUNTS RECEIVABLE, NET

A detail of trade accounts receivable, net as of September 30, 2016 and December 31, 2015 is as follows (in thousands):

	September 30, 2016			December 31, 2015
Trade accounts receivable	$	84,573		$	95,114
Allowance for doubtful accounts	(2,144		)	(5,165		)
Receivables transferred	(357		)	(298		)
Receivables purchased	4,098			2,918
Trade accounts receivable, net	$	86,170		$	92,569

Bad debt expense was zero for the three and nine months ended September 30, 2016 and was $0.9 million and $1.1 million for the three and nine months ended September 30, 2015 respectively.

From time to time, we transfer to third parties certain of our accounts receivable balances on a non-recourse basis in return for advancement on payment to achieve a faster cash collection. As of September 30, 2016 and December 31, 2015, there remained a balance of $0.4 million and $0.3 million, respectively, in transferred receivables pursuant to the terms of the original agreement. For the three months ended September 30, 2016 and 2015, the Company received advanced payments of $0.1 million and $0.3 million, respectively. During the same time period, the Company transferred $0.8 million and $1.4 million of receivables, net of advancement of payment. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee. For the nine months ended September 30, 2016 and 2015, the Company received advanced payments of $0.6 million and $1.4 million, respectively. During the same time period, the Company transferred $4.9 million and $5.2 million of receivables, respectively. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee.

Athas, Peak Neuromonitoring (“Peak”), and Nobilis Surgical Assist (“First Assist”) purchase receivables from physicians, at a discount, on a non-recourse basis. The discount and purchase price vary by specialty and are recorded at the date of purchase, which generally occurs 30 to 45 days after the accounts are billed. These purchased receivables are billed and collected by Athas, Peak, and First Assist and they retain 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables. Gross revenue from purchased receivables was $4.6 million and $3.2 million for the three months ended September 30, 2016 and 2015, respectively. Gross revenue from purchased receivables was $11.2 million and $8.3 million for the nine months ended September 30, 2016 and 2015, respectively. Revenue, net of the discounted purchase price, was $2.4 million and $1.8 million for the three months ended September 30, 2016 and 2015, respectively. Revenue, net of the discounted purchase price, was $5.9 million and $4.5 million for the nine months ended September 30, 2016 and 2015, respectively. Accounts receivable for purchased receivables was $4.1 million and $2.9 million for the nine months ended September 30, 2016 and year-ended December 31, 2015, respectively. Revenue from receivables purchased is recorded in the factoring revenue line item within the Consolidated Statements of Operations.

NOTE 6 – INVESTMENTS IN ASSOCIATES

During the first quarter of 2015, The Company completed the deconsolidation of two imaging centers and one urgent care clinic in Houston, which consisted of the following entities: Spring Northwest Management, LLC, Spring Northwest Operating, LLC, Willowbrook Imaging, LLC, GRIP Medical Diagnostics, LLC and KIRPA Holdings, LLC. The Company resigned as the manager of these facilities resulting in loss of control and its rights to exercise significant influence. The Company retained investments in these facilities that are accounted for as cost method investments beginning January 1, 2015. The carrying value as of September 30, 2016 and December 31, 2015 was $0.7 million. The investments are classified as other long-term assets in the Consolidated Balance Sheets.

In March 2016, the Company acquired a 58% interest in Athelite Holdings LLC ("Athelite"), a holding company with a 70% interest in Dallas Metro Surgery Center LLC ("Dallas Metro"), a company formed to provide management services to a Hospital Outpatient Department (“HOPD”). In April 2016, Athelite interest in Dallas Metro was reduced to 62%. The Athelite investment is accounted for as an equity method investment as the Company did not obtain the necessary level of control for the investment to be accounted for as a business combination. This is due to the fact that the Company does not have the ability to directly appoint a majority of the board members of Dallas Metro or independently make strategic operational decisions. The carrying value as of September 30, 2016 was $0.5 million. The investment is classified as other long-term assets in the Consolidated Balance Sheets.

10

NOTE 7 – FINANCIAL INSTRUMENTS AND CONCENTRATION

In common with all other businesses, the Company is exposed to risks that arise from its use of financial instruments. This note describes the Company’s objectives, policies and processes for managing those risks and the methods used to measure them. Further quantitative information in respect to these risks is presented throughout these consolidated financial statements.

Principal financial instruments

The principal financial instruments used by the Company, from which financial instrument risk arises, are as follows:

• Accounts receivable and other receivables

• Investments in associates

• Accounts payable, accrued liabilities and other current liabilities

• Other liabilities and notes payable

• Capital leases

• Lines of credit

• Debt

• Warrants

• Non-employee stock options

The carrying amounts of the Company’s cash, accounts receivable and other receivables, accounts payable, accrued liabilities, other current liabilities and other liabilities as reflected in the consolidated financial statements approximate fair value due to their short term maturity. The estimated fair value of the Company's other long-term debt instruments approximate their carrying amounts as the interest rates approximate the Company's current borrowing rate for similar debt instruments of comparable maturity, or have variable interest rates.

Financial instruments - risk management

The Company’s financial instrument risks include, but are not limited to the following:

• Credit risk

• Fair value risk

• Foreign exchange risk

• Other market price risk

• Liquidity risk

• Interest rate risk

Credit risk

Credit risk is the risk of financial loss to the Company if a patient, non-partner surgeon or insurance company fails to meet its contractual obligations. The Company, in the normal course of business, is exposed mainly to credit risk on its accounts receivable from insurance companies, other third-party payors, and physicians. Accounts receivables are net of applicable bad debt reserves, which are established based on specific credit risk associated with insurance companies, payors and other relevant information.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due and arises from the Company’s management of working capital. The Company’s objective to managing liquidity risk is to ensure that it will have sufficient cash to allow it to meet its liabilities when they become due. To achieve this objective, it seeks to maintain cash balances (or agreed credit facilities) to meet expected requirements. The liquidity risk of the Company and its subsidiaries is managed centrally by the Company’s finance function. The Company believes that there are currently no concerns of its ability to meet its liabilities as they become due for the foreseeable future.

11

The following tables set forth certain information with respect to the Company’s payor concentration. Patient and net professional fee revenues by payor are summarized below for the applicable periods:

MEDICAL SEGMENT

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.3	%	94.4	%	96.2	%	94.7	%
Workers compensation	3.4	%	5.1	%	3.4	%	4.8	%
Medicare	0.3	%	0.5	%	0.4	%	0.5	%
Total	100	%	100	%	100	%	100	%

MARKETING SEGMENT

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	100.0	%	100.0	%	100.0	%	100.0	%
Workers compensation	0.0	%	0.0	%	0.0	%	0.0	%
Medicare	0.0	%	0.0	%	0.0	%	0.0	%
Total	100	%	100	%	100	%	100	%

CONSOLIDATED SEGMENTS

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.8	%	95.1	%	96.7	%	95.2	%
Workers compensation	3.0	%	4.5	%	3.0	%	4.3	%
Medicare	0.2	%	0.4	%	0.3	%	0.5	%
Total	100	%	100	%	100	%	100	%

Three facilities represent approximately 75.1% and 83.0% of the Company’s contracted marketing revenue for the three and nine months ended September 30, 2016, and three facilities represent approximately 83.6% of the Company’s contracted marketing accounts receivable as of September 30, 2016.

Market risk

Market risk is the risk that the fair value of future cash flows of financial instruments will fluctuate due to changes in interest rates and/or foreign currency exchange rates.

Interest rate risk

The Company entered into a revolving line of credit that, from time to time, may increase interest rates based on market index.

Foreign exchange risk

Foreign exchange risk arises because the Company has certain expenses that are incurred in Canadian dollars.

12

The Company is also exposed to currency risk on purchases made from vendors based in Canada. The Company has Canadian denominated cash (“Cdn”) of $0.2 million and a nominal amount of trade payables at September 30, 2016. The Company had Cdn of $0.3 million and a nominal amount of trade payables at December 31, 2015.

NOTE 8 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The following table presents a summary of items comprising accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Accrued expenses:
Accrued salaries and related benefits	$	3,941	$	5,309
Other	16,720		11,339
Total accrued expenses	$	20,661	$	16,648
Other current liabilities:
Estimated amounts due to third party payors	$	6,348	$	3,795
Other	454		1,230
Total other current liabilities	$	6,802	$	5,025

NOTE 9 – OTHER LONG-TERM LIABILITIES

The Company assumed real property leases as part of certain acquisitions which required the Company to pay above market rentals through the remainder of the lease terms. Of the $3.5 million balance in other long-term liabilities at September 30, 2016, approximately $3.2 million of that balance relates to unfavorable leases. The unfavorable lease liability is amortized as a reduction to rent expense over the contractual periods the Company is required to make rental payments under the leases. Estimated amortization of unfavorable leases for the five years and thereafter subsequent to December 31, 2015, is $0.1 million for the remainder of 2016, $0.5 million for 2017 and $0.3 million for 2018, 2019, 2020, and $2.2 million thereafter.

NOTE 10 – LINES OF CREDIT

On March 31, 2015, the Company secured a $5.0 million revolving line of credit from Healthcare Financial Services, LLC (f/k/a General Electric Capital Corporation), or “HFS” (the “HFS Revolver”) maturing in March 2020, which was subsequently amended and increased to $11.6 million on August 19, 2016. The HFS Revolver bears interest at a rate of 4% plus LIBOR per annum (effective rate of 5.24% at September 30, 2016) and requires quarterly interest payments. Principal amounts borrowed under the HFS Revolver may be repaid and re-borrowed periodically. The HFS Revolver is collateralized in the same manner as the HFS term loan discussed in Note 11 - Debt. As of September 30, 2016 and December 31, 2015, $8.1 million and $3.0 million, respectively, were outstanding under the HFS Revolver.

The revolving line of credit is subject to certain restrictive covenants in conjunction with the HFS Term Loan, as defined in Note 11 - Debt.

On July 30, 2015, the Company issued a $1.5 million letter of credit to the Landlord of the PSH (“PSH Landlord”) facility in connection with the execution of the hospital facility lease. The PSH Landlord shall have the right to draw upon the letter of credit in an event of default. The letter of credit is secured by the $5.0 million HFS Revolver, which was subsequently amended and increased to $11.6 million on August 19, 2016.

On May 18, 2016, the Company secured a $3.0 million revolving line of credit from Legacy Texas Bank (the “Legacy Revolver”). The Legacy Revolver bears interest at a rate of 4% plus LIBOR per annum on drawn funds and requires monthly payments of interest. Monthly payments of principal commenced in September 2016. As of September 30, 2016, the outstanding balance was zero and the Legacy Revolver was extinguished using the increased borrowing capacity acquired through the Seventh Amendment to Credit Agreement ( the "Seventh Amendment") discussed in Note 11 - Debt.

13

NOTE 11 – DEBT

On March 31, 2015, the Company secured a $20.0 million term loan from HFS (the “HFS Term Loan”), which was subsequently amended and increased to $25.0 million on August 19, 2016. The HFS Term Loan bears interest at a rate of 4% plus LIBOR per annum (effective rate of 5.24% at September 30, 2016) and requires quarterly payments of principal and interest until it matures in March 2020. The HFS Term Loan provides for a 0.70% LIBOR floor. The HFS Term Loan is collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries.

The HFS Term Loan primarily served to refinance all previously held debt and lines of credit. Debt issuance costs associated with the new credit facility approximated $1.0 million. The issuance costs are a direct deduction from the carrying value of the HFS Term Loan, amortized using the interest method and reported as interest expense on our statement of operations. As of September 30, 2016, the outstanding balance of the HFS Term Loan was $24.7 million.

The Company entered into the Sixth Amendment to Credit Agreement (the "Sixth Amendment"), dated as of August 1, 2016, among Northstar Healthcare Acquisitions, L.L.C. ("NHA"), HFS and the credit parties named therein. The Sixth Amendment among other things, added a cap on Investments in Nobilis Health Anesthesia Network, PLLC of $2.0 million; increased the permitted indebtedness of the Company pursuant to that certain Loan Agreement, dated as of July 30, 2015, between PSH and Legacy Texas Bank from 7.0 to 7.05; modified the maximum leverage ratio as of March 31, 2016, to 3.05 to 1.00; and modified the definition of "Subsidiary" to exclude the following entities: Athelite, Dallas Metro, Marsh Lane Surgical Hospital, LLC, Nobilis Health Network, Inc. ("NHN") and the subsidiaries of NHN.

The Company entered into the Seventh Amendment, dated as of August 19, 2016, among HFS, other credit parties named therein and other financial institutions. The Seventh Amendment, among other things, increased total borrowing capacity to $36.6 million from $30.6 million. The increased borrowing capacity provided under the Seventh Amendment consisted of aggregate term and revolving loan commitments from HFS of $25 million and $11.6 million, respectively.

The Seventh Amendment includes material financial covenants, ratios and tests. The Company must maintain a Consolidated Leverage Ratio of not more than 2.00 to 1.00 and a Consolidated Fixed Charge Coverage Ratio of at least 3.00 to 1.00. Capital Lease Obligations allowed under the covenants increased from $3.0 million to $6.1 million and the HFS Term Loan's quarterly amortization payment increased under the Seventh Amendment from $250,000 to $312,500 per quarter.

The Company entered into the Eighth Amendment to Credit Agreement and Limited Waiver (the "Eighth Amendment"), dated as of October 20, 2016, by and among NHA, other credit parties named therein, HFS and other financial institutions. The purpose of the Amendment was to (i) modify the covenant regarding the Company’s holding company status to permit certain business activities thereunder (ii) define a new permitted lien and an applicable basket with regard to a lien filed by a Company vendor and (iii) amend the management fees covenant to permit payment of certain management fees under the Loan Agreement. As a result, the Company was in compliance with its covenants under the HFS Term Loan as of September 30, 2016.

On July 30, 2015, the Company secured a $4.5 million term loan from Legacy Texas Bank (the “Legacy Bank Term Loan”). The term loan bears interest at a rate of 4% plus LIBOR per annum and requires monthly payments of interest. Monthly payments of principal commenced in August 2016. The Legacy Bank Term Loan matures in July 2020 and is subordinated to the Company’s term loan and revolver with HFS. As of September 30, 2016, the outstanding balance was zero and the Legacy Bank Term Loan was extinguished using the increased borrowing capacity acquired through the Seventh Amendment.

Loan origination fees are deferred and the net amount is amortized over the contractual life of the related loans.

Debt at September 30, 2016 and December 31, 2015 consisted of the following (in thousands):

	September 30, 2016		December 31, 2015
Gross debt	$	24,687	$	23,275
Less: unamortized loan fees	855		563
Debt, net of unamortized loan fees	23,832		22,712
Less: current portion of term loan, net of unamortized loan fees	1,006		1,243
Long-term debt, net of unamortized loan fees	$	22,826	$	21,469

14

NOTE 12 – FAIR VALUE MEASUREMENTS

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrant and stock option derivative liabilities. There have been no transfers between fair value measurement levels during the nine months ended September 30, 2016 and 2015.

The following table summarizes our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
December 31, 2015:
Warrant and stock option derivative liabilities	$	—	$	—	$	2,951	$	2,951
Total	$	—	$	—	$	2,951	$	2,951
September 30, 2016:
Warrant and stock option derivative liabilities	$	—	$	—	$	1,917	$	1,917
Total	$	—	$	—	$	1,917	$	1,917

In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that were measured at estimated fair value on a recurring basis consist of warrant and stock option derivative liabilities. The estimated fair values of the warrant and stock option derivative liabilities were measured using the Black-Scholes valuation model (refer to Note 14 - Warrants and options liabilities). Due to the nature of valuation inputs, the valuation of the warrants is considered a Level 3 measurement.

NOTE 13 – SHARE BASED COMPENSATION

Restricted Share Units (“RSUs”)

The Company had no stock compensation expense relative to RSUs for both the three months ended September 30, 2016 and 2015. The Company recorded stock compensation expense relative to RSUs of nil and $5.4 million for the nine months ended September 30, 2016 and 2015, respectively. There were no grants during the three and nine months ended September 30, 2016 and 2015.

During the nine months ended September 30, 2015, two key executives experienced triggering events, as defined in their employee agreements, which accelerated all unrecognized stock compensation expense on their outstanding RSUs. As a result of this acceleration, the Company recognized $4.5 million of stock compensation expense during the nine months ended September 30, 2015.

The Company had no outstanding RSUs at September 30, 2016 and 2015.

Stock Options

The Company granted a total of 350,000 and 2,457,075 stock options during the three and nine months ended September 30, 2016, respectively. Of the options granted during the nine months ended September 30, 2016, 297,075 of those vest immediately and 2,160,000 vest ratably over a three-year period.

The Company granted a total of 3,166,782 stock options during the year ended December 31, 2015. Of the options granted during the year ended December 31, 2015, 451,782 of those vest immediately, 450,000 vest ratably over a one-year period, 1,865,000 vest ratably over a three-year period, and 400,000 cliff vest at the end of a five-year period.

15

The following table summarizes stock option activity for the nine months ended September 30, 2016 and 2015:

	Shares Underlying Options		Weighted- Average Exercise Price		Weighted-Average Remaining Life (years)
Outstanding at January 1, 2015	3,118,218		$	1.45	9.80
Granted	2,601,782		$	5.50	9.78
Exercised	(447,787	)	$	1.26	—
Forfeited	(372,213	)	$	1.11	—
Outstanding at September 30, 2015	4,900,000		$	3.65	9.47
Exercisable at
Exercisable at September 30, 2015	1,408,461		$	2.54	9.47
Exercisable at
Outstanding at January 1, 2016	5,465,000		$	2.97	9.20
Granted	2,457,075		$	2.14	9.40
Exercised	(1,083,750	)	$	1.91	—
Forfeited	(966,800	)	$	3.01	—
Outstanding at September 30, 2016	5,871,525		$	2.77	8.90
Outstanding at
Exercisable at September 30, 2016	2,234,025		$	2.32	8.50

The above table includes 650,000 options issued to non-employees, all of which are still outstanding at September 30, 2016. Refer to Note 14 - Warrants and options liabilities for discussion regarding the classification of these options within the Consolidated Balance Sheet.

The total intrinsic value of stock options exercised was $1.3 million and $2.9 million during the nine months ended September 30, 2016 and 2015, respectively. The total intrinsic value for all in-the-money vested outstanding stock options at September 30, 2016 was $1.8 million. Assuming all stock options outstanding at September 30, 2016 were vested, the total intrinsic value of in-the-money outstanding stock options would have been $4.2 million at September 30, 2016.

The Company recorded total stock compensation expense relative to employee stock options of $1.6 million and $1.3 million for the three months ended September 30, 2016 and 2015, respectively, and $5.0 million and $4.3 million for the nine months ended September 30, 2016 and 2015, respectively.

The fair values of the employee stock options used in recording compensation expense are computed using the Black-Scholes option pricing model. The table below shows the assumptions used in the model for options awarded during the nine months ended September 30, 2016 and 2015.

	Nine Months Ended September 30,
	2016		2015
Expected price volatility	114% - 117%		113% - 122%
Risk free interest rate	1.03% - 1.53%		1.34% - 1.87%
Expected annual dividend yield	0	%	0	%
Expected option term (years)	5 - 6		5 - 6
Expected forfeiture rate	0.5% - 11.6%		1.3% - 8.8%
Grant date fair value per share	$1.73 - $2.41		$2.97 - $6.31
Grant date exercise price per share	$1.99 - $2.82		$2.53 - $6.10

For stock options, the Company recognizes share-based compensation net of estimated forfeitures and revises the estimates in the subsequent periods if actual forfeitures differ from the estimates. Forfeiture rates are estimated based on historical experience as well as expected future behavior.

16

NOTE 14 – WARRANTS AND OPTIONS LIABILITIES

Warrants and Options Issued in Private Placements

The Company issued warrants and compensatory options in connection with private placements completed in December 2013, September 2014 and May 2015. These warrants and options have exercise prices denominated in Canadian dollars and as such may not be considered indexed to our stock which is valued in U.S. dollars. Hence, these warrants and options are classified as liabilities under the caption “Warrants and Options Derivative Liability” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period are recorded in the Consolidated Statements of Operations under the caption “Change in fair value of warrant and stock option derivative liabilities”.

The estimated fair values of warrants and options accounted for as liabilities were determined on the date of the private placements and at each balance sheet date following using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	0.26% - 0.59%		0.11% - 0.64%
Expected life in years	0.25 - 1.15		0.25 - 2.0
Expected volatility	76% - 112%		71% - 89%
Expected dividend yield	0	%	0	%

The changes in fair value of the warrants and options (excluding non-employees) liability during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016			2015
Balance at beginning of year	$	2,109		$	6,657
Issuance of warrants and options	—			12,797
Transferred to equity upon exercise	—			(8,882		)
Change in fair value recorded in earnings	(1,729		)	(4,742		)
Balance as of September 30, 2016 and 2015	$	380		$	5,830

The following warrants and options were outstanding at September 30, 2016:

	Exercise price in Cdn$		Number of warrants and options	Remaining contractual life (years)
2015 Warrants	$	11.50	3,923,834	0.90
2015 Options	$	9.00	392,383	0.90
Outstanding and Exercisable as of September 30, 2016			4,316,217

As of September 30, 2016, there were no warrants or options outstanding from the 2014 issuances.

Options Issued to Non-Employees

As discussed in Note 13 - Share based compensation, in 2014 the Company issued options to professionals providing services to the organization. These professionals do not meet the definition of an employee under U.S. GAAP. At September 30, 2016, there were 650,000 options outstanding to these non-employees.

Under U.S. GAAP, the value of these option awards is determined at the performance completion date. The Company recognizes expense for the estimated total value of the awards during the period from their issuance until performance completion since the professional services are being rendered during this time. The total expense recognized is adjusted to the final value of the award as determined on the performance completion date.

17

The estimated values of the option awards are determined using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	1.01% - 1.14%		1.37% - 1.56%
Expected life in years	4 - 5		5 - 6
Expected volatility	103% - 114%		113% - 115%
Expected dividend yield	0	%	0	%

For the three month periods ended September 30, 2016 and 2015, the Company recorded expense for non-employee stock options of $0.1 million and $0.2 million, respectively. For the nine months ended September 30, 2016 and 2015, the Company recorded expense for non-employee stock options of $0.2 million and $2.8 million, respectively.

The changes in fair value of the liability related to vested yet un-exercised options issued to non-employees during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016		2015
Balance at beginning of year	$	841	$	—
Vested during the period	533		1,531
Change in fair value recorded in earnings	163		65
Balance as of September 30, 2016 and 2015	$	1,537	$	1,596

Options issued to non-employees are reclassified from equity to liabilities on the performance completion date. Under U.S. GAAP, such options may not be considered indexed to our stock because they have exercise prices denominated in Canadian dollars. Hence, these will be classified as liabilities under the caption “Warrant and stock option liabilities” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period will be recorded in the Consolidated Statements of Operations under the caption “Change in fair value of warrant and stock option liabilities”. At September 30, 2016, there were 0.6 million unexercised non-employee options requiring liability classification.

18

NOTE 15 – EARNINGS PER SHARE

Basic net earnings attributable to Nobilis common shareholders, per common share, excludes dilution and is computed by dividing net earnings attributable to Nobilis common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to Nobilis common shareholders, per common share, is computed by dividing net earnings attributable to Nobilis common shareholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable upon the vesting stock option awards, warrants and RSUs as determined under the treasury stock method. A detail of the Company’s earnings per share is as follows (in thousands except for share and per share amounts):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016			2015
Basic:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Net (loss) income per common share	$	(0.04	)	$	0.15	$	(0.04	)	$	0.09
Diluted:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Dilutive effect of stock options, warrants, RSUs	—			6,720,676		—			6,720,676
Athas share consideration	—			—		—			3,036,337
Weighted average common shares outstanding assuming dilution	76,774,967			77,656,263		76,114,538			75,067,623
Net (loss) income per fully diluted share	$	(0.04	)	$	0.14	$	(0.04	)	$	0.08

19

NOTE 16 – NONCONTROLLING INTERESTS

Noncontrolling interests at September 30, 2016 and December 31, 2015 represent an 8.1% interest in The Palladium for Surgery - Houston, Ltd, 75% interest in the Medical Ambulatory Suites, L.P., 65% interest in Microsurgery Institute, LLC., 2.3% interest in Houston Microsurgery Institute, LLC., 50% in Northstar Healthcare Dallas Management, LLC., 65% in NHC ASC – Dallas, LLC., 49% in First Nobilis, LLC., 40% in First Nobilis Hospital Management, LLC., 45% in Hermann Drive Surgical Hospital, LP., and 40% in Perimeter Road Surgical Hospital, LLC.

Agreements with the third party equity owners in NHC - ASC Dallas and First Nobilis give these owners limited rights to require the Company to repurchase their equity interests upon the occurrence of certain events, none of which were probable of occurring as of September 30, 2016 and December 31, 2015. The contingently redeemable noncontrolling interests associated with these entities are classified in the Company’s Consolidated Balance Sheets as “temporary” or mezzanine equity. Changes in contingently redeemable noncontrolling interests are as follows (in thousands):

	NHC - ASC Dallas			First Nobilis			Total
Balance at January 1, 2015	$	6,654		$	6,213		$	12,867
Distributions	(3,892		)	(7,617		)	(11,509		)
Net income attributable to noncontrolling interests	631			10,236			10,867
Total contingently redeemable noncontrolling interests at December 31, 2015	$	3,393		$	8,832		$	12,225
Balance at January 1, 2016	$	3,393		$	8,832		$	12,225
Distributions	(2,929		)	(600		)	(3,529		)
Net (loss) income attributable to noncontrolling interests	(210		)	2,081			1,871
Total contingently redeemable noncontrolling interests at September 30, 2016	$	254		$	10,313		$	10,567

Certain of our consolidated subsidiaries that are less than wholly owned meet the definition of a Variable Interest Entity (“VIE”), and we hold voting interests in all such entities. We consolidate the activities of VIE’s for which we are the primary beneficiary. In order to determine whether we own a variable interest in a VIE, we perform qualitative analysis of the entity’s design, organizational structure, primary decision makers and relevant agreements. Such variable interests include our voting interests, and may also include other interests and rights, including those gained through management contracts.

Since our core business is the management and operation of health care facilities, our subsidiaries that are determined to be VIE’s represent entities that own, manage and operate such facilities. Voting interests in such entities are typically owned by us, by physicians practicing at these facilities (or entities controlled by them) and other parties associated with the operation of the facilities. In forming such entities, we typically seek to retain operational control and, as a result, in some cases, voting rights we hold are not proportionate to the economic share of our ownership in these entities, which causes them to meet the VIE definition. We consolidate such VIE’s if we determine that we are the primary beneficiary because (i) we have the power to direct the activities that most significantly impact the economic performance of the VIE via our rights and obligations associated with the management and operation of the VIE’s health care facilities, and (ii) as a result of our obligation to absorb losses and the right to receive residual returns that could potentially be significant to the VIE, which we have through our equity interests.

20

The following table summarizes the carrying amount of the assets and liabilities of our material VIE’s included in the Company’s Consolidated Balance Sheets (after elimination of intercompany transactions and balances) (in thousands):

	September 30, 2016			December 31, 2015
Total cash and short term investments	$	1,071		$	191
Total accounts receivable	8,638			8,660
Total other current assets	1,768			1,582
Total property and equipment	17,547			5,227
Total other assets	165			144
Total assets	$	29,189		$	15,804
Total accounts payable	$	3,847		$	2,286
Total other liabilities	5,924			7,059
Total accrued liabilities	4,242			2,664
Long term - capital lease	11,543			780
Noncontrolling interest	(8,547		)	(1,488		)
Total liabilities	$	17,009		$	11,301

21

NOTE 17 – INCOME TAXES

The Company is a corporation subject to federal income tax at a statutory rate of 35% of pretax earnings. The Company estimates an annual effective income tax rate of 32.5% for U.S. and none for Canada based on projected results for the year and applies this rate to income before taxes to calculate income tax expense. The following items caused the third quarter effective income tax rate to be significantly different from the statutory rate:

• Canada is excluded from the worldwide annual effective tax rate calculation because Canada has losses but does not expect to realize them, which reduces the third quarter effective tax rate by approximately 3.8% for the nine months ended September 30, 2016.

• All of the Partnership’s earnings are included in the Company’s net income; however, the Company is not required to record income tax expense or benefit with respect to the portion of the Partnership’s earnings allocated to its noncontrolling public limited partners, which reduces the third quarter effective tax rate by approximately 4.5% for the nine months ended September 30, 2016.

• The Company adjusted the prior year tax provision. The adjustment to the existing deferred tax assets and liabilities decreases the third quarter effective tax rate by approximately 1.6% for the nine months ended September 30, 2016.

• The third quarter effective tax rate includes a discrete item for the stock compensation shortfall, which reduces the effective tax rate by approximately 3.8% for the nine months ended September 30, 2016.

• The net tax for the three and nine months ended September 30, 2016 was $0.5 million expense and $1.7 million benefit, respectively, resulting in an effective tax rate of approximately -29.3% and 21.1% respectively. The net tax includes $0.3 million and $0.8 million of state tax expense, respectively. The Company did not recognize any federal or foreign tax expense or benefit for the three and nine months ended September 30, 2015 as the Company had a full valuation allowance against deferred tax assets at that time. The state tax expense for the three and nine months ended September 30, 2015 was $0.3 million and $0.9 million, respectively.

On April 22, 2016, the Company received notification from the Internal Revenue Service to examine our December 31, 2014 and 2013 Federal income tax return. Based on management tax analysis, the Company did not have any uncertain tax positions as of September 30, 2016.

22

NOTE 18 – BUSINESS SEGMENT INFORMATION

A summary of the business segment information for the three months ended September 30, 2016 and 2015 is as follows (in thousands):

	Three months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	65,419		$	5,264		$	—		$	70,683
Operating expenses	60,871			2,958			—			63,829
Corporate costs	—			—			7,955			7,955
Income (loss) from operations	4,548			2,306			(7,955		)	(1,101		)
Change in fair value of warrant and option liabilities	—			—			133			133
Interest expense	329			1			414			744
Other (income) expense	(199		)	(57		)	58			(198		)
Income (loss) before income taxes	$	4,418		$	2,362		$	(8,560	)	$	(1,780	)
Other data:
Depreciation and amortization expense	$	1,564		$	388		$	79		$	2,031
Income tax expense	$	205		$	78		$	200		$	483
Capital expenditures	$	1,289		$	—		$	72		$	1,361

	Three months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	46,150		$	6,333		$	—		$	52,483
Operating expenses	36,466			5,670			—			42,136
Corporate costs	—			—			7,296			7,296
Income (loss) from operations	9,684			663			(7,296		)	3,051
Change in fair value of warrant and option liabilities	—			—			(6,381		)	(6,381		)
Interest expense (income)	169			(15		)	168			322
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,583			(205		)	(1,484		)	(106		)
Income before income taxes	$	12,290		$	883		$	401		$	13,574
Other data:
Depreciation and amortization expense	$	1,178		$	344		$	43		$	1,565
Income tax expense	$	176		$	80		$	—		$	256
Capital expenditures	$	1,041		$	—		$	—		$	1,041
Non-cash acquisition of property	$	10,485		$	—		$	—		$	10,485
Non-cash acquisition of intangibles and goodwill	$	1,534		$	—		$	—		$	1,534

23

A summary of the business segment information for the nine months ended September 30, 2016 and 2015 is as follows (in thousands):

	Nine months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	166,922		$	16,905		$	—		$	183,827
Operating expenses	158,471			11,716			—			170,187
Corporate costs	—			—			24,380			24,380
Income (loss) from operations	8,451			5,189			(24,380		)	(10,740		)
Change in fair value of warrant and option liabilities	—			—			(1,566		)	(1,566		)
Interest expense	1,074			4			1,037			2,115
Other income	(1,682		)	(305		)	(1,024		)	(3,011		)
Income (loss) before income taxes	$	9,059		$	5,490		$	(22,827	)	$	(8,278	)
Other data:
Depreciation and amortization expense	$	5,026		$	1,436		$	209		$	6,671
Income tax expense (benefit)	$	662		$	149		$	(2,577	)	$	(1,766	)
Capital expenditures	$	4,000		$	—		$	388		$	4,388
Intangible assets	$	5,246		$	13,022		$	—		$	18,268
Goodwill	$	25,822		$	19,011		$	—		$	44,833
Total assets	$	175,279		$	44,413		$	21,291		$	240,983
Total liabilities	$	55,602		$	6,928		$	38,237		$	100,767

24

	Nine months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	123,638		$	15,563		$	—		$	139,201
Operating expenses	94,589			13,471			—			108,060
Corporate costs	—			—			23,071			23,071
Income (loss) from operations	29,049			2,092			(23,071		)	8,070
Change in fair value of warrant and option liabilities	—			—			(4,677		)	(4,677		)
Interest expense	169			65			872			1,106
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,383			(446		)	(2,455		)	(1,518		)
Income (loss) before income taxes	$	31,855		$	2,473		$	(16,811	)	$	17,517
Other data:
Depreciation and amortization expense	$	2,079		$	1,035		$	99		$	3,213
Income tax expense	$	703		$	159		$	—		$	862
Capital expenditures	$	2,406		$	127		$	—		$	2,533
Intangible assets	$	5,734		$	14,172		$	—		$	19,906
Goodwill	$	14,163		$	19,011		$	—		$	33,174
Non-cash acquisition of property	$	15,345		$	—		$	—		$	15,345
Non-cash acquisition of intangibles and goodwill	$	13,532		$	—		$	—		$	13,532
Total assets	$	103,836		$	43,528		$	18,158		$	165,522
Total liabilities	$	38,360		$	3,909		$	22,831		$	65,100

25

NOTE 19 – RELATED PARTY TRANSACTIONS

The minority interest holder of First Nobilis Hospital, a fully consolidated entity, is also a partial owner of First Street Hospital, L.P. and First Street Surgical Center, L.P., both of which have an ongoing business relationship with the Company. At September 30, 2016, the Company has a net amount due from these related parties of $1.4 million. In addition, the Company leases certain medical equipment and facility space from these related parties. Equipment lease costs of approximately $0.5 million and $0.6 million were incurred during the quarter ended September 30, 2016 and 2015, respectively. Facility lease costs of approximately $0.4 million were incurred during both the three months ended September 30, 2016 and 2015. Equipment lease costs of approximately $1.6 million and $1.7 million were incurred during the nine months ended September 30, 2016 and 2015, respectively. Facility lease costs of approximately $1.3 million were incurred during both the nine months ended September 30, 2016 and 2015, respectively.

In March 2016, the Company acquired an interest in Athelite, a holding company which owns an interest in Dallas Metro, a company formed to provide management services to an HOPD. The Athelite investment is accounted for as an equity method investment (refer to Note 6 - Investments in associates). At September 30, 2016, the Company had $3.6 million in accounts receivable from the HOPD and $0.9 million in accounts receivable from Dallas Metro. The Company also rents, on a monthly basis, certain medical equipment to Dallas Metro and subleases operation facility to Benton Transitional.

Physician Related Party Transactions

Nobilis maintains certain medical directorship, consulting and marketing agreements with various physicians who are also equity owners in Nobilis entities. Material related party arrangements of this nature are described below:

• In October 2014 the Company entered into a marketing services agreement with an entity controlled by a physician equity owner. In June 2015, the Company expanded the relationship with this physician equity owner to include consulting, medical supplies, medical directorship and on-call agreements. The Company incurred expenses of $2.5 million and $2.5 million as of September 30, 2016 and 2015, respectively. The Company has incurred expenses of $1.9 million and $0.2 million in fees owed pursuant to the service agreements as of September 30, 2016 and 2015, respectively.

• In July 2014, the Company entered into a marketing services agreement with a physician equity owner and an entity owned by that physician equity owner’s brother. The Company incurred expenses of $1.0 million and $0.3 million as of September 30, 2016 and 2015, respectively.

• In September 2013, the Company entered into a book deal with a physician equity owner. In March 2015, the Company entered into a marketing agreement with that physician equity owner and a marketing services company owned by the physician equity owner’s father. The Company incurred expenses of $3.9 million and $2.4 million as of September 30, 2016 and 2015, respectively.

26

NOTE 20 – COMMITMENTS AND CONTINGENCIES

Litigation

In the normal course of our business, we are subject to legal proceedings brought by or against us and our subsidiaries. In the opinion of management, the amount of ultimate liability with respect to these actions will not materially impact the financial position, results of operations or liquidity of the Company.

Shareholder Lawsuits

After the Company announced it would be restating its 2014 annual financial statements and 2015 first and second quarter interim financial statements, one complaint, Schott v. Nobilis Health Corp. et al, was filed in the United States District Court for the Southern District of Texas against the Company, our former chief executive officer and our current chief financial officer. The complaint sought class action status on behalf of our shareholders and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 arising out of the restatement. The defendants vigorously defended against these claims and filed motions to dismiss the consolidated complaint for failure to plead particularized facts supporting a strong inference of scienter on the part of the individual defendants.On June 1, 2016 the court heard oral arguments on the Company’s pending motion to dismiss which the court later granted on September 29, 2016. The court ultimately dismissed the case with prejudice on October 24, 2016.

In addition, a statement of claim (complaint), Vince Capelli v Nobilis Health Corp. et. al, was filed on January 8, 2016 in the Ontario Superior Court of Justice under court file number CV-16-544173 naming Nobilis Health Corp., certain current and former officers and the Company’s former auditors as defendants. The statement of claim seeks to advance claims on behalf of the plaintiff and on behalf of a class comprised of certain of our shareholders related to, among other things, alleged certain violations of the Ontario Securities Act and seeks damages in the amount of C$80 million plus interest. The defendants intend to vigorously defend against these claims. At this time the Company believes the likelihood of loss, if any, is remote.

27

NOTE 21 – SUBSEQUENT EVENTS

The Company entered into the Eighth Amendment on October 20, 2016, by and among NHA, other credit parties named therein, HFS and other financial institutions. The purpose of the Amendment was to (i) modify the covenant regarding the Company’s holding company status to permit certain business activities thereunder (ii) define a new permitted lien and an applicable basket with regard to a lien filed by a Company vendor and (iii) amend the management fees covenant to permit payment of certain management fees under the Loan Agreement. As a result, the Company was in compliance with its covenants under the HFS Term Loan as of September 30, 2016.

On October 28, 2016, the Company entered into an $82.5 million credit agreement (the “Compass Bank Loans”) with Compass Bank.  The credit agreement includes a $52.5 million term loan and a $30.0 million revolving credit facility.  The proceeds will be used to refinance all previously held debt and lines of credit and for the acquisition of Arizona Vein and Vascular Centers.  As of September 30, 2016, the outstanding balance of the HFS Term Loan and Revolver was $24.7 million and $8.1 million, respectively.  The Compass Bank loans are collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries.  The Compass Bank Loans require the Company to maintain a consolidated leverage ratio of 2.75 to 1.00 through September 30, 2018, 2.50 to 1.00 for December 31, 2018 to September 30, 2019, 2.25 to 1.00 for December 31, 2019 to September 30, 2020 and 2.00 to 1.00 through December 31, 2020; and a consolidated fixed charge coverage ratio of 2.00 to 1.00.  

The Compass Bank Loans bear interest from the closing date to the first business day immediately following the date on which Compass Bank receives a compliance certificate from the Company for the fiscal quarter ending March 31, 2017; 2.75% per annum for base rate loans, 3.75% per annum for Eurodollar Rate Loans, 3.75% for line of credit fees, and 0.500% per annum for the commitment fee.  Thereafter, the Compass Bank Loans bear interest based on the Company’s consolidated leverage ratio as follows:  (i) Less than 1.00 to 1.00; base rate margin 2.00%, LIBOR margin 3.00%, commitment fee rate 0.375%, (ii) Less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00; base rate margin 2.25%, LIBOR margin 3.25%, commitment fee rate 0.375%, (iii) Less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00; base rate margin 2.50%, LIBOR margin 3.50%, commitment fee rate 0.450%, (iv) Greater than or equal to 2.50 to 1.00; base rate margin 2.75%, LIBOR margin 3.75%, commitment fee rate 0.500%. 

The Compass Bank term loan requires quarterly payments of Principal as follows: (i) March 31, 2017 to December 31, 2018 of $0.7 million, (ii) March 31, 2019 to December 31, 2020 of $1.3 million, (iii) March 31, 2021 to September 30, 2021 of $2.0 million, (iv) October 28, 2021, the remaining principal balance of the term.   The Compass Bank Loans mature on October 28, 2021.

In connection with the funding of the Compass Bank Loans, the Company also completed the acquisition of the operating assets of Arizona Center for Minimally Invasive Surgery, LLC, an Arizona limited liability company (“ACMIS”), L. Philipp Wall, M.D., P.C., an Arizona professional corporation (“PC”), Arizona Vein & Vascular Center, LLC, an Arizona limited liability company and wholly owned subsidiary of PC, (“AVVC” and with ACMIS and PC, each a “Seller” and collectively “Sellers”), and L. Philipp Wall (“Owner”). The Company, Northstar Healthcare Acquisitions, L.L.C. ("Buyer"), Sellers and Owner entered into an amended and restated purchase agreement (the “Amended and Restated Purchase Agreement”) dated as of October 28, 2016.

Buyer received substantially all of the operating assets of Sellers in exchange for an aggregate purchase price of approximately $22.0 million, consisting of $17.0 million in cash (subject to a holdback described below), $2.5 million of NHC’s common shares, and $2.50 million the form of a convertible promissory note (“Convertible Promissory Note”) between Buyer and ACMIS.

In addition, the Sellers may receive an additional earnout payment based on the growth in trailing twelve month EBITDA of the new vascular division on the twelve-month anniversary of closing (as compared to the trailing twelve month EBITDA for the twelve months prior to closing). The earnout payment shall be equal to fifty percent (50%) of such growth.

As part of the Amended and Restated Purchase Agreement, $1.05 million of the cash purchase price was held back and is subject to the Amended and Restated Purchase Agreement’s indemnification provisions. On the twelve-month anniversary of closing, fifty percent (50%) of the amount held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner. The remaining amounts held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner on the twenty-four-month anniversary of closing.

28

The common shares issued to Owner at closing were issued at a price per share based on the NYSE MKT closing price of NHC’s common shares on the day prior to closing. The common shares are restricted under Rule 144 of the Securities Act of 1933, as amended, and are subject to additional contractual lock-up provisions, which lift in one-quarter increments on the twelve-month, fifteen-month, eighteen-month and twenty-first month anniversaries of closing.

On October 31, 2016, the Company increased its ownership interest in SLH from 60% to 75%.  Pursuant to a subscription agreement, the Company was the only member to participate in the capital raise and acquired an additional 60 Class C Units.

29

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsForward-Looking Statements

This Quarterly Report and the documents that are incorporated herein by reference contain certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words including, but not limited to the following: “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “continue” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy. These forward-looking statements are based on the Company's current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to the following:

• our ability to successfully maintain effective internal controls over financial reporting, including the impact of material weaknesses identified by management and our ability to remediate such control deficiencies;

• our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses;

• the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance;

• the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase;

• adverse developments affecting the medical practices of our physician limited partners;

• our ability to maintain favorable relations with our physician limited partners;

• our ability to grow revenues by increasing case and procedure volume while maintaining profitability;

• failure to timely or accurately bill for services;

• our ability to compete for physician partners, patients and strategic relationships;

• the risk of changes in patient volume and patient mix;

• the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease;

• the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and

• the risk of potential decreases in our reimbursement rates.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. There could be additional factors besides those listed herein that also could affect us in an adverse manner.

This Quarterly Report should be read completely and with the understanding that actual future results may be materially different from what we may expect. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, when evaluating the information presented in this Quarterly Report or other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of the Company.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the risk factors set forth elsewhere in this report and in our 2015 Annual Report filed with the SEC on March 15, 2016.

The following discussion relates to the Company and its consolidated subsidiaries and should be read in conjunction with our consolidated financial statements and accompanying notes included under Part I, Item 1—Financial Statements of this Quarterly Report, as well as our consolidated financial statements, accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) included in our 2015 Annual Report.

30

Executive Overview

Our operations consist of two reportable business segments, the Medical Segment and the Marketing Segment, each of which is described in more detail in the following paragraphs. Our Medical Segment owns and/or manages outpatient surgery centers and surgical hospitals. It focuses on improving patient outcomes by providing minimally invasive procedures that can be performed in low-cost, outpatient settings. Our business also utilizes innovative direct-to-patient marketing and proprietary technologies to drive patient engagement and education. Our Marketing Segment provides these services to the facilities that comprise our Medical Segment; we also provide these services to third parties as a stand-alone business line, which is a separate reportable business segment.

Medical Segment

Our Medical Segment broadly includes our ownership and operation of healthcare facilities (the “Nobilis Facilities”) (which include outpatient surgery centers and hospitals) and ancillary service providers (“Nobilis Ancillary Service Lines”).

There are nine Nobilis Facilities, consisting of four hospitals (three in Texas and one in Arizona) and five ambulatory surgery centers (three in Houston, Texas, one in Dallas, Texas and one in Scottsdale, Arizona). We earn revenue in our Medical Segment from the “facility fees” or “technical fees” from third party payors or patients for the services rendered at the Nobilis Facilities. The Nobilis Facilities are each licensed in the state where they are located and provide surgical procedures in a limited number of clinical specialties, which enables them to develop routines, procedures and protocols to maximize operating efficiency and productivity while offering an enhanced healthcare experience for both physicians and patients. These clinical specialties include orthopedic surgery, podiatric surgery, ear nose and throat (“ENT”) surgery, pain management, gastro-intestinal surgery, gynecology and general surgery. The Nobilis ASCs do not offer the full range of services typically found in traditional hospitals, allowing the Nobilis ASCs to operate with lower operating expenses. The Nobilis Hospitals do offer the services typically found in traditional hospitals and, as a result, have ability to take on more complex cases and cases that may require an overnight stay.

There are three Nobilis Ancillary Service Lines: intraoperative monitoring, surgical assist and anesthesia. Peak Neuromonitoring, a wholly owned subsidiary, oversees our intraoperative monitoring service line, and Nobilis Surgical Assist oversees our surgical assist service line. There are several small subsidiaries through which we provide anesthesia services. In the third quarter of 2016, we added laboratory services.

Marketing Segment

Our Marketing Segment provides marketing services, patient education services and patient care coordination management services to the Nobilis Facilities, to third party facilities in states where we currently do not operate, and to physicians. We market several minimally-invasive medical procedures and brands, which include the following:

• North American Spine: promotion of minimally invasive spine procedures (pain management musculoskeletal, musculoskeletal and spine);

• Migraine Treatment Centers of America: promotion of procedures related to chronic migraine pain (interventional headache procedure);

• NueStep: promotion of surgical procedures designed to treat pain in the foot, ankle and leg (podiatry);

• Evolve-The Experts in Weight Loss Surgery: promotion of surgical weight loss procedures (bariatrics);

• Minimally Invasive Reproductive Surgery Institute (“MIRI”): promotion of women’s health related procedures; and

• Onward Orthopedics: promotion of general orthopedics, sports medicine related to orthopedics (orthopedics and pain management interventions);

• Clarity Vein and Vascular: promotion of cosmetic and medical vein and vascular treatments.

Our Marketing Segment does not directly provide medical services to patients; rather, we identify candidates for our branded procedures, educate these potential patients about the relevant procedure and direct those patients to affiliated physicians who diagnose and treat those patients at affiliated facilities. Through our Marketing Segment, we have contractual relationships with facilities and physicians in several states.

We earn service fees from our partner facilities that, depending on the laws of the state in which a partner facility is located, are either charged as a flat monthly fee or are calculated based on a portion of the “facility fee” revenue generated by the partner facility for a given procedure.

Our revenues from physician-related services are, depending on the laws of the state in which a partner-physician practices, either earned directly from professional fees or through the purchase of accounts receivable. In Texas, we engage physicians through

31

entities exempt from Texas corporate practice of medicine laws that directly earn professional fees for partner-physician services and, in turn, pay partner-physicians a reasonable fee for rendering those professional services. In other states, we manage our partner-physicians’ practices and purchase the accounts receivable of those practices through accounts receivable purchase agreements.

Recent Developments

Compass Bank Loans

On October 28, 2016, the Company entered into a $82.5 million credit agreement (the “Compass Bank Loans”) with Compass Bank.  The credit agreement includes a $52.5 million term loan and a $30.0 million revolving credit facility.  The proceeds will be used to refinance all previously held debt and lines of credit and for the acquisition of Arizona Vein and Vascular Centers.  As of September 30, 2016, the outstanding balance of the HFS Term Loan and Revolver was $24.7 million and $8.1 million, respectively.  The Compass Bank loans are collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries.  The Compass Bank Loans require the Company to maintain a consolidated leverage ratio of 2.75 to 1.00 through September 30, 2018, 2.50 to 1.00 for December 31, 2018 to September 30, 2019, 2.25 to 1.00 for December 31, 2019 to September 30, 2020 and 2.00 to 1.00 through December 31, 2020; and a consolidated fixed charge coverage ratio of 2.00 to 1.00.  

The Compass Bank Loans bear interest from the closing date to the first business day immediately following the date on which Compass Bank receives a compliance certificate from the Company for the fiscal quarter ending March 31, 2017; 2.75% per annum for base rate loans, 3.75% per annum for Eurodollar Rate Loans, 3.75% for line of credit fees, and 0.500% per annum for the commitment fee.  Thereafter, the Compass Bank Loans bear interest based on the Company’s consolidated leverage ratio as follows:  (i) Less than 1.00 to 1.00; base rate margin 2.00%, LIBOR margin 3.00%, commitment fee rate 0.375%, (ii) Less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00; base rate margin 2.25%, LIBOR margin 3.25%, commitment fee rate 0.375%, (iii) Less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00; base rate margin 2.50%, LIBOR margin 3.50%, commitment fee rate 0.450%, (iv) Greater than or equal to 2.50 to 1.00; base rate margin 2.75%, LIBOR margin 3.75%, commitment fee rate 0.500%. 

The Compass Bank term loan requires quarterly payments of Principal as follows: (i) March 31, 2017 to December 31, 2018 of $0.7 million, (ii) March 31, 2019 to December 31, 2020 of $1.3 million, (iii) March 31, 2021 to September 30, 2021 of $2.0 million, (iv) October 28, 2016, the remaining principal balance of the term.   The Compass Bank Loans mature on October 28, 2021.

Acquisition of Arizona Vein and Vascular

In connection with the funding of the Compass Bank Loans, the Company also completed the acquisition of the operating assets of Arizona Center for Minimally Invasive Surgery, LLC, an Arizona limited liability company (“ACMIS”), L. Philipp Wall, M.D., P.C., an Arizona professional corporation (“PC”), Arizona Vein & Vascular Center, LLC, an Arizona limited liability company and wholly owned subsidiary of PC, (“AVVC” and with ACMIS and PC, each a “Seller” and collectively “Sellers”), and L. Philipp Wall (“Owner”). The Company, Northstar Healthcare Acquisitions, L.L.C. ("Buyer"), Sellers and Owner entered into an amended and restated purchase agreement (the “Amended and Restated Purchase Agreement”) dated as of October 28, 2016.

Buyer received substantially all of the operating assets of Sellers in exchange for an aggregate purchase price of approximately $22 million, consisting of $17 million in cash (subject to a holdback described below), $2.5 million of the Company's common shares, and $2.5 million the form of a convertible promissory note (“Convertible Promissory Note”) between Buyer and ACMIS.

In addition, the Sellers may receive an additional earnout payment based on the growth in trailing twelve month EBITDA of the new vascular division on the twelve-month anniversary of closing (as compared to the trailing twelve month EBITDA for the twelve months prior to closing). The earnout payment shall be equal to fifty percent (50%) of such growth.

As part of the Amended and Restated Purchase Agreement, $1.05 million of the cash purchase price was held back and is subject to the Amended and Restated Purchase Agreement’s indemnification provisions. On the twelve-month anniversary of closing, fifty percent (50%) of the amount held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner. The remaining amounts held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner on the twenty-four-month anniversary of closing.

32

The common shares issued to Owner at closing were issued at a price per share based on the NYSE MKT closing price of our common shares on the day prior to closing. The common shares are restricted under Rule 144 of the Securities Act of 1933, as amended, and are subject to additional contractual lock-up provisions, which lift in one-quarter increments on the twelve-month, fifteen-month, eighteen-month and twenty-first month anniversaries of closing.

See Part I, Item 1-“Financial Statements, Note 21 - Subsequent events” of this Quarterly Report for more information on the Compass Bank Loans and the Transaction.

We recently partnered with a group purchasing organization (GPO) who maintains over $28.5 billion purchasing power and provides us access to the highest quality of products and industry leading contract pricing from suppliers.  The GPO will partner with us to drive best operating and clinical practices, and accelerate cost savings across the Nobilis Facilities. The agreement contemplates immediate contract value from the GPO's committed portfolio as well as access to clinical and sourcing experts that will be closely integrated with the our service lines, operations and supply chain leadership.

Seasonality of the Business

The surgical segment of the healthcare industry tends to be impacted by seasonality because most benefit plans reset on a calendar year basis. As patients utilize and reduce their remaining deductible, surgical ASCs and hospitals typically experience an increase in volume throughout the year, with the biggest impact coming in the fourth quarter. Historically, approximately 35% - 40% of our annual revenues have been recognized in the fourth quarter.

Operating Environment

The Medical Segment depends primarily upon third-party reimbursement from private insurers to pay for substantially all of the services rendered to our patients. The majority of the revenues attributable to the Medical Segment are from reimbursement to the Nobilis Hospitals and Nobilis ASCs as “out-of-network” providers. This means the Nobilis Facilities are not contracted with a major medical insurer as an “in-network” participant. Participation in such networks offer the benefit of larger patient populations and defined, predictable payment rates. The reimbursement to in-network providers, however, is typically far less than that paid to out of network providers. To a far lesser degree, the Nobilis Facilities earn fees from governmental payor programs such as Medicare. For the three and nine months ended September 30, 2016 and 2015, we derived approximately 0.2% and 0.3% for the respective periods 2016, and 0.4% and 0.5% for 2015 of our Medical Segment’s net revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payers and patient co-pays, coinsurance, and deductibles.

We receive a relatively small amount of revenue from Medicare. We also receive a relatively small portion of revenue directly from uninsured patients, who pay out of pocket for the services they receive. Insured patients are responsible for services not covered by their health insurance plans, deductibles, co-payments and co-insurance obligations under their plans. The amount of these deductibles, co-payments and coinsurance obligations has increased in recent years but does not represent a material component of the revenue generated by the Nobilis Facilities. The surgical center fees of the Nobilis Facilities are generated by the physician limited partners and the other physicians who utilize the Nobilis Facilities to provide services.

Revenue Model and Case Mix

Revenues earned by the Nobilis Facilities vary depending on the procedures performed. For every medical procedure performed there are usually three separately invoiced patient billings:

• the surgical center fee for the use of infrastructure, surgical equipment, nursing staff, non-surgical professional services, supplies and other support services, which is earned by the Nobilis Facilities;

• the professional fee, which is separately earned, billed and collected by the physician performing the procedure, separate and apart from the fees charged by the Nobilis Facilities; and

• the anesthesiology fee, which is separately earned, billed and collected by the anesthesia provider, separate and apart from the fees charged by the Nobilis Facilities and the physicians.

Overall facility revenue depends on procedure volume, case mix and payment rates of the respective payors.

33

Three Months Ended September 30, 2016 and 2015

	Three Months Ended September 30,
	2016			2015
Revenues:
Patient and net professional fees	$	65,666		$	46,237
Contracted marketing revenues	2,604			4,410
Factoring revenues	2,413			1,836
Total revenues	70,683			52,483
Operating expenses:
Salaries and benefits	13,209			10,255
Drugs and supplies	15,473			8,405
General and administrative	33,195			21,025
Bad debt expense	—			929
Depreciation and amortization	1,952			1,522
Facility operating expenses	63,829			42,136
Corporate expenses:
Salaries and benefits	1,765			1,540
General and administrative	4,576			5,192
Legal expenses	1,535			521
Depreciation	79			43
Total corporate costs	7,955			7,296
(Loss) income from operations	(1,101		)	3,051
Other expense (income) :
Change in fair value of warrant and stock option derivative liabilities	133			(6,381		)
Interest expense	744			322
Bargain purchase gain	—			(4,358		)
Other income, net	(198		)	(106		)
Total other expense (income)	679			(10,523		)
(Loss) income before income taxes and noncontrolling interests	(1,780		)	13,574
Income tax expense	483			256
Net (loss) income	$	(2,263	)	$	13,318

Revenues

Total revenues for the three months ended September 30, 2016, totaled $70.7 million, an increase of $18.2 million or 34.7%, compared to $52.5 million in the prior corresponding period. Total cases increased 679 or 15.4% versus the prior corresponding period. Medical Segment revenues increased by $19.2 million to $65.4 million, or 41.7% compared to $46.2 million from the prior corresponding period, while the Marketing Segment offset this increase by $1.0 million.

Salaries and Benefits

Operating salaries and benefits for the three months ended September 30, 2016, totaled $13.2 million, an increase of $3.0 million, or 28.8%, compared to $10.3 million in the prior corresponding period. The Medical Segment increased by $2.4 million, or 29.4%, and the Marketing Segment increased $0.5 million period over period.

Drugs and Supplies

Drugs and supplies expense for the three months ended September 30, 2016, totaled $15.5 million, an increase of $7.1 million or 84.1% compared to $8.4 million in the prior corresponding period. The Medical Segment increased by $6.8 million or 83.7%, while the Marketing Segment increased $0.3 million period over period.

General and Administrative

Operating general and administrative expense for three months ended September 30, 2016, totaled $33.2 million, an increase of $12.2 million, or 57.9%, compared to $21.0 million in the prior corresponding period. The Medical Segment accounted for $16.2 million of the increase, offset by a decrease of $4.0 million in the Marketing Segment.

34

Depreciation and Amortization

Depreciation for the three months ended September 30, 2016, totaled $2.0 million, an increase of $0.5 million or 34.8%, compared to $1.5 million the prior corresponding period. This increase is primarily due to an increase in property and equipment acquired through our purchase of three hospitals.

Total Corporate Costs

To illustrate our operational efficiency, corporate costs are presented separate of operating expenses of the revenue generating facilities. Corporate costs totaled $8.0 million, an increase of $0.7 million or 9.0%, compared to $7.3 million in the prior corresponding period. Salaries and benefits for the three months ended September 30, 2016, totaled $1.8 million, an increase of $0.2 million or 14.6%, compared to $1.5 million from the prior corresponding period. The $0.2 million increase is due to the hiring of additional corporate staff in 2016 related to accounting, finance and information technology. Legal expenses for the three months ended September 30, 2016, totaled $1.5 million, an increase of $1.0 million or 194.6%, compared to $0.5 in from the prior corresponding period. The increase in legal expenses was attributable to litigation expenses. General and administrative expenses for the three months ended September 30, 2016, totaled $4.6 million, a decrease of $0.6 million or 11.9%, compared to $5.2 million in the prior corresponding period. The decrease in general and administrative expense was primarily attributable to a decline in non-cash compensation expense for the three months ended September 30, 2016.

Other Expense(Income)

For the three months ended September 30, 2016, the Company recognized $0.7 million of other expense compared to $10.5 million of other income. The change primarily related to a change in warrant and stock option derivative liability of $6.5 million. These warrants and options have exercise prices denominated in Canadian dollars and as such may not be considered indexed to our stock which is valued in U.S. dollars and therefore recorded as derivative liabilities. Change in fair value of warrant and stock option derivative liabilities are a result of adjusting the estimated fair value at the end of the period, using the Black-Scholes Model.

There was a change of $4.4 million bargain purchase gain in the prior period related the acquisition of one of our facilities.

Lastly, interest expense increased $0.4 million as a result of average increase in borrowings and amortization of debt issuance costs.

Income tax expense

The net tax expense for the three months ended September 30, 2016 was $0.5 million, compared to $0.3 million from the prior corresponding period. The temporary differences attributable to the projected taxable income include goodwill amortization, net operating loss carryforward-U.S. and other accrued liabilities. For the three months ended September 30, 2016, the effective tax rate differs from the annual tax rate primarily due to equity compensation, return to provision true-ups, Canada's loss that we do not expect to realize, and noncontrolling interests. The Company’s state tax expense was $0.3 million for the three months ended September 30, 2016. Our effective tax rate during the three months ended September 30, 2016 was approximately -29.3%. The Company estimates an annual effective income tax rate of 32.5% for U.S., and none for Canada, based on projected results for the year.

Noncontrolling Interests

Net income attributable to noncontrolling interests are based on ownership percentages in the Nobilis Facilities that are owned by third parties.

35

MEDICAL SEGMENT

REVENUES

The following table sets out our comparable changes in Medical Segment revenue and case volume for our facilities as of the three months ended September 30, 2016 and 2015 (in thousands, except case and per case data):

	Three Months Ended September 30,
	Revenue (in thousands)				Number of Cases (1)		Revenue per Case (2)
	2016		2015		2016	2015	2016		2015
Hospitals	$	51,886	$	27,954	3,057	1,270	$	16,973	$	22,011
ASCs	11,717		17,313		1,878	2,781	6,239		6,225
Ancillary services	1,816		883		—	—	—		—
Total	$	65,419	$	46,150	4,935	4,051	$	13,256	$	11,392

Notes

(1) This table refers to all cases performed, regardless of their contribution to revenue.

(2) Calculated by dividing revenues by the number of cases.

CASE MIX

The following table sets forth the combined number of cases by medical specialty performed for three months ended September 30, 2016 and 2015:

	2016	2016 %		2015	2015 %
Specialty	Cases	Cases		Cases	Cases
Pain Management	1,852	37.5	%	1,177	29.1	%
Orthopedics	422	8.6	%	420	10.4	%
Spine	511	10.4	%	349	8.6	%
Podiatry	89	1.8	%	130	3.2	%
Gastro-intestinal	9	0.2	%	64	1.6	%
General Surgery	154	3.1	%	187	4.6	%
Plastic & Reconstructive	466	9.4	%	357	8.8	%
Bariatrics	1,063	21.5	%	999	24.7	%
Gynecology	179	3.6	%	231	5.7	%
Urology	—	—	%	3	0.1	%
ENT	190	3.9	%	134	3.3	%
TOTAL	4,935	100	%	4,051	100	%

Notes:     

(1) The table listed above is exclusive of ancillary services which include neuromonitoring, surgical assist and anesthesia services.

36

INN - ONN CONRACT MIX OF TOTAL MEDICAL CASES PERFORMED

The following table sets out the contract mix of cases performed that were in network (“INN”) compared to cases performed that were out of network (“OON”) at our Medical Segment for the three months ended September 30, 2016 and 2015.

	2016		2015
Contract Network Type	Contract Mix		Contract Mix
OON	88.5	%	84.4	%
INN	11.5	%	15.6	%
TOTAL	100	%	100	%

Revenues

Revenues for the Medical Segment increased by $19.2 million to $65.4 million, or 41.5% compared to $46.2 million from the prior corresponding period. Net service patient revenues increased$1,864 per case period over period. Revenues increased primarily due to a 12% increase in the Medical Segment's case volume, and higher acuity cases performed in hospitals receiving larger reimbursements. New center facilities for the Medical Segment increased$19.7 million or 271.1% and we added 1,293 cases or 214.8% primarily due to the acquisition of three hospitals in 2015. Same center facilities for the Medical Segment decreased$0.5 million or 1.2% and cases declined by 409 cases or 11.9% primarily attributable to a decline in ASC revenue, due to the closing of operations of an ASC in Dallas, whose cases were shifted to one of our acquired hospitals.

Salaries and Benefits

Salaries and Benefits for the Medical Segment increased by $2.4 million to $10.5 million, or 29.4% compared to $8.2 million from the prior corresponding period. The staffing costs for the Medical Segment at new facilities accounted for $3.1 million of the increase, while the remaining $0.7 milliondecrease is attributable to staffing at same center facilities driven by case volume declines due to cases being shifted to one of our new hospitals. Operating salaries and benefits increased primarily due to the acquisition of hospitals in 2015 and the additional facility resources required to accommodate the increase in cases over prior year.

Drugs and Supplies

Drugs and supplies expense for the Medical Segment increased by $6.8 million to $14.9 million, or 83.7% compared to $8.1 million from the prior corresponding period. Medical supplies costs for the Medical Segment at new facilities accounted for $6.8 million of the increase. Drugs and supplies increased compared to the prior corresponding period primarily due to the acquisition of three hospitals in 2015. Hospitals require higher drugs and supply costs than ASCs as a result of performing more complex and higher acuity cases.

General and Administrative

General and administrative expense for the Medical Segment increased by $16.2 million to $34.3 million, or 88.9% compared to $18.2 million. The Medical Segment new facilities contributed $11.4 million of the increase while the remaining $4.8 millionincrease was attributable to same center facilities. The increase in the Medical Segment is due to an increase in marketing expenses, and operations associated with Medical Segment facilities, primarily due to the acquisition of hospitals in 2015 and expenses associated with our new lab service line. We accelerated our marketing expense, by deploying a portion of the fourth quarter's marketing budget in the third quarter, related to digital online, social media and direct response television.  The marketing expense acceleration allowed us to avoid higher fourth quarter premiums as a result of the presidential election, continue our strategic growth initiatives and the marketing of our specialty services to hospitals acquired in 2015. In addition, during the third quarter of 2016 we increased our physician marketing expense by adding several new physicians to our direct to consumer marketing program in an effort to drive additional cases in the fourth quarter of 2016, our seasonably highest quarter.

For the three months ended September 30, 2016, marketing expenses allocated to the Medical Segment increased by $6.2 million to $13.5 million, compared to $7.3 million for the corresponding period. These marketing cost are allocated from our Marketing Segment for cases performed at Nobilis Facilities. The acquisition of hospitals allows us to send more cases to owned facilities, resulting in larger allocations of marketing expense from our Marketing Segment to our Medical Segment. As a result, there was a decrease in general and administrative costs within our Marketing Segment, discussed later herein.

37

MARKETING SEGMENT

REVENUES

The following table set out our comparable changes in Marketing Segment revenue and case volumes for our facilities as of the three months ended September 30, 2016 and 2015 (in thousands, except cases and per case data):

	Three Months Ended September 30,
	Revenues						Revenues
	(in thousands)				Number of Cases (1)		per Case (2)
	2016		2015		2016	2015	2016		2015
Marketing	$	5,264	$	6,333	162	367	$	32,494	$	17,256
Total	$	5,264	$	6,333	162	367	$	32,494	$	17,256

Notes

(1) This table refers to all cases performed, regardless of their contribution to revenue.

(2) Calculated by dividing revenues by the number of cases.

CASE MIX

The following table sets forth the combined number of marketing cases for three months ended September 30, 2016 and 2015:

	2016	2016 %		2015	2015 %
Specialty	Cases	Cases		Cases	Cases
Pain Management	87	53.7	%	195	53.1	%
Spine	75	46.3	%	169	46.0	%
Gynecology	—	—	%	3	0.9	%
TOTAL	162	100	%	367	100	%

Notes:

(1) The table listed above is exclusive of ancillary services which include neuromonitoring, surgical assist and

anesthesia services.

INN - ONN CONTRACT MIX OF TOTAL CASES PERFORMED

The following table sets out the contract mix of cases performed that were INN compared to cases performed that were OON at our Marketing Segment for the three months ended September 30, 2016 and 2015.

Contract Network Type	2016 Contract Mix		2015 Contract Mix
OON	56	%	23.9	%
INN	44	%	76.1	%
TOTAL	100	%	100	%

Revenues

Revenues for the Marketing Segment decreased by $1.0 million to $5.3 million, or 16.6% compared to $6.3 million from the prior corresponding period. Marketing Segment revenues decreased primarily due to a decrease of 205 cases. During the third quarter

38

of 2016 management drove more cases to Nobilis owned facilities in the Medical Segment. Revenues increased $15,238 per case period over period, primarily attributable to higher concentrations of OON cases.

Salaries and Benefits

Salaries and benefits for the Marketing Segment increased$0.5 million to $2.6 million compared to $2.1 million from the prior period primarily due to headcount increases to support the continued strategic growth initiatives for expansion related to marketing our specialty programs to two hospitals acquired in 2015.

General and Administrative

General and administrative expense for the Marketing Segment decreased by $4.0 million compared to $2.8 million for the corresponding period. Marketing costs are allocated to our Medical Segment for cases performed at Nobilis Facilities. The decrease in the Marketing Segment's general and administrative expense is attributable to driving cases to our Nobilis facilities. The acquisition of hospitals allows us to send more cases to owned facilities, resulting in larger allocations of marketing expense from our Marketing Segment to our Medical Segment. As a result, we see a decrease in general and administrative costs within our Marketing Segment, discussed later herein.

39

Nine Months Ended September 30, 2016 and 2015

	Nine Months Ended September 30,
	2016			2015
Revenues:
Patient and net professional fees	$	167,199		$	126,661
Contracted marketing revenues	10,754			8,059
Factoring revenues	5,874			4,481
Total revenues	183,827			139,201
Operating expenses:
Salaries and benefits	38,377			26,927
Drugs and supplies	39,670			22,265
General and administrative	85,678			54,625
Bad debt expense	—			1,129
Depreciation and amortization	6,462			3,114
Facility operating expenses	170,187			108,060
Corporate expenses:
Salaries and benefits	5,077			3,532
General and administrative	14,984			17,707
Legal expenses	4,110			1,733
Depreciation	209			99
Total corporate costs	24,380			23,071
(Loss) income from operations	(10,740		)	8,070
Other expense (income) :
Change in fair value of warrant and stock option derivative liabilities	(1,566		)	(4,677		)
Interest expense	2,115			1,106
Bargain purchase gain	—			(4,358		)
Other income, net	(3,011		)	(1,518		)
Total other expense (income)	(2,462		)	(9,447		)
(Loss) income before income taxes and noncontrolling interests	(8,278		)	17,517
Income tax (benefit) expense	(1,766		)	862
Net (loss) income	(6,512		)	16,655

Revenues

Total revenues for the nine months ended September 30, 2016, totaled $183.8 million, an increase of $44.6 million or 32.1%, compared to $139.2 million in the prior corresponding period. Total cases increased1,385 or 11.0% versus the prior corresponding period. Medical Segment revenues increased by $43.3 million to $166.9 million, or 35.1% compared to $123.6 million from the prior corresponding period, while the Marketing Segment accounted for $1.3 million of the increase.

Salaries and Benefits

Operating salaries and benefits for the nine months ended September 30, 2016, totaled $38.4 million, an increase of $11.5 million, or 42.6%, compared to $26.9 million from the prior corresponding period. The Medical Segment increased by $10.7 million, or 52.4%, while the Marketing Segment increased $0.8 million period over period.

Drugs and Supplies

Drugs and supplies expense for the nine months ended September 30, 2016, totaled $39.7 million, an increase of $17.4 million, or 78.2%, compared to $22.3 million from the prior corresponding period. The Medical Segment increased by $17.0 million or 80.8%, while the Marketing Segment increased $0.4 million period over period.

40

General and Administrative

Operating general and administrative expense for the nine months ended September 30, 2016, totaled $85.7 million, an increase of $31.1 million, or 56.8%, compared to $54.6 million from the prior corresponding period. The Medical Segment accounted for $34.1 million of the increase, offset by a decrease of $3.0 million in the Marketing Segment.

Depreciation and Amortization

Operating depreciation for the nine months ended September 30, 2016, totaled $6.5 million, an increase of $3.4 million or 110.7%, compared to $3.1 million from the prior corresponding period. This increase is primarily due to an increase in property and equipment acquired through our purchase of hospitals.

Total Corporate Costs

To illustrate our operational efficiency, corporate costs are presented separate of operating expenses of the revenue generating facilities. Corporate costs for the nine months ended September 30, 2016, totaled $24.4 million, an increase of $1.3 million or 5.7%, compared to $23.1 million from the prior corresponding period. Corporate salaries and benefits for the nine months ended September 30, 2016, totaled $5.1 million, an increase of $1.5 million or 43.7%, compared to $3.5 million from the prior corresponding period. The increase in salaries and benefits is due to the hiring of additional corporate staff in 2016 related to accounting, finance and information technology. Legal expenses for the nine months ended September 30, 2016, totaled $4.1 million, an increase of $2.4 million or 137.2%, compared to $1.7 million from the prior corresponding period. The increase in legal expenses was attributable to increased litigation expenses. General and administrative expenses for the nine months ended September 30, 2016, totaled $15.0 million, a decrease of $2.7 million or 15.4%, compared to $17.7 million from the prior corresponding period. The decrease in general and administrative expense was primarily attributable to a decline in non-cash compensation expense for the nine months ended September 30, 2016, partially offset by an increase in insurance and corporate marketing expense.

Other (Income) Expense

For the nine months ended September 30, 2016, the Company recognized $2.5 million of other income compared to $9.4 million from the corresponding prior period. The change primarily related to a decrease in warrant and stock option derivative liability of $3.1 million. These warrants and options have exercise prices denominated in Canadian dollars and as such may not be considered indexed to our stock which is valued in U.S dollars and therefore recorded as derivative liabilities. Change in fair value of warrant and stock option derivative liabilities are a result of adjusting the estimated fair value at the end of the period, using the Black-Scholes Model.

There was a change of $4.4 million bargain purchase gain in the prior period related to the acquisition of one of our facilities. Other income and a change in warrant and option liability fair value of $3.1 million for the prior corresponding period.

Lastly, interest expense increased $1.0 million as a result of average increase in borrowings and amortization of debt issuance costs.

Income tax (benefit) expense

The net tax benefit for the nine months ended September 30, 2016 was $1.7 million, compared to an income tax expense of $0.9 million from the prior corresponding period. The temporary differences attributable to the projected taxable income include goodwill amortization, net operating loss carryforward-U.S. and other accrued liabilities. For the nine months ended September 30, 2016, the effective tax rate differs from the annual tax rate primarily due to a reduction of 3.8 % due to equity compensation, a 1.6% effective deferred tax rate change, a 3.8% change attributable to Canada's loss that we do not expect to realize and a 4.5% change attributable to noncontrolling interests. The Company’s state tax expense was $0.9 million for the nine months ended September 30, 2016. Our effective tax rate during the nine months ended September 30, 2016 was approximately 21.1%. The Company estimates an annual effective income tax rate of 32.5% for U.S., and none for Canada, based on projected results for the year.

Noncontrolling Interests

Net income attributable to noncontrolling interests are based on ownership percentages in the Nobilis Facilities that are owned by third parties.

41

MEDICAL SEGMENT

REVENUES

The following table sets out our comparable changes in Medical Segment revenue and case volume for our facilities as of the nine months ended September 30, 2016 and 2015 (in thousands, except cases):

	Nine Months Ended September 30, 2016
	Revenue (in thousands)				Number of Cases (1)		Revenue per Case (2)
	2016		2015		2016	2015	2016		2015
Hospitals	$	131,002	$	60,908	7,631	2,771	$	17,167	$	21,981
ASCs	30,464		61,558		5,630	8,788	5,411		7,005
Ancillary services	5,456		1,173		—	—	—		—
Total	$	166,922	$	123,639	13,261	11,559	$	12,587	$	10,696

Notes

(1) This table refers to all cases performed, regardless of their contribution to service revenue.

(2) Calculated by dividing service revenues by the number of cases.

CASE MIX

The following table sets forth the combined number of cases by medical specialty performed for the nine months ended September 30, 2016 and 2015:

	2016	2016 %		2015	2015 %
Specialty	Cases	Cases		Cases	Cases
Pain Management	4,882	36.8	%	3,999	34.6	%
Orthopedics	1,186	8.9	%	946	8.2	%
Spine	1,140	8.6	%	671	5.8	%
Podiatry	260	2.0	%	374	3.2	%
Gastro-intestinal	86	0.6	%	246	2.1	%
General Surgery	481	3.6	%	502	4.3	%
Plastic & Reconstructive	1,262	9.5	%	1,142	9.9	%
Bariatrics	2,872	21.7	%	2,675	23.1	%
Gynecology	569	4.3	%	571	4.9	%
Urology	2	—	%	10	—	%
ENT	521	3.9	%	423	3.8	%
TOTAL	13,261	100	%	11,559	100	%

Notes:     

(1) The table listed above is exclusive of ancillary services which include neuromonitoring, surgical assist and anesthesia services.

42

INN - ONN CONRACT MIX OF TOTAL MEDICAL CASES PERFORMED

The following table sets out the contract mix of cases performed that were INN compared to cases performed that were OON at our Medical Segment for the nine months ended September 30, 2016 and 2015.

Contract Network Type	2016 Contract Mix		2015 Contract Mix
OON	86.4	%	87.8	%
INN	13.6	%	12.2	%
TOTAL	100	%	100	%

Revenues

Revenues for the Medical Segment increased by $43.3 million to $166.9 million, or 35.1% compared to $123.6 million from the prior corresponding period. Revenues also increased $1,891 per case period over period. Revenues increased primarily due to a 12% increase in the Medical Segment's case volume, and higher acuity cases performed in hospitals receiving larger reimbursements. New center facilities for the Medical Segment increased$55.5 million or 557.9% and we added 3,838 cases or 390.8% primarily due to the acquisition of hospitals in 2015. Same center facilities for the Medical Segment decreased$12.2 million or 10.7% and cases declined by 2,136 or 20.2% primarily attributable to a decline in ASC revenue, due to the closing of operations of an ASC in Dallas, whose cases were shifted to one of our acquired hospitals.

Salaries and Benefits

Salaries and Benefits for the Medical Segment increased by $10.7 million to $31.1 million, or 52.4% compared to $20.4 million from the prior corresponding period. The staffing costs for the Medical Segment at new facilities accounted for $12.0 million of the increase, while the remaining $1.3 milliondecrease is attributable to staffing at same center facilities driven by case volume declines due to cases being shifted to one of our new hospitals. Operating salaries and benefits increased primarily due to the acquisition of hospitals in 2015 and the additional facility resources required to accommodate the increase in cases over prior year.

Drugs and Supplies

Drugs and supplies expense for the Medical Segment increased by $17.0 million to $38.0 million, or 80.8% compared to $21.0 million from the prior corresponding period. Medical supplies costs for the Medical Segment at new facilities accounted for $18.5 million of the increase, while the remaining $1.5 milliondecrease was attributable to same center facilities. Drugs and supplies increased compared to the prior corresponding period primarily due to the acquisition of hospitals in 2015. Hospitals require higher drugs and supply costs than ASCs as a result of performing more complex and higher acuity cases.

General and Administrative

General and administrative expense for the Medical Segment increased by $34.1 million to $84.1 million, or 68.2% compared to $50.0 million from the corresponding period. The Medical Segment new facilities contributed to $29.8 million of the increase while the remaining $4.3 millionincrease was attributable to same center facilities. The $34.1 millionincrease in the Medical Segment is due to an increase in marketing expenses and operations associated with Medical Segment facilities, primarily due to the acquisition of hospitals in 2015 and expenses associated with our new lab service line. We accelerated our marketing expense, by deploying a portion of the fourth quarter's marketing budget in the third quarter, related to digital online, social media and direct response television.  The marketing expense acceleration allowed us to avoid higher fourth quarter premiums as a result of the presidential election, continue our strategic growth initiatives and the marketing of our specialty services to hospitals acquired in 2015. In addition, during the third quarter of 2016 we increased our physician marketing expense by adding several new physicians to our direct to consumer marketing program in an effort to drive additional cases in the fourth quarter of 2016, our seasonably highest quarter.

For the nine months ended September 30, 2016, marketing expenses allocated to the Medical Segment increased by $10.1 million to $29.1 million, compared to $19.0 million for the corresponding period. The increase in marketing expenses is attributable to the continued strategic growth initiatives and the marketing of our specialty services to hospitals acquired in 2015.

These marketing cost are allocated from our Marketing Segment for cases performed at Nobilis Facilities. The acquisition of hospitals allows us to send more cases to owned facilities, resulting in larger allocations of marketing expense from our Marketing Segment to our Medical Segment. As a result, there was a decrease in general and administrative costs within our Marketing Segment, discussed later herein.

43

MARKETING SEGMENT

REVENUES

The following table sets out our comparable changes in Marketing Segment revenue and case volumes for our facilities as of the nine months ended September 30, 2016 and 2015 (in thousands, except cases):

	Nine Months Ended September 30, 2016
	Revenue								Revenue
	(in thousands)				Number of Cases (1)				per Case (2)
	2016		2015		2016		2015		2016		2015
Marketing	16,905		15,563		673		990		25,119		15,720
Total	$	16,905	$	15,563	$	673	$	990	$	25,119	$	15,720

Notes

(1) This table refers to all cases performed, regardless of their contribution to service revenue.

(2) Calculated by dividing service revenues by the number of cases.

CASE MIX

The following table sets forth the combined number of marketing cases for the nine months ended September 30, 2016 and 2015:

	2016	2016 %		2015	2015 %
Specialty	Cases	Cases		Cases	Cases
Pain Management	287	42.6	%	590	59.6	%
Spine	382	56.8	%	397	40.1	%
Gynecology	—	—	%	3	0.3	%
Podiatry	3	0.4	%	—	—	%
Bariatrics	1	0.1	%	—	—	%
TOTAL	673	100	%	990	100	%

Notes:

(1) The table listed above is exclusive of ancillary services which include neuromonitoring, surgical assist and

anesthesia services.

INN - ONN CONTRACT MIX OF TOTAL CASES PERFORMED

The following table sets out the contract mix of cases performed that were INN compared to cases performed that were OON at our Marketing Segment for the nine months ended September 30, 2016 and 2015.

Contract Network Type	2016 Contract Mix		2015 Contract Mix
OON	35.1	%	26.5	%
INN	64.9	%	73.5	%
TOTAL	100	%	100	%

Revenues

Revenues for the Marketing Segment increased by $1.3 million to $16.9 million, or 8.4% compared to $15.6 million from the prior corresponding period. Although marketing cases declined 317 cases, during the third quarter of 2016 management drove

44

more cases to Nobilis owned facilities in the Medical Segment. The Marketing Segment's Revenues per case increased$9,399 period over period, primarily attributable to higher concentrations of OON cases.

Salaries and Benefits

Salaries and benefits for the Marketing Segment increased$0.8 million to $7.3 million, or 11.5% compared to $6.5 million period over period primarily due to headcount increases to support the continued strategic growth initiatives related to marketing our specialty programs to hospitals acquired in 2015.

General and Administrative

General and administrative expenses for the Marketing Segment decreased by $3.0 million to $1.6 million, or 65.8% compared to $4.6 million for the prior corresponding period. The increase in marketing expenses is attributable to the continued strategic growth related to marketing our specialty programs to hospitals acquired in 2015.Marketing costs are allocated from our Marketing Segment for cases performed at Nobilis Facilities. The acquisition of hospitals allows us to send more cases to owned facilities, resulting in larger allocations of marketing expense from our Marketing Segment to our Medical Segment. As a result, we see a decrease in general and administrative costs within our Marketing Segment, discussed herein.

Balance Sheet

The Company experienced material variances in certain balance sheet accounts as discussed herein.

Trade Accounts Receivable, net

Accounts receivable as of September 30, 2016, totaled $86.2 million, a decrease of $6.4 million or 6.9%, compared to $92.6 million for the year-ended December 31, 2015. The decrease is a result of strong collections for the nine months ended September 30, 2016

Liquidity and Capital Resources

We are dependent upon cash generated from our operations, which is the major source of financing for our operations and for meeting our contractual obligations. We currently believe we have adequate liquidity to fund operations during the near term through the generation of operating cash flows, cash on hand and access to our senior secured revolving credit facility provided under the Loan Agreement. Our ability to borrow funds under this Loan Agreement is subject to, among other things, the financial viability of the participating financial institutions. While we do not anticipate any of our current lenders defaulting on their obligations, we are unable to provide assurance that any particular lender will not default at a future date.

Cash and cash equivalents at September 30, 2016 and December 31, 2015 were $19.6 million and $15.7 million, respectively.

For the nine months ended September 30, 2016, the Company experienced an increase in net cash provided by operating activities of $6.5 million attributable to a decrease in trade accounts receivable due to lower case volume during the period due to seasonality and cash collections on 2015 accounts. The Company experienced a decrease in net cash used for investing activities of $1.8 million attributable to the purchase of property and equipment and an investment in a surgical facility management company. Net cash used for financing activities decreased by $17.9 million primarily due to proceeds from a one-time private placement in 2015, which did not reoccur in 2016.

As of September 30, 2016, the Company had consolidated net working capital of $61.8 million compared to $63.7 million as of December 31, 2015. The decrease is primarily due to a net decrease of accounts receivable and accounts payable.

We have a $25.0 million debt financing facility with Healthcare Financial Services, LLC ("HFS") (the successor in interest to General Electric Capital Corporation) (the “HFS Term Loan”). Pursuant to the Credit Agreement and ancillary agreements (collectively, the “Loan Agreement”), the HFS Term Loan bears interest at a rate of 4.0% plus LIBOR per annum and amortizes over 20 years with required quarterly payments of principal and interest until the loan matures in March 2020. The revolving loan (the “HFS Revolver”) also bears interest at a rate of 4.0% plus LIBOR per annum and amounts borrowed under the HFS Revolver may be repaid and re-borrowed periodically with a maturity of March 2020. The credit facility is collateralized by the accounts receivable and physical equipment of all 100% owned subsidiaries as well as the Company’s ownership interest in all less-than-wholly owned subsidiaries.

45

We entered into the Sixth Amendment to Credit Agreement (the “Sixth Amendment”), dated as of August 1, 2016, among Northstar Healthcare Acquisitions, L.L.C., HFS and the Credit Parties named therein amending, among other things, added a cap on Investments in Nobilis Health Anesthesia Network, PLLC of $2.0 million; increased the permitted indebtedness of the Company pursuant to that certain Loan Agreement, dated as of July 30, 2015 between PSH and Legacy Texas Bank from 7.0 to 7.05; modified the maximum leverage ratio as of March 31, 2016, to 3.05 to 1.00; and modified the definition of "Subsidiary" to exclude the following entities: Athelite, Dallas Metro, Marsh Lane Surgical Hospital, LLC, Nobilis Health Network, Inc. ("NHN") and the subsidiaries of NHN. As a result, we were in compliance with our covenants under the HFS Term Loan as of September 30, 2016.

We entered into the Seventh Amendment to Credit Agreement (the "Seventh Amendment"), dated as of August 19, 2016, among Healthcare Financial Solutions, LLC, HFS, other credit parties named therein and other financial institutions party thereto. The Seventh Amendment, among other things, increased total borrowing capacity to $36.6 million from $30.6 million. The increased borrowing capacity provided under the Seventh Amendment consist of aggregate term and revolving loan commitments from HFS of $25 million and $11.6 million, respectively.

The Seventh Amendment includes material financial covenants, ratios or tests. The Company must maintain a Consolidated Leverage Ratio of not more than 2.00 to 1.00 and a Consolidated Fixed Charge Coverage Ratio of at least 3.00 to 1.00. Capital Lease Obligations allowed under the covenants increased from $3 million to $6.1 million and the Term Notes' quarterly amortization payment increased under the Seventh Amendment from $250,000 to $312,500 per quarter.

We entered into the Eighth Amendment to Credit Agreement and Limited Waiver, (the "Eighth Amendment"), dated as of October 20, 2016, by and among NHA, other credit parties named therein, HFS and other financial institutions. The purpose of the Amendment was to (i) modify the covenant regarding the Company’s holding company status to permit certain business activities thereunder (ii) define a new permitted lien and an applicable basket with regard to a lien filed by a Company vendor and (iii) amend the management fees covenant to permit payment of certain management fees under the Loan Agreement. As a result, the Company was in compliance with its covenants under the HFS Term Loan as of September 30, 2016.

On July 30, 2015, we secured a $4.5 million term loan from Legacy Texas Bank (the “Legacy Bank Term Loan”). The term loan bears interest at a rate of 4.0% plus LIBOR per annum and requires monthly payments of interest. Monthly payments of principal will commence in August 2016. The Legacy Bank Term Loan matures in July 2020 and is subordinated to the Company’s term loan and revolver with HFS. As of September 30, 2016, the outstanding balance was zero and the Legacy Bank Term Loan was extinguished using the increased borrowing capacity acquired through the Seventh Amendment.

Critical Accounting Policies

Our critical accounting policies are further described 2015 Annual Report. There have been no changes in the nature of our critical accounting policies or the application of those policies since December 31, 2015.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources other than operating leases disclosed in Note 15 included in Part II, Item 8 —"Financial Statements and Supplementary Data” in our 2015 Annual Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The following market risk disclosures should be read in conjunction with the unaudited consolidated financial statements and notes thereto included in this Quarterly Report.

We are subject to market risk from exposure to changes in interest rates based on our financing, investing and cash management activities. We do not, however, hold or issue financial instruments or derivatives for trading or speculative purposes. At September 30, 2016, the following components of our Loan Agreement bears interest at variable rates at specified margins above either the agent bank’s alternate base rate or the LIBOR rate: (i) a $25 million, 5-year term loan; and (ii) an $11.6 million, 5-year revolving credit facility.

Although changes in the alternate base rate or the LIBOR rate would affect the cost of funds borrowed in the future, we believe the effect, if any, of reasonably possible near-term changes in interest rates on our remaining variable rate debt or our consolidated financial position, results of operations or cash flows would not be material. Holding other variables constant, including levels of

46

indebtedness, a 0.125% increase in current interest rates would have no estimated impact on pre-tax earnings and cash flows for the next twelve month period given the 0.70215% LIBOR floor that exists in our Loan Agreement.

Foreign Currency Exchange Rate Risk

The Company holds cash balances in both U.S. and Canadian dollars. We transact most of our business in U.S. and Canadian dollars. As a result, currency exchange fluctuations may impact our operating costs. We do not manage our foreign currency exchange rate risk through the use of financial or derivative instruments, forward contracts or hedging activities.

In general, the strengthening of the U.S. dollar will positively impact our expenses transacted in Canadian dollars. Conversely, any weakening of the U.S dollar will increase our expenses transacted in Canadian dollars. We do not believe that any weakening of the U.S. dollar as compared to the Canadian dollar will have an adverse material effect on our operations.

Interest Rate Risk

The Company’s investment policy for its cash and cash equivalents is focused on the preservation of capital and supporting the liquidity requirements of the Company. The Company’s interest earned on its cash balances is impacted on the fluctuations of U.S. and Canadian interest rates. We do not use interest rate derivative instruments to manage exposure to interest rate changes. We do not believe that interest rate fluctuations will have any effect on our operations.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, consisting of controls and other procedures designed to give reasonable assurance that information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our chief executive officer (“CEO”) and our chief financial officer (“CFO”), to allow timely decisions regarding such required disclosure.

Under the supervision and with the participation of our management, including our CEO and our CFO, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, at the end of the period covered by this report (the “evaluation date”). In conducting its evaluation, management considered the material weaknesses in our disclosure controls and procedures and internal control over financial reporting described in Part II, Item 9A—Controls and Procedures of our 2015 Annual Report.

We are currently working to remediate the material weaknesses identified in our 2015 Annual Report and in this Quarterly Report. As of the evaluation date, our CEO and CFO have concluded that we did not maintain disclosure controls and procedures that were effective in providing reasonable assurances that information required to be disclosed in our reports filed under the Securities Exchange act of 1934 was recorded, processed, summarized and reported within the time periods prescribed by SEC rules and regulations, and that such information was not accumulated and communicated to our management to allow timely decisions regarding required disclosures.

In light of these material weaknesses, in preparing our financial statements as of and for the quarters ended September 30, 2016 and 2015, we performed additional analyses and procedures to ensure that our consolidated financial statements included in this Quarterly Report have been prepared in accordance with U.S. GAAP.

Our management has been actively engaged in remediation efforts to address the material weaknesses, as well as other identified areas of risk. These remediation efforts, outlined below, are intended to address the identified material weaknesses and to enhance our overall control environment:

• On July 9, 2015, we appointed Mr. Kenneth Klein to serve as the Company’s Chief Financial Officer. Our previous CFO assumed other responsibilities with our accounting and finance organization.

• On May 9, 2016, we appointed Mr. Marcos Rodriguez to serve as the Company’s Chief Accounting Officer.

• We strengthened our accounting and financial reporting group with the addition of several new professionals with knowledge, experience and training in the application of U.S. GAAP to our accounting and finance organization. We also engaged third party accountants during the fourth quarter of 2015 who are providing assistance with significant, infrequently occurring transactions.

47

• We are currently reviewing and implementing remediation steps providing for more detailed supervisory review processes as part of our financial statement close process.

• On September 21, 2015, we appointed Dr. Lee McMillian to serve as the Company’s Vice President of Information Technology. This was a newly created position for the Company.

• During the fourth quarter of 2015 and the first quarter of 2016, we strengthened our information technology department by adding six information technology professionals with knowledge of security, networking and infrastructure.

• We have also invested approximately $320 thousand in hardware and software upgrades.

• As of January 2016, we implemented a process to review third party service providers’ Service Organization Controls reports.

• In February 2016, we implemented a control to periodically review the access granted in order to ensure that users of our information systems had the appropriate access relative to the user’s job responsibilities. A new user access form was created that captured appropriate authorizations, not only for access to financial systems but for other sensitive systems as well. Furthermore, certain sensitive levels of access have been identified, which require further approvals from Company’s management.

• In February 2016, we created controls to ensure that policies and procedures are followed with respect to application change management in certain of the Company’s proprietary software, which involves multiple levels of approval and periodic change management review.

• In February 2016, we began restricting and maintaining network access accounts to only employees in the information technology department and implemented compensating controls, including periodic audits of network access.

• During the third quarter of 2016, we engaged third party internal control consultants to perform a benchmarking review of our internal control environment and documentation.

Management believes that the foregoing efforts will effectively remediate the material weaknesses. As we continue to evaluate and work to improve our internal control over financial reporting, management may determine to take additional measures to address the material weaknesses or to modify the remediation plan described above. The material weaknesses will not be considered remediated until the enhanced controls have been tested and determined to be designed and operating effectively.

Our executive management team, together with our Board of Directors, is committed to achieving and maintaining a strong control environment, high ethical standards, and financial reporting integrity.

Changes in Internal Control Over Financial Reporting

Except as discussed immediately above in the Evaluation of Disclosure Controls and Procedures, there has been no change in our internal control over financial reporting during the nine months ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

See Part I, Item 1—"Financial Statements, Note 20 - Commitments and contingencies" of this Quarterly Report for an update on ongoing legal proceedings. Such information is incorporated into this Part II, Item 1—"Legal Proceedings" by reference.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our 2015 Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

48

Item 5. Other Information

None.

49

Item 6. Exhibits

Exhibit	Description
10.1	Amended and Restated Purchase Agreement among Northstar Healthcare Acquisitions L.L.C., Nobilis Health Corp., Arizona Center for Minimally Invasive Surgery, LLC, Arizona Vein & Vascular Center, LLC, L. Philipp Wall, M.D., P.C., and L. Philipp Wall dated October 28, 2016 (incorporated by reference to Exhibit 10.1 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
10.2	Convertible Promissory Note in principal amount of $2,250,000 dated October 28, 2016 (incorporated by reference to Exhibit 10.2 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
10.3	Employment Agreement by and between Nobilis Health Corp., Northstar Healthcare Acquisitions, LLC and L. Philipp Wall, MD dated October 28, 2016 (incorporated by reference to Exhibit 10.3 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
10.4	Credit Agreement dated as of October 28, 2016 among Nobilis Health Corp., Northstar Healthcare Holdings, Inc., Northstar Healthcare Acquisitions, L.L.C., the Loan Parties named therein, Compass Bank, LegacyTexas Bank, the other lenders party thereto, and BBVA Compass (incorporated by reference to Exhibit 10.4 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
10.5	Pledge Agreement in favor of Compass Bank dated as of October 28, 2016 (incorporated by reference to Exhibit 10.5 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
10.6	Guaranty and Security Agreement dated as of October 28, 2016 by and among Northstar Healthcare Acquisitions, L.L.C., the other parties thereto and Compass Bank (incorporated by reference to Exhibit 10.6 to Nobilis Health Corp.'s Current Report on Form 8-K filed with the SEC on November 3, 2016)
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002
32.1*	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
* 101.INS	XBRL Instance Document
* 101.SCH	XBRL Taxonomy Extension Schema Document
* 101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
* 101.LAB	XBRL Taxonomy Extension Label Linkbase Document
* 101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
* 101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

*filed herewith

50

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NOBILIS HEALTH CORP.

Date: November 7, 2016
By:	/s/ Kenneth Klein
	Kenneth Klein
	Chief Financial Officer
	(Principal Financial and Duly Authorized Officer)

51

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Harry Fleming, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2016 of Nobilis Health Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016

/s/ Harry Fleming

Harry Fleming

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kenneth Klein, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2016 of Nobilis Health Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2016

/s/ Kenneth Klein

Kenneth Klein

Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Nobilis Health Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Harry Fleming, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/ s/ Harry Fleming

Harry Fleming

Chief Executive Officer

November 7, 2016

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Nobilis Health Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kenneth Klein, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Kenneth Klein

Kenneth Klein

Chief Financial Officer

November 7, 2016

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 28, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Trading Symbol	hlth
Entity Registrant Name	Nobilis Health Corp.
Entity Central Index Key	0001409916
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		76,877,014
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 19,614	$ 15,666
Trade accounts receivable, net of allowance of $2,144 at September 30, 2016 and $5,165 at December 31, 2015	86,170	92,569
Medical supplies	4,321	4,493
Prepaid expenses and other current assets	3,727	2,789
Total current assets	113,832	115,517
Property and equipment, net	34,638	35,303
Intangible assets, net	18,268	19,619
Goodwill	44,833	44,833
Deferred tax asset	27,470	25,035
Other long-term assets	1,942	1,720
Total Assets	240,983	242,027
Current Liabilities:
Trade accounts payable	19,702	23,381
Accrued expenses	20,661	16,648
Current portion of capital leases	3,484	5,193
Current portion of long-term debt	1,006	1,243
Current portion of warrant and stock option derivative liabilities	380	332
Other current liabilities	6,802	5,025
Total current liabilities	52,035	51,822
Lines of credit	8,135	3,000
Long-term capital leases, net of current portion	12,711	13,654
Long-term debt, net of current portion	22,826	21,469
Warrant and stock option derivative liabilities, net of current portion	1,537	2,619
Other long-term liabilities	3,523	3,386
Total liabilities	100,767	95,950
Commitments and Contingencies
Contingently redeemable noncontrolling interest	10,567	12,225
Shareholders' Equity:
Common shares, no par value, unlimited shares authorized, 76,855,014 and 73,675,979 shares issued and outstanding, respectively	0	0
Additional paid in capital	218,724	211,827
Accumulated deficit	(88,410)	(85,491)
Total shareholders’ equity attributable to Nobilis Health Corp.	130,314	126,336
Noncontrolling interests	(665)	7,516
Total shareholders' equity	129,649	133,852
Total Liabilities and Shareholders' Equity	$ 240,983	$ 242,027

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 2,144	$ 5,165
Common shares issued (in shares)	76,885,014	73,675,979
Common shares outstanding (in shares)	76,885,014	73,675,979

XML

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Patient and net professional fees	$ 65,666	$ 46,237	$ 167,199	$ 126,661
Contracted marketing revenues	2,604	4,410	10,754	8,059
Factoring revenues	2,413	1,836	5,874	4,481
Total revenues	70,683	52,483	183,827	139,201
Bad debt expense			0	1,129
(Loss) income from operations	(1,101)	3,051	(10,740)	8,070
Other expense (income) :
Change in fair value of warrant and stock option derivative liabilities	133	(6,381)	(1,566)	(4,677)
Interest expense	744	322	2,115	1,106
Bargain purchase gain	0	(4,358)	0	(4,358)
Other income, net	(198)	(106)	(3,011)	(1,518)
Total other expense (income)	679	(10,523)	(2,462)	(9,447)
(Loss) income before income taxes and noncontrolling interests	(1,780)	13,574	(8,278)	17,517
Income tax expense (benefit)	483	256	(1,766)	862
Net (loss) income	(2,263)	13,318	(6,512)	16,655
Net income (loss) attributable to noncontrolling interests	496	2,375	(3,594)	10,617
Net (loss) income attributable to Nobilis Health Corp.	$ (2,759)	$ 10,943	$ (2,918)	$ 6,038
Net (loss) income per basic common share (in dollars per share)	$ (0.04)	$ 0.15	$ (0.04)	$ 0.09
Net (loss) income per fully diluted common share (in dollars per share)	$ (0.04)	$ 0.14	$ (0.04)	$ 0.08
Weighted average shares outstanding (basic) (in shares)	76,774,967	70,935,587	76,114,538	65,310,610
Weighted average shares outstanding (fully diluted) (in shares)	76,774,967	77,656,264	76,114,538	75,067,623
Operating expenses:
Revenues:
Salaries and benefits	$ 13,209	$ 10,255	$ 38,377	$ 26,927
Drugs and supplies	15,473	8,405	39,670	22,265
General and administrative	33,195	21,025	85,678	54,625
Bad debt expense	0	929	0	1,129
Depreciation and amortization	1,952	1,522	6,462	3,114
Operating expenses	63,829	42,136	170,187	108,060
Corporate expenses:
Revenues:
Salaries and benefits	1,765	1,540	5,077	3,532
General and administrative	4,576	5,192	14,984	17,707
Legal expenses	1,535	521	4,110	1,733
Depreciation and amortization	79	43	209	99
Operating expenses	$ 7,955	$ 7,296	$ 24,380	$ 23,071

XML

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (6,512)	$ 16,655
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	6,671	3,213
Bad debt expense	0	1,129
Share-based compensation, net	5,226	12,469
Change in fair value of warrant and stock option derivative liabilities	(1,566)	(4,677)
Recoupment of indemnified expenses	0	(1,700)
Deferred income taxes	(2,435)	0
Bargain purchase gain	0	(4,358)
Gain on sale of property and equipment	(265)	0
Earnings from equity method investment	(1,000)	0
Amortization of deferred financing fees	112	66
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed:
Trade accounts receivable	6,399	(11,962)
Medical supplies	172	(612)
Prepaid expenses and other current assets	(938)	(2,095)
Other long-term assets	152	(37)
Trade accounts payable and accrued liabilities	334	(4,372)
Other current liabilities	1,777	(900)
Other long-term liabilities	137	19
Distributions from equity method investments	1,079	0
Net cash provided by operating activities	9,343	2,838
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,388)	(2,533)
Investment in associate	0	(206)
Purchase of equity method investment	(609)	0
Note receivable, net	(150)	197
Acquisition of Victory	0	(1,436)
Acquisition of Peak	0	(849)
Acquisition of Peak, net of cash acquired	0	(1,299)
Deconsolidation of imaging centers and urgent care clinic	0	(166)
Net cash used for investing activities	(4,847)	(6,686)
CASH FLOWS FROM FINANCING ACTIVITIES:
Distributions to noncontrolling interests	(6,245)	(9,015)
Proceeds from exercise of stock options	2,074	521
Proceeds from exercise of stock warrants	130	4,343
Proceeds from private placement	0	28,395
Payments on capital lease obligations	(2,652)	(719)
Proceeds (payments) from line of credit	5,135	(5,420)
Proceeds from debt	6,440	20,000
Payments on debt	(5,026)	(20,124)
Deferred financing fees	(404)	(662)
Net cash (used for) provided by financing activities	(548)	17,319
NET INCREASE IN CASH	3,948	13,525
CASH — Beginning of period	15,666	7,568
CASH — End of period	$ 19,614	$ 21,093

XML

COMPANY DESCRIPTION

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

COMPANY DESCRIPTION

COMPANY DESCRIPTION

Nobilis Health Corp. (“Nobilis” or the “Company”) was incorporated on March 16, 2007 under the name "Northstar Healthcare Inc." pursuant to the provisions of the British Columbia Business Corporations Act. On December 5, 2014, Northstar Healthcare Inc. changed its name to Nobilis Health Corp. The Company owns and manages health care facilities in the States of Texas and Arizona, consisting primarily of ambulatory surgery centers and acute-care surgical hospitals. In 2014, through its acquisition of Athas Health, LLC (“Athas”), the Company expanded its service offering within the health care industry to include providing contracted marketing services and accounts receivable factoring.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying interim consolidated financial statements have not been audited by the Company’s independent registered public accounting firm, except that the Consolidated Balance Sheet at December 31, 2015, is derived from previously audited consolidated financial statements. In the opinion of management, all material adjustments, consisting of normal recurring adjustments, necessary for fair presentation have been included. These interim consolidated financial statements include all accounts of the Company. All significant intercompany transactions and accounts have been eliminated upon consolidation.

Certain reclassifications have been made to prior period amounts to conform to current period financial statement classifications. The reclassifications included in these comparative consolidated financial statements are (i) a change in presentation of other comprehensive income and (ii) a reclassification from cost of goods sold to operating expenses. The reclassifications were deemed to be immaterial to the consolidated financial statements both individually and in the aggregate.

These consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. Therefore, these interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Annual Report”) filed with the SEC on March 15, 2016. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

There have been no material changes to the Company’s critical accounting policies or estimates from those disclosed in the 2015 Annual Report.

Recent Accounting Pronouncements

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). This update changes how entities account for and measure the fair value of certain equity investments and updates the presentation and disclosure of certain financial assets and liabilities. This new ASU is effective for annual and interim periods beginning on or after December 15, 2017, and for interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact that ASU 2016-01 will have on the Company’s consolidated financial position and disclosures.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net) (“ASU 2016-08”). The amendments address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The ASU clarifies that an entity should evaluate whether it is the principal or the agent for each specified good or service promised in a contract with a customer. The amendments affect the guidance in ASU 2014-09 which is not yet effective. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company is currently evaluating the new guidance to determine the method of adoption that it will use and the impact it will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU-2016-09"). ASU 2016-09 impacts several aspects of the accounting for share-based payment transactions, including classification of certain items on the Consolidated Statement of Cash Flows and accounting for income taxes. Specifically, the ASU requires that excess tax benefits and tax deficiencies (the difference between the deduction for tax purposes and the compensation cost recognized for financial reporting purposes) be recognized as income tax expense or benefit in the Consolidated Statement of Operations, introducing a new element of volatility to the provision for income taxes. ASU No. 2016-09 is effective on January 1, 2017, with early adoption permitted. The transition method varies for each of the areas in the ASU. The Company is currently evaluating the impact of adopting this new accounting standard on its results of operations and financial position.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies the guidance in ASU 2014-09 regarding assessing whether promises to transfer goods or services are distinct, and whether an entity's promise to grant a license provides a customer with a right to use or right to access the entity's intellectual property. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). This Update provides for amendments to ASU 2014-09, amending the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. Specifically, ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides guidance on how certain cash receipts and cash payments are to be presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.

XML

SUPPLEMENTAL CASH FLOWS

9 Months Ended

Sep. 30, 2016

Supplemental Cash Flow Elements [Abstract]

SUPPLEMENTAL CASH FLOWS

SUPPLEMENTAL CASH FLOWS

The supplemental cash flows information for the nine months ended September 30, 2016 and 2015 are comprised of the following (in thousands):

	Nine Months Ended September 30,
	2016		2015
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	2,052	$	1,129
Cash paid for taxes	$	2,279	$	633
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash acquisition of property and equipment	$	—	$	15,345
Non-cash acquisition of goodwill and intangibles	$	—	$	13,532
Non-cash deconsolidation of property and equipment	$	—	$	2,828
Non-cash deconsolidation of goodwill	$	—	$	701
Athas settlement in lieu of contingent shares	$	—	$	5,685

XML

ACQUISITIONS

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

ACQUISITIONS

ACQUISITIONS

Scottsdale Liberty Hospital (SLH)

In November 2015, the Company acquired a 60% interest in Freedom Pain Hospital (n/k/a SLH) located in Scottsdale, Arizona. The Company acquired management control of the entity which was formed to own and operate the successor hospital. The transaction was treated as a business combination.

The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition (in thousands):

	November 1, 2015
Net assets acquired:
Trade accounts receivable	$	82
Prepaid expenses and other current assets	36
Inventory	69
Property and equipment	13,266
Other long-term assets	113
Goodwill	6,932
Tradename	160
Hospital license	12
Net assets acquired	$	20,670
Net liabilities assumed:
Trade accounts payable	$	2,668
Accrued liabilities	419
Current portion of capital leases	658
Long-term portion of capital leases	12,213
Total liabilities assumed	$	15,958
Consideration:
Cash, net of cash acquired	$	3,180
Noncontrolling Interest	1,532
Total consideration	$	4,712

Unaudited Supplemental Pro Forma Information

The following unaudited supplemental pro forma financial information includes the results of operations for SLH, and is presented as if the acquired company had been consolidated as of the beginning of the year immediately preceding the year in which the company was acquired. The unaudited supplemental pro forma financial information has been provided for illustrative purposes only and does not purport to be indicative of the actual results that would have been achieved by combining the companies for the periods presented, or of the results that may be achieved by the combined companies in the future. Further, results may vary significantly from the results reflected in the following unaudited supplemental pro forma financial information because of future events and transactions, as well as other factors.

There were no acquisitions during the period ended September 30, 2016, thus the consolidated financial statements for the period include full financial results of all consolidated subsidiaries. The following table shows our pro forma results for the nine months ended September 30, 2015(in thousands, except per share amounts):

	September 30, 2015
Revenue	$	139,774
Income from operations	$	8,225
Net income attributable to noncontrolling interests	$	10,360
Net income attributable to common stockholders	$	6,282
Net income per basic common share	$	0.10

XML

TRADE ACCOUNTS RECEIVABLE, NET

9 Months Ended

Sep. 30, 2016

Receivables [Abstract]

TRADE ACCOUNTS RECEIVABLE, NET

TRADE ACCOUNTS RECEIVABLE, NET

A detail of trade accounts receivable, net as of September 30, 2016 and December 31, 2015 is as follows (in thousands):

	September 30, 2016			December 31, 2015
Trade accounts receivable	$	84,573		$	95,114
Allowance for doubtful accounts	(2,144		)	(5,165		)
Receivables transferred	(357		)	(298		)
Receivables purchased	4,098			2,918
Trade accounts receivable, net	$	86,170		$	92,569

Bad debt expense was zero for the three and nine months ended September 30, 2016 and was $0.9 million and $1.1 million for the three and nine months ended September 30, 2015 respectively.

From time to time, we transfer to third parties certain of our accounts receivable balances on a non-recourse basis in return for advancement on payment to achieve a faster cash collection. As of September 30, 2016 and December 31, 2015, there remained a balance of $0.4 million and $0.3 million, respectively, in transferred receivables pursuant to the terms of the original agreement. For the three months ended September 30, 2016 and 2015, the Company received advanced payments of $0.1 million and $0.3 million, respectively. During the same time period, the Company transferred $0.8 million and $1.4 million of receivables, net of advancement of payment. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee. For the nine months ended September 30, 2016 and 2015, the Company received advanced payments of $0.6 million and $1.4 million, respectively. During the same time period, the Company transferred $4.9 million and $5.2 million of receivables, respectively. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee.

Athas, Peak Neuromonitoring (“Peak”), and Nobilis Surgical Assist (“First Assist”) purchase receivables from physicians, at a discount, on a non-recourse basis. The discount and purchase price vary by specialty and are recorded at the date of purchase, which generally occurs 30 to 45 days after the accounts are billed. These purchased receivables are billed and collected by Athas, Peak, and First Assist and they retain 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables. Gross revenue from purchased receivables was $4.6 million and $3.2 million for the three months ended September 30, 2016 and 2015, respectively. Gross revenue from purchased receivables was $11.2 million and $8.3 million for the nine months ended September 30, 2016 and 2015, respectively. Revenue, net of the discounted purchase price, was $2.4 million and $1.8 million for the three months ended September 30, 2016 and 2015, respectively. Revenue, net of the discounted purchase price, was $5.9 million and $4.5 million for the nine months ended September 30, 2016 and 2015, respectively. Accounts receivable for purchased receivables was $4.1 million and $2.9 million for the nine months ended September 30, 2016 and year-ended December 31, 2015, respectively. Revenue from receivables purchased is recorded in the factoring revenue line item within the Consolidated Statements of Operations.

XML

INVESTMENTS IN ASSOCIATES

9 Months Ended

Sep. 30, 2016

Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]

INVESTMENTS IN ASSOCIATES

INVESTMENTS IN ASSOCIATES

During the first quarter of 2015, The Company completed the deconsolidation of two imaging centers and one urgent care clinic in Houston, which consisted of the following entities: Spring Northwest Management, LLC, Spring Northwest Operating, LLC, Willowbrook Imaging, LLC, GRIP Medical Diagnostics, LLC and KIRPA Holdings, LLC. The Company resigned as the manager of these facilities resulting in loss of control and its rights to exercise significant influence. The Company retained investments in these facilities that are accounted for as cost method investments beginning January 1, 2015. The carrying value as of September 30, 2016 and December 31, 2015 was $0.7 million. The investments are classified as other long-term assets in the Consolidated Balance Sheets.

In March 2016, the Company acquired a 58% interest in Athelite Holdings LLC ("Athelite"), a holding company with a 70% interest in Dallas Metro Surgery Center LLC ("Dallas Metro"), a company formed to provide management services to a Hospital Outpatient Department (“HOPD”). In April 2016, Athelite interest in Dallas Metro was reduced to 62%. The Athelite investment is accounted for as an equity method investment as the Company did not obtain the necessary level of control for the investment to be accounted for as a business combination. This is due to the fact that the Company does not have the ability to directly appoint a majority of the board members of Dallas Metro or independently make strategic operational decisions. The carrying value as of September 30, 2016 was $0.5 million. The investment is classified as other long-term assets in the Consolidated Balance Sheets.

XML

FINANCIAL INSTRUMENTS AND CONCENTRATION

9 Months Ended

Sep. 30, 2016

Investments, All Other Investments [Abstract]

FINANCIAL INSTRUMENTS AND CONCENTRATION

FINANCIAL INSTRUMENTS AND CONCENTRATION

In common with all other businesses, the Company is exposed to risks that arise from its use of financial instruments. This note describes the Company’s objectives, policies and processes for managing those risks and the methods used to measure them. Further quantitative information in respect to these risks is presented throughout these consolidated financial statements.

Principal financial instruments

The principal financial instruments used by the Company, from which financial instrument risk arises, are as follows:

• Accounts receivable and other receivables

• Investments in associates

• Accounts payable, accrued liabilities and other current liabilities

• Other liabilities and notes payable

• Capital leases

• Lines of credit

• Debt

• Warrants

• Non-employee stock options

The carrying amounts of the Company’s cash, accounts receivable and other receivables, accounts payable, accrued liabilities, other current liabilities and other liabilities as reflected in the consolidated financial statements approximate fair value due to their short term maturity. The estimated fair value of the Company's other long-term debt instruments approximate their carrying amounts as the interest rates approximate the Company's current borrowing rate for similar debt instruments of comparable maturity, or have variable interest rates.

Financial instruments - risk management

The Company’s financial instrument risks include, but are not limited to the following:

• Credit risk

• Fair value risk

• Foreign exchange risk

• Other market price risk

• Liquidity risk

• Interest rate risk

Credit risk

Credit risk is the risk of financial loss to the Company if a patient, non-partner surgeon or insurance company fails to meet its contractual obligations. The Company, in the normal course of business, is exposed mainly to credit risk on its accounts receivable from insurance companies, other third-party payors, and physicians. Accounts receivables are net of applicable bad debt reserves, which are established based on specific credit risk associated with insurance companies, payors and other relevant information.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due and arises from the Company’s management of working capital. The Company’s objective to managing liquidity risk is to ensure that it will have sufficient cash to allow it to meet its liabilities when they become due. To achieve this objective, it seeks to maintain cash balances (or agreed credit facilities) to meet expected requirements. The liquidity risk of the Company and its subsidiaries is managed centrally by the Company’s finance function. The Company believes that there are currently no concerns of its ability to meet its liabilities as they become due for the foreseeable future.

The following tables set forth certain information with respect to the Company’s payor concentration. Patient and net professional fee revenues by payor are summarized below for the applicable periods:

MEDICAL SEGMENT

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.3	%	94.4	%	96.2	%	94.7	%
Workers compensation	3.4	%	5.1	%	3.4	%	4.8	%
Medicare	0.3	%	0.5	%	0.4	%	0.5	%
Total	100	%	100	%	100	%	100	%

MARKETING SEGMENT

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	100.0	%	100.0	%	100.0	%	100.0	%
Workers compensation	0.0	%	0.0	%	0.0	%	0.0	%
Medicare	0.0	%	0.0	%	0.0	%	0.0	%
Total	100	%	100	%	100	%	100	%

CONSOLIDATED SEGMENTS

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.8	%	95.1	%	96.7	%	95.2	%
Workers compensation	3.0	%	4.5	%	3.0	%	4.3	%
Medicare	0.2	%	0.4	%	0.3	%	0.5	%
Total	100	%	100	%	100	%	100	%

Three facilities represent approximately 75.1% and 83.0% of the Company’s contracted marketing revenue for the three and nine months ended September 30, 2016, and three facilities represent approximately 83.6% of the Company’s contracted marketing accounts receivable as of September 30, 2016.

Market risk

Market risk is the risk that the fair value of future cash flows of financial instruments will fluctuate due to changes in interest rates and/or foreign currency exchange rates.

Interest rate risk

The Company entered into a revolving line of credit that, from time to time, may increase interest rates based on market index.

Foreign exchange risk

Foreign exchange risk arises because the Company has certain expenses that are incurred in Canadian dollars.

The Company is also exposed to currency risk on purchases made from vendors based in Canada. The Company has Canadian denominated cash (“Cdn”) of $0.2 million and a nominal amount of trade payables at September 30, 2016. The Company had Cdn of $0.3 million and a nominal amount of trade payables at December 31, 2015.

XML

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The following table presents a summary of items comprising accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Accrued expenses:
Accrued salaries and related benefits	$	3,941	$	5,309
Other	16,720		11,339
Total accrued expenses	$	20,661	$	16,648
Other current liabilities:
Estimated amounts due to third party payors	$	6,348	$	3,795
Other	454		1,230
Total other current liabilities	$	6,802	$	5,025

XML

OTHER LONG-TERM LIABILITIES

9 Months Ended

Sep. 30, 2016

Other Liabilities Disclosure [Abstract]

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES

The Company assumed real property leases as part of certain acquisitions which required the Company to pay above market rentals through the remainder of the lease terms. Of the $3.5 million balance in other long-term liabilities at September 30, 2016, approximately $3.2 million of that balance relates to unfavorable leases. The unfavorable lease liability is amortized as a reduction to rent expense over the contractual periods the Company is required to make rental payments under the leases. Estimated amortization of unfavorable leases for the five years and thereafter subsequent to December 31, 2015, is $0.1 million for the remainder of 2016, $0.5 million for 2017 and $0.3 million for 2018, 2019, 2020, and $2.2 million thereafter.

XML

LINES OF CREDIT

9 Months Ended

Sep. 30, 2016

Line of Credit Facility [Abstract]

LINES OF CREDIT

LINES OF CREDIT

On March 31, 2015, the Company secured a $5.0 million revolving line of credit from Healthcare Financial Services, LLC (f/k/a General Electric Capital Corporation), or “HFS” (the “HFS Revolver”) maturing in March 2020, which was subsequently amended and increased to $11.6 million on August 19, 2016. The HFS Revolver bears interest at a rate of 4% plus LIBOR per annum (effective rate of 5.24% at September 30, 2016) and requires quarterly interest payments. Principal amounts borrowed under the HFS Revolver may be repaid and re-borrowed periodically. The HFS Revolver is collateralized in the same manner as the HFS term loan discussed in Note 11 - Debt. As of September 30, 2016 and December 31, 2015, $8.1 million and $3.0 million, respectively, were outstanding under the HFS Revolver.

The revolving line of credit is subject to certain restrictive covenants in conjunction with the HFS Term Loan, as defined in Note 11 - Debt.

On July 30, 2015, the Company issued a $1.5 million letter of credit to the Landlord of the PSH (“PSH Landlord”) facility in connection with the execution of the hospital facility lease. The PSH Landlord shall have the right to draw upon the letter of credit in an event of default. The letter of credit is secured by the $5.0 million HFS Revolver, which was subsequently amended and increased to $11.6 million on August 19, 2016.

On May 18, 2016, the Company secured a $3.0 million revolving line of credit from Legacy Texas Bank (the “Legacy Revolver”). The Legacy Revolver bears interest at a rate of 4% plus LIBOR per annum on drawn funds and requires monthly payments of interest. Monthly payments of principal commenced in September 2016. As of September 30, 2016, the outstanding balance was zero and the Legacy Revolver was extinguished using the increased borrowing capacity acquired through the Seventh Amendment to Credit Agreement ( the "Seventh Amendment") discussed in Note 11 - Debt.

XML

DEBT

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

DEBT

DEBT

On March 31, 2015, the Company secured a $20.0 million term loan from HFS (the “HFS Term Loan”), which was subsequently amended and increased to $25.0 million on August 19, 2016. The HFS Term Loan bears interest at a rate of 4% plus LIBOR per annum (effective rate of 5.24% at September 30, 2016) and requires quarterly payments of principal and interest until it matures in March 2020. The HFS Term Loan provides for a 0.70% LIBOR floor. The HFS Term Loan is collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries.

The HFS Term Loan primarily served to refinance all previously held debt and lines of credit. Debt issuance costs associated with the new credit facility approximated $1.0 million. The issuance costs are a direct deduction from the carrying value of the HFS Term Loan, amortized using the interest method and reported as interest expense on our statement of operations. As of September 30, 2016, the outstanding balance of the HFS Term Loan was $24.7 million.

The Company entered into the Sixth Amendment to Credit Agreement (the "Sixth Amendment"), dated as of August 1, 2016, among Northstar Healthcare Acquisitions, L.L.C. ("NHA"), HFS and the credit parties named therein. The Sixth Amendment among other things, added a cap on Investments in Nobilis Health Anesthesia Network, PLLC of $2.0 million; increased the permitted indebtedness of the Company pursuant to that certain Loan Agreement, dated as of July 30, 2015, between PSH and Legacy Texas Bank from 7.0 to 7.05; modified the maximum leverage ratio as of March 31, 2016, to 3.05 to 1.00; and modified the definition of "Subsidiary" to exclude the following entities: Athelite, Dallas Metro, Marsh Lane Surgical Hospital, LLC, Nobilis Health Network, Inc. ("NHN") and the subsidiaries of NHN.

The Company entered into the Seventh Amendment, dated as of August 19, 2016, among HFS, other credit parties named therein and other financial institutions. The Seventh Amendment, among other things, increased total borrowing capacity to $36.6 million from $30.6 million. The increased borrowing capacity provided under the Seventh Amendment consisted of aggregate term and revolving loan commitments from HFS of $25 million and $11.6 million, respectively.

The Seventh Amendment includes material financial covenants, ratios and tests. The Company must maintain a Consolidated Leverage Ratio of not more than 2.00 to 1.00 and a Consolidated Fixed Charge Coverage Ratio of at least 3.00 to 1.00. Capital Lease Obligations allowed under the covenants increased from $3.0 million to $6.1 million and the HFS Term Loan's quarterly amortization payment increased under the Seventh Amendment from $250,000 to $312,500 per quarter.

The Company entered into the Eighth Amendment to Credit Agreement and Limited Waiver (the "Eighth Amendment"), dated as of October 20, 2016, by and among NHA, other credit parties named therein, HFS and other financial institutions. The purpose of the Amendment was to (i) modify the covenant regarding the Company’s holding company status to permit certain business activities thereunder (ii) define a new permitted lien and an applicable basket with regard to a lien filed by a Company vendor and (iii) amend the management fees covenant to permit payment of certain management fees under the Loan Agreement. As a result, the Company was in compliance with its covenants under the HFS Term Loan as of September 30, 2016.

On July 30, 2015, the Company secured a $4.5 million term loan from Legacy Texas Bank (the “Legacy Bank Term Loan”). The term loan bears interest at a rate of 4% plus LIBOR per annum and requires monthly payments of interest. Monthly payments of principal commenced in August 2016. The Legacy Bank Term Loan matures in July 2020 and is subordinated to the Company’s term loan and revolver with HFS. As of September 30, 2016, the outstanding balance was zero and the Legacy Bank Term Loan was extinguished using the increased borrowing capacity acquired through the Seventh Amendment.

Loan origination fees are deferred and the net amount is amortized over the contractual life of the related loans.

Debt at September 30, 2016 and December 31, 2015 consisted of the following (in thousands):

	September 30, 2016		December 31, 2015
Gross debt	$	24,687	$	23,275
Less: unamortized loan fees	855		563
Debt, net of unamortized loan fees	23,832		22,712
Less: current portion of term loan, net of unamortized loan fees	1,006		1,243
Long-term debt, net of unamortized loan fees	$	22,826	$	21,469

XML

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrant and stock option derivative liabilities. There have been no transfers between fair value measurement levels during the nine months ended September 30, 2016 and 2015.

The following table summarizes our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
December 31, 2015:
Warrant and stock option derivative liabilities	$	—	$	—	$	2,951	$	2,951
Total	$	—	$	—	$	2,951	$	2,951
September 30, 2016:
Warrant and stock option derivative liabilities	$	—	$	—	$	1,917	$	1,917
Total	$	—	$	—	$	1,917	$	1,917

In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that were measured at estimated fair value on a recurring basis consist of warrant and stock option derivative liabilities. The estimated fair values of the warrant and stock option derivative liabilities were measured using the Black-Scholes valuation model (refer to Note 14 - Warrants and options liabilities). Due to the nature of valuation inputs, the valuation of the warrants is considered a Level 3 measurement.

XML

SHARE BASED COMPENSATION

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE BASED COMPENSATION

SHARE BASED COMPENSATION

Restricted Share Units (“RSUs”)

The Company had no stock compensation expense relative to RSUs for both the three months ended September 30, 2016 and 2015. The Company recorded stock compensation expense relative to RSUs of nil and $5.4 million for the nine months ended September 30, 2016 and 2015, respectively. There were no grants during the three and nine months ended September 30, 2016 and 2015.

During the nine months ended September 30, 2015, two key executives experienced triggering events, as defined in their employee agreements, which accelerated all unrecognized stock compensation expense on their outstanding RSUs. As a result of this acceleration, the Company recognized $4.5 million of stock compensation expense during the nine months ended September 30, 2015.

The Company had no outstanding RSUs at September 30, 2016 and 2015.

Stock Options

The Company granted a total of 350,000 and 2,457,075 stock options during the three and nine months ended September 30, 2016, respectively. Of the options granted during the nine months ended September 30, 2016, 297,075 of those vest immediately and 2,160,000 vest ratably over a three-year period.

The Company granted a total of 3,166,782 stock options during the year ended December 31, 2015. Of the options granted during the year ended December 31, 2015, 451,782 of those vest immediately, 450,000 vest ratably over a one-year period, 1,865,000 vest ratably over a three-year period, and 400,000 cliff vest at the end of a five-year period.

The following table summarizes stock option activity for the nine months ended September 30, 2016 and 2015:

	Shares Underlying Options		Weighted- Average Exercise Price		Weighted-Average Remaining Life (years)
Outstanding at January 1, 2015	3,118,218		$	1.45	9.80
Granted	2,601,782		$	5.50	9.78
Exercised	(447,787	)	$	1.26	—
Forfeited	(372,213	)	$	1.11	—
Outstanding at September 30, 2015	4,900,000		$	3.65	9.47
Exercisable at
Exercisable at September 30, 2015	1,408,461		$	2.54	9.47
Exercisable at
Outstanding at January 1, 2016	5,465,000		$	2.97	9.20
Granted	2,457,075		$	2.14	9.40
Exercised	(1,083,750	)	$	1.91	—
Forfeited	(966,800	)	$	3.01	—
Outstanding at September 30, 2016	5,871,525		$	2.77	8.90
Outstanding at
Exercisable at September 30, 2016	2,234,025		$	2.32	8.50

The above table includes 650,000 options issued to non-employees, all of which are still outstanding at September 30, 2016. Refer to Note 14 - Warrants and options liabilities for discussion regarding the classification of these options within the Consolidated Balance Sheet.

The total intrinsic value of stock options exercised was $1.3 million and $2.9 million during the nine months ended September 30, 2016 and 2015, respectively. The total intrinsic value for all in-the-money vested outstanding stock options at September 30, 2016 was $1.8 million. Assuming all stock options outstanding at September 30, 2016 were vested, the total intrinsic value of in-the-money outstanding stock options would have been $4.2 million at September 30, 2016.

The Company recorded total stock compensation expense relative to employee stock options of $1.6 million and $1.3 million for the three months ended September 30, 2016 and 2015, respectively, and $5.0 million and $4.3 million for the nine months ended September 30, 2016 and 2015, respectively.

The fair values of the employee stock options used in recording compensation expense are computed using the Black-Scholes option pricing model. The table below shows the assumptions used in the model for options awarded during the nine months ended September 30, 2016 and 2015.

	Nine Months Ended September 30,
	2016		2015
Expected price volatility	114% - 117%		113% - 122%
Risk free interest rate	1.03% - 1.53%		1.34% - 1.87%
Expected annual dividend yield	0	%	0	%
Expected option term (years)	5 - 6		5 - 6
Expected forfeiture rate	0.5% - 11.6%		1.3% - 8.8%
Grant date fair value per share	$1.73 - $2.41		$2.97 - $6.31
Grant date exercise price per share	$1.99 - $2.82		$2.53 - $6.10

For stock options, the Company recognizes share-based compensation net of estimated forfeitures and revises the estimates in the subsequent periods if actual forfeitures differ from the estimates. Forfeiture rates are estimated based on historical experience as well as expected future behavior.

XML

WARRANTS AND OPTIONS LIABILITIES

9 Months Ended

Sep. 30, 2016

Warrants and Rights Note Disclosure [Abstract]

WARRANTS AND OPTIONS LIABILITIES

WARRANTS AND OPTIONS LIABILITIES

Warrants and Options Issued in Private Placements

The Company issued warrants and compensatory options in connection with private placements completed in December 2013, September 2014 and May 2015. These warrants and options have exercise prices denominated in Canadian dollars and as such may not be considered indexed to our stock which is valued in U.S. dollars. Hence, these warrants and options are classified as liabilities under the caption “Warrants and Options Derivative Liability” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period are recorded in the Consolidated Statements of Operations under the caption “Change in fair value of warrant and stock option derivative liabilities”.

The estimated fair values of warrants and options accounted for as liabilities were determined on the date of the private placements and at each balance sheet date following using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	0.26% - 0.59%		0.11% - 0.64%
Expected life in years	0.25 - 1.15		0.25 - 2.0
Expected volatility	76% - 112%		71% - 89%
Expected dividend yield	0	%	0	%

The changes in fair value of the warrants and options (excluding non-employees) liability during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016			2015
Balance at beginning of year	$	2,109		$	6,657
Issuance of warrants and options	—			12,797
Transferred to equity upon exercise	—			(8,882		)
Change in fair value recorded in earnings	(1,729		)	(4,742		)
Balance as of September 30, 2016 and 2015	$	380		$	5,830

The following warrants and options were outstanding at September 30, 2016:

	Exercise price in Cdn$		Number of warrants and options	Remaining contractual life (years)
2015 Warrants	$	11.50	3,923,834	0.90
2015 Options	$	9.00	392,383	0.90
Outstanding and Exercisable as of September 30, 2016			4,316,217

As of September 30, 2016, there were no warrants or options outstanding from the 2014 issuances.

Options Issued to Non-Employees

As discussed in Note 13 - Share based compensation, in 2014 the Company issued options to professionals providing services to the organization. These professionals do not meet the definition of an employee under U.S. GAAP. At September 30, 2016, there were 650,000 options outstanding to these non-employees.

Under U.S. GAAP, the value of these option awards is determined at the performance completion date. The Company recognizes expense for the estimated total value of the awards during the period from their issuance until performance completion since the professional services are being rendered during this time. The total expense recognized is adjusted to the final value of the award as determined on the performance completion date.

The estimated values of the option awards are determined using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	1.01% - 1.14%		1.37% - 1.56%
Expected life in years	4 - 5		5 - 6
Expected volatility	103% - 114%		113% - 115%
Expected dividend yield	0	%	0	%

For the three month periods ended September 30, 2016 and 2015, the Company recorded expense for non-employee stock options of $0.1 million and $0.2 million, respectively. For the nine months ended September 30, 2016 and 2015, the Company recorded expense for non-employee stock options of $0.2 million and $2.8 million, respectively.

The changes in fair value of the liability related to vested yet un-exercised options issued to non-employees during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016		2015
Balance at beginning of year	$	841	$	—
Vested during the period	533		1,531
Change in fair value recorded in earnings	163		65
Balance as of September 30, 2016 and 2015	$	1,537	$	1,596

Options issued to non-employees are reclassified from equity to liabilities on the performance completion date. Under U.S. GAAP, such options may not be considered indexed to our stock because they have exercise prices denominated in Canadian dollars. Hence, these will be classified as liabilities under the caption “Warrant and stock option liabilities” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period will be recorded in the Consolidated Statements of Operations under the caption “Change in fair value of warrant and stock option liabilities”. At September 30, 2016, there were 0.6 million unexercised non-employee options requiring liability classification.

XML

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

Basic net earnings attributable to Nobilis common shareholders, per common share, excludes dilution and is computed by dividing net earnings attributable to Nobilis common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to Nobilis common shareholders, per common share, is computed by dividing net earnings attributable to Nobilis common shareholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable upon the vesting stock option awards, warrants and RSUs as determined under the treasury stock method. A detail of the Company’s earnings per share is as follows (in thousands except for share and per share amounts):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016			2015
Basic:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Net (loss) income per common share	$	(0.04	)	$	0.15	$	(0.04	)	$	0.09
Diluted:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Dilutive effect of stock options, warrants, RSUs	—			6,720,676		—			6,720,676
Athas share consideration	—			—		—			3,036,337
Weighted average common shares outstanding assuming dilution	76,774,967			77,656,263		76,114,538			75,067,623
Net (loss) income per fully diluted share	$	(0.04	)	$	0.14	$	(0.04	)	$	0.08

XML

NONCONTROLLING INTERESTS

9 Months Ended

Sep. 30, 2016

Noncontrolling Interest [Abstract]

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS

Noncontrolling interests at September 30, 2016 and December 31, 2015 represent an 8.1% interest in The Palladium for Surgery - Houston, Ltd, 75% interest in the Medical Ambulatory Suites, L.P., 65% interest in Microsurgery Institute, LLC., 2.3% interest in Houston Microsurgery Institute, LLC., 50% in Northstar Healthcare Dallas Management, LLC., 65% in NHC ASC – Dallas, LLC., 49% in First Nobilis, LLC., 40% in First Nobilis Hospital Management, LLC., 45% in Hermann Drive Surgical Hospital, LP., and 40% in Perimeter Road Surgical Hospital, LLC.

Agreements with the third party equity owners in NHC - ASC Dallas and First Nobilis give these owners limited rights to require the Company to repurchase their equity interests upon the occurrence of certain events, none of which were probable of occurring as of September 30, 2016 and December 31, 2015. The contingently redeemable noncontrolling interests associated with these entities are classified in the Company’s Consolidated Balance Sheets as “temporary” or mezzanine equity. Changes in contingently redeemable noncontrolling interests are as follows (in thousands):

	NHC - ASC Dallas			First Nobilis			Total
Balance at January 1, 2015	$	6,654		$	6,213		$	12,867
Distributions	(3,892		)	(7,617		)	(11,509		)
Net income attributable to noncontrolling interests	631			10,236			10,867
Total contingently redeemable noncontrolling interests at December 31, 2015	$	3,393		$	8,832		$	12,225
Balance at January 1, 2016	$	3,393		$	8,832		$	12,225
Distributions	(2,929		)	(600		)	(3,529		)
Net (loss) income attributable to noncontrolling interests	(210		)	2,081			1,871
Total contingently redeemable noncontrolling interests at September 30, 2016	$	254		$	10,313		$	10,567

Certain of our consolidated subsidiaries that are less than wholly owned meet the definition of a Variable Interest Entity (“VIE”), and we hold voting interests in all such entities. We consolidate the activities of VIE’s for which we are the primary beneficiary. In order to determine whether we own a variable interest in a VIE, we perform qualitative analysis of the entity’s design, organizational structure, primary decision makers and relevant agreements. Such variable interests include our voting interests, and may also include other interests and rights, including those gained through management contracts.

Since our core business is the management and operation of health care facilities, our subsidiaries that are determined to be VIE’s represent entities that own, manage and operate such facilities. Voting interests in such entities are typically owned by us, by physicians practicing at these facilities (or entities controlled by them) and other parties associated with the operation of the facilities. In forming such entities, we typically seek to retain operational control and, as a result, in some cases, voting rights we hold are not proportionate to the economic share of our ownership in these entities, which causes them to meet the VIE definition. We consolidate such VIE’s if we determine that we are the primary beneficiary because (i) we have the power to direct the activities that most significantly impact the economic performance of the VIE via our rights and obligations associated with the management and operation of the VIE’s health care facilities, and (ii) as a result of our obligation to absorb losses and the right to receive residual returns that could potentially be significant to the VIE, which we have through our equity interests.

The following table summarizes the carrying amount of the assets and liabilities of our material VIE’s included in the Company’s Consolidated Balance Sheets (after elimination of intercompany transactions and balances) (in thousands):

	September 30, 2016			December 31, 2015
Total cash and short term investments	$	1,071		$	191
Total accounts receivable	8,638			8,660
Total other current assets	1,768			1,582
Total property and equipment	17,547			5,227
Total other assets	165			144
Total assets	$	29,189		$	15,804
Total accounts payable	$	3,847		$	2,286
Total other liabilities	5,924			7,059
Total accrued liabilities	4,242			2,664
Long term - capital lease	11,543			780
Noncontrolling interest	(8,547		)	(1,488		)
Total liabilities	$	17,009		$	11,301

XML

INCOME TAXES

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The Company is a corporation subject to federal income tax at a statutory rate of 35% of pretax earnings. The Company estimates an annual effective income tax rate of 32.5% for U.S. and none for Canada based on projected results for the year and applies this rate to income before taxes to calculate income tax expense. The following items caused the third quarter effective income tax rate to be significantly different from the statutory rate:

• Canada is excluded from the worldwide annual effective tax rate calculation because Canada has losses but does not expect to realize them, which reduces the third quarter effective tax rate by approximately 3.8% for the nine months ended September 30, 2016.

• All of the Partnership’s earnings are included in the Company’s net income; however, the Company is not required to record income tax expense or benefit with respect to the portion of the Partnership’s earnings allocated to its noncontrolling public limited partners, which reduces the third quarter effective tax rate by approximately 4.5% for the nine months ended September 30, 2016.

• The Company adjusted the prior year tax provision. The adjustment to the existing deferred tax assets and liabilities decreases the third quarter effective tax rate by approximately 1.6% for the nine months ended September 30, 2016.

• The third quarter effective tax rate includes a discrete item for the stock compensation shortfall, which reduces the effective tax rate by approximately 3.8% for the nine months ended September 30, 2016.

• The net tax for the three and nine months ended September 30, 2016 was $0.5 million expense and $1.7 million benefit, respectively, resulting in an effective tax rate of approximately -29.3% and 21.1% respectively. The net tax includes $0.3 million and $0.8 million of state tax expense, respectively. The Company did not recognize any federal or foreign tax expense or benefit for the three and nine months ended September 30, 2015 as the Company had a full valuation allowance against deferred tax assets at that time. The state tax expense for the three and nine months ended September 30, 2015 was $0.3 million and $0.9 million, respectively.

On April 22, 2016, the Company received notification from the Internal Revenue Service to examine our December 31, 2014 and 2013 Federal income tax return. Based on management tax analysis, the Company did not have any uncertain tax positions as of September 30, 2016.

XML

BUSINESS SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2016

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

A summary of the business segment information for the three months ended September 30, 2016 and 2015 is as follows (in thousands):

	Three months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	65,419		$	5,264		$	—		$	70,683
Operating expenses	60,871			2,958			—			63,829
Corporate costs	—			—			7,955			7,955
Income (loss) from operations	4,548			2,306			(7,955		)	(1,101		)
Change in fair value of warrant and option liabilities	—			—			133			133
Interest expense	329			1			414			744
Other (income) expense	(199		)	(57		)	58			(198		)
Income (loss) before income taxes	$	4,418		$	2,362		$	(8,560	)	$	(1,780	)
Other data:
Depreciation and amortization expense	$	1,564		$	388		$	79		$	2,031
Income tax expense	$	205		$	78		$	200		$	483
Capital expenditures	$	1,289		$	—		$	72		$	1,361

	Three months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	46,150		$	6,333		$	—		$	52,483
Operating expenses	36,466			5,670			—			42,136
Corporate costs	—			—			7,296			7,296
Income (loss) from operations	9,684			663			(7,296		)	3,051
Change in fair value of warrant and option liabilities	—			—			(6,381		)	(6,381		)
Interest expense (income)	169			(15		)	168			322
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,583			(205		)	(1,484		)	(106		)
Income before income taxes	$	12,290		$	883		$	401		$	13,574
Other data:
Depreciation and amortization expense	$	1,178		$	344		$	43		$	1,565
Income tax expense	$	176		$	80		$	—		$	256
Capital expenditures	$	1,041		$	—		$	—		$	1,041
Non-cash acquisition of property	$	10,485		$	—		$	—		$	10,485
Non-cash acquisition of intangibles and goodwill	$	1,534		$	—		$	—		$	1,534

A summary of the business segment information for the nine months ended September 30, 2016 and 2015 is as follows (in thousands):

	Nine months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	166,922		$	16,905		$	—		$	183,827
Operating expenses	158,471			11,716			—			170,187
Corporate costs	—			—			24,380			24,380
Income (loss) from operations	8,451			5,189			(24,380		)	(10,740		)
Change in fair value of warrant and option liabilities	—			—			(1,566		)	(1,566		)
Interest expense	1,074			4			1,037			2,115
Other income	(1,682		)	(305		)	(1,024		)	(3,011		)
Income (loss) before income taxes	$	9,059		$	5,490		$	(22,827	)	$	(8,278	)
Other data:
Depreciation and amortization expense	$	5,026		$	1,436		$	209		$	6,671
Income tax expense (benefit)	$	662		$	149		$	(2,577	)	$	(1,766	)
Capital expenditures	$	4,000		$	—		$	388		$	4,388
Intangible assets	$	5,246		$	13,022		$	—		$	18,268
Goodwill	$	25,822		$	19,011		$	—		$	44,833
Total assets	$	175,279		$	44,413		$	21,291		$	240,983
Total liabilities	$	55,602		$	6,928		$	38,237		$	100,767

	Nine months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	123,638		$	15,563		$	—		$	139,201
Operating expenses	94,589			13,471			—			108,060
Corporate costs	—			—			23,071			23,071
Income (loss) from operations	29,049			2,092			(23,071		)	8,070
Change in fair value of warrant and option liabilities	—			—			(4,677		)	(4,677		)
Interest expense	169			65			872			1,106
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,383			(446		)	(2,455		)	(1,518		)
Income (loss) before income taxes	$	31,855		$	2,473		$	(16,811	)	$	17,517
Other data:
Depreciation and amortization expense	$	2,079		$	1,035		$	99		$	3,213
Income tax expense	$	703		$	159		$	—		$	862
Capital expenditures	$	2,406		$	127		$	—		$	2,533
Intangible assets	$	5,734		$	14,172		$	—		$	19,906
Goodwill	$	14,163		$	19,011		$	—		$	33,174
Non-cash acquisition of property	$	15,345		$	—		$	—		$	15,345
Non-cash acquisition of intangibles and goodwill	$	13,532		$	—		$	—		$	13,532
Total assets	$	103,836		$	43,528		$	18,158		$	165,522
Total liabilities	$	38,360		$	3,909		$	22,831		$	65,100

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2016

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

The minority interest holder of First Nobilis Hospital, a fully consolidated entity, is also a partial owner of First Street Hospital, L.P. and First Street Surgical Center, L.P., both of which have an ongoing business relationship with the Company. At September 30, 2016, the Company has a net amount due from these related parties of $1.4 million. In addition, the Company leases certain medical equipment and facility space from these related parties. Equipment lease costs of approximately $0.5 million and $0.6 million were incurred during the quarter ended September 30, 2016 and 2015, respectively. Facility lease costs of approximately $0.4 million were incurred during both the three months ended September 30, 2016 and 2015. Equipment lease costs of approximately $1.6 million and $1.7 million were incurred during the nine months ended September 30, 2016 and 2015, respectively. Facility lease costs of approximately $1.3 million were incurred during both the nine months ended September 30, 2016 and 2015, respectively.

In March 2016, the Company acquired an interest in Athelite, a holding company which owns an interest in Dallas Metro, a company formed to provide management services to an HOPD. The Athelite investment is accounted for as an equity method investment (refer to Note 6 - Investments in associates). At September 30, 2016, the Company had $3.6 million in accounts receivable from the HOPD and $0.9 million in accounts receivable from Dallas Metro. The Company also rents, on a monthly basis, certain medical equipment to Dallas Metro and subleases operation facility to Benton Transitional.

Physician Related Party Transactions

Nobilis maintains certain medical directorship, consulting and marketing agreements with various physicians who are also equity owners in Nobilis entities. Material related party arrangements of this nature are described below:

• In October 2014 the Company entered into a marketing services agreement with an entity controlled by a physician equity owner. In June 2015, the Company expanded the relationship with this physician equity owner to include consulting, medical supplies, medical directorship and on-call agreements. The Company incurred expenses of $2.5 million and $2.5 million as of September 30, 2016 and 2015, respectively. The Company has incurred expenses of $1.9 million and $0.2 million in fees owed pursuant to the service agreements as of September 30, 2016 and 2015, respectively.

• In July 2014, the Company entered into a marketing services agreement with a physician equity owner and an entity owned by that physician equity owner’s brother. The Company incurred expenses of $1.0 million and $0.3 million as of September 30, 2016 and 2015, respectively.

• In September 2013, the Company entered into a book deal with a physician equity owner. In March 2015, the Company entered into a marketing agreement with that physician equity owner and a marketing services company owned by the physician equity owner’s father. The Company incurred expenses of $3.9 million and $2.4 million as of September 30, 2016 and 2015, respectively.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Litigation

In the normal course of our business, we are subject to legal proceedings brought by or against us and our subsidiaries. In the opinion of management, the amount of ultimate liability with respect to these actions will not materially impact the financial position, results of operations or liquidity of the Company.

Shareholder Lawsuits

After the Company announced it would be restating its 2014 annual financial statements and 2015 first and second quarter interim financial statements, one complaint, Schott v. Nobilis Health Corp. et al, was filed in the United States District Court for the Southern District of Texas against the Company, our former chief executive officer and our current chief financial officer. The complaint sought class action status on behalf of our shareholders and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 arising out of the restatement. The defendants vigorously defended against these claims and filed motions to dismiss the consolidated complaint for failure to plead particularized facts supporting a strong inference of scienter on the part of the individual defendants.On June 1, 2016 the court heard oral arguments on the Company’s pending motion to dismiss which the court later granted on September 29, 2016. The court ultimately dismissed the case with prejudice on October 24, 2016.

In addition, a statement of claim (complaint), Vince Capelli v Nobilis Health Corp. et. al, was filed on January 8, 2016 in the Ontario Superior Court of Justice under court file number CV-16-544173 naming Nobilis Health Corp., certain current and former officers and the Company’s former auditors as defendants. The statement of claim seeks to advance claims on behalf of the plaintiff and on behalf of a class comprised of certain of our shareholders related to, among other things, alleged certain violations of the Ontario Securities Act and seeks damages in the amount of C$80 million plus interest. The defendants intend to vigorously defend against these claims. At this time the Company believes the likelihood of loss, if any, is remote.

XML

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

The Company entered into the Eighth Amendment on October 20, 2016, by and among NHA, other credit parties named therein, HFS and other financial institutions. The purpose of the Amendment was to (i) modify the covenant regarding the Company’s holding company status to permit certain business activities thereunder (ii) define a new permitted lien and an applicable basket with regard to a lien filed by a Company vendor and (iii) amend the management fees covenant to permit payment of certain management fees under the Loan Agreement. As a result, the Company was in compliance with its covenants under the HFS Term Loan as of September 30, 2016.

On October 28, 2016, the Company entered into an $82.5 million credit agreement (the “Compass Bank Loans”) with Compass Bank.  The credit agreement includes a $52.5 million term loan and a $30.0 million revolving credit facility.  The proceeds will be used to refinance all previously held debt and lines of credit and for the acquisition of Arizona Vein and Vascular Centers.  As of September 30, 2016, the outstanding balance of the HFS Term Loan and Revolver was $24.7 million and $8.1 million, respectively.  The Compass Bank loans are collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries.  The Compass Bank Loans require the Company to maintain a consolidated leverage ratio of 2.75 to 1.00 through September 30, 2018, 2.50 to 1.00 for December 31, 2018 to September 30, 2019, 2.25 to 1.00 for December 31, 2019 to September 30, 2020 and 2.00 to 1.00 through December 31, 2020; and a consolidated fixed charge coverage ratio of 2.00 to 1.00.  

The Compass Bank Loans bear interest from the closing date to the first business day immediately following the date on which Compass Bank receives a compliance certificate from the Company for the fiscal quarter ending March 31, 2017; 2.75% per annum for base rate loans, 3.75% per annum for Eurodollar Rate Loans, 3.75% for line of credit fees, and 0.500% per annum for the commitment fee.  Thereafter, the Compass Bank Loans bear interest based on the Company’s consolidated leverage ratio as follows:  (i) Less than 1.00 to 1.00; base rate margin 2.00%, LIBOR margin 3.00%, commitment fee rate 0.375%, (ii) Less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00; base rate margin 2.25%, LIBOR margin 3.25%, commitment fee rate 0.375%, (iii) Less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00; base rate margin 2.50%, LIBOR margin 3.50%, commitment fee rate 0.450%, (iv) Greater than or equal to 2.50 to 1.00; base rate margin 2.75%, LIBOR margin 3.75%, commitment fee rate 0.500%. 

The Compass Bank term loan requires quarterly payments of Principal as follows: (i) March 31, 2017 to December 31, 2018 of $0.7 million, (ii) March 31, 2019 to December 31, 2020 of $1.3 million, (iii) March 31, 2021 to September 30, 2021 of $2.0 million, (iv) October 28, 2021, the remaining principal balance of the term.   The Compass Bank Loans mature on October 28, 2021.

In connection with the funding of the Compass Bank Loans, the Company also completed the acquisition of the operating assets of Arizona Center for Minimally Invasive Surgery, LLC, an Arizona limited liability company (“ACMIS”), L. Philipp Wall, M.D., P.C., an Arizona professional corporation (“PC”), Arizona Vein & Vascular Center, LLC, an Arizona limited liability company and wholly owned subsidiary of PC, (“AVVC” and with ACMIS and PC, each a “Seller” and collectively “Sellers”), and L. Philipp Wall (“Owner”). The Company, Northstar Healthcare Acquisitions, L.L.C. ("Buyer"), Sellers and Owner entered into an amended and restated purchase agreement (the “Amended and Restated Purchase Agreement”) dated as of October 28, 2016.

Buyer received substantially all of the operating assets of Sellers in exchange for an aggregate purchase price of approximately $22.0 million, consisting of $17.0 million in cash (subject to a holdback described below), $2.5 million of NHC’s common shares, and $2.50 million the form of a convertible promissory note (“Convertible Promissory Note”) between Buyer and ACMIS.

In addition, the Sellers may receive an additional earnout payment based on the growth in trailing twelve month EBITDA of the new vascular division on the twelve-month anniversary of closing (as compared to the trailing twelve month EBITDA for the twelve months prior to closing). The earnout payment shall be equal to fifty percent (50%) of such growth.

As part of the Amended and Restated Purchase Agreement, $1.05 million of the cash purchase price was held back and is subject to the Amended and Restated Purchase Agreement’s indemnification provisions. On the twelve-month anniversary of closing, fifty percent (50%) of the amount held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner. The remaining amounts held back, less any amounts paid as, or claimed as, indemnification, will be paid to the Owner on the twenty-four-month anniversary of closing.

The common shares issued to Owner at closing were issued at a price per share based on the NYSE MKT closing price of NHC’s common shares on the day prior to closing. The common shares are restricted under Rule 144 of the Securities Act of 1933, as amended, and are subject to additional contractual lock-up provisions, which lift in one-quarter increments on the twelve-month, fifteen-month, eighteen-month and twenty-first month anniversaries of closing.

On October 31, 2016, the Company increased its ownership interest in SLH from 60% to 75%.  Pursuant to a subscription agreement, the Company was the only member to participate in the capital raise and acquired an additional 60 Class C Units.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying interim consolidated financial statements have not been audited by the Company’s independent registered public accounting firm, except that the Consolidated Balance Sheet at December 31, 2015, is derived from previously audited consolidated financial statements. In the opinion of management, all material adjustments, consisting of normal recurring adjustments, necessary for fair presentation have been included. These interim consolidated financial statements include all accounts of the Company. All significant intercompany transactions and accounts have been eliminated upon consolidation.

Certain reclassifications have been made to prior period amounts to conform to current period financial statement classifications. The reclassifications included in these comparative consolidated financial statements are (i) a change in presentation of other comprehensive income and (ii) a reclassification from cost of goods sold to operating expenses. The reclassifications were deemed to be immaterial to the consolidated financial statements both individually and in the aggregate.

These consolidated financial statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. Therefore, these interim consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Annual Report”) filed with the SEC on March 15, 2016. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

There have been no material changes to the Company’s critical accounting policies or estimates from those disclosed in the 2015 Annual Report.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Topic 825): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). This update changes how entities account for and measure the fair value of certain equity investments and updates the presentation and disclosure of certain financial assets and liabilities. This new ASU is effective for annual and interim periods beginning on or after December 15, 2017, and for interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact that ASU 2016-01 will have on the Company’s consolidated financial position and disclosures.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net) (“ASU 2016-08”). The amendments address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The ASU clarifies that an entity should evaluate whether it is the principal or the agent for each specified good or service promised in a contract with a customer. The amendments affect the guidance in ASU 2014-09 which is not yet effective. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company is currently evaluating the new guidance to determine the method of adoption that it will use and the impact it will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU-2016-09"). ASU 2016-09 impacts several aspects of the accounting for share-based payment transactions, including classification of certain items on the Consolidated Statement of Cash Flows and accounting for income taxes. Specifically, the ASU requires that excess tax benefits and tax deficiencies (the difference between the deduction for tax purposes and the compensation cost recognized for financial reporting purposes) be recognized as income tax expense or benefit in the Consolidated Statement of Operations, introducing a new element of volatility to the provision for income taxes. ASU No. 2016-09 is effective on January 1, 2017, with early adoption permitted. The transition method varies for each of the areas in the ASU. The Company is currently evaluating the impact of adopting this new accounting standard on its results of operations and financial position.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies the guidance in ASU 2014-09 regarding assessing whether promises to transfer goods or services are distinct, and whether an entity's promise to grant a license provides a customer with a right to use or right to access the entity's intellectual property. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). This Update provides for amendments to ASU 2014-09, amending the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. Specifically, ASU 2016-12 clarifies that, for a contract to be considered completed at transition, all (or substantially all) of the revenue must have been recognized under legacy GAAP. In addition, ASU 2016-12 clarifies how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard’s contract criteria. The effective date and transition requirements for the amendments in this ASU are the same as the effective date and transition of ASU 2014-09, which will be effective for the Company for reporting periods beginning after December 15, 2017. The Company does not expect these amendments to have a material effect on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides guidance on how certain cash receipts and cash payments are to be presented and classified in the statement of cash flows. For public entities, ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the potential impact of adopting this guidance on our consolidated financial statements.

XML

SUPPLEMENTAL CASH FLOWS (Tables)

9 Months Ended

Sep. 30, 2016

Supplemental Cash Flow Elements [Abstract]

Schedule of Cash Flow, Supplemental Disclosures

The supplemental cash flows information for the nine months ended September 30, 2016 and 2015 are comprised of the following (in thousands):

	Nine Months Ended September 30,
	2016		2015
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	2,052	$	1,129
Cash paid for taxes	$	2,279	$	633
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash acquisition of property and equipment	$	—	$	15,345
Non-cash acquisition of goodwill and intangibles	$	—	$	13,532
Non-cash deconsolidation of property and equipment	$	—	$	2,828
Non-cash deconsolidation of goodwill	$	—	$	701
Athas settlement in lieu of contingent shares	$	—	$	5,685

XML

ACQUISITIONS (Tables)

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Schedule of Fair Value of Identifiable Assets

The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition (in thousands):

	November 1, 2015
Net assets acquired:
Trade accounts receivable	$	82
Prepaid expenses and other current assets	36
Inventory	69
Property and equipment	13,266
Other long-term assets	113
Goodwill	6,932
Tradename	160
Hospital license	12
Net assets acquired	$	20,670
Net liabilities assumed:
Trade accounts payable	$	2,668
Accrued liabilities	419
Current portion of capital leases	658
Long-term portion of capital leases	12,213
Total liabilities assumed	$	15,958
Consideration:
Cash, net of cash acquired	$	3,180
Noncontrolling Interest	1,532
Total consideration	$	4,712

Business Acquisition, Pro Forma Information

The following table shows our pro forma results for the nine months ended September 30, 2015(in thousands, except per share amounts):

	September 30, 2015
Revenue	$	139,774
Income from operations	$	8,225
Net income attributable to noncontrolling interests	$	10,360
Net income attributable to common stockholders	$	6,282
Net income per basic common share	$	0.10

XML

TRADE ACCOUNTS RECEIVABLE, NET (Tables)

9 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable

A detail of trade accounts receivable, net as of September 30, 2016 and December 31, 2015 is as follows (in thousands):

	September 30, 2016			December 31, 2015
Trade accounts receivable	$	84,573		$	95,114
Allowance for doubtful accounts	(2,144		)	(5,165		)
Receivables transferred	(357		)	(298		)
Receivables purchased	4,098			2,918
Trade accounts receivable, net	$	86,170		$	92,569

XML

FINANCIAL INSTRUMENTS AND CONCENTRATION (Tables)

9 Months Ended

Sep. 30, 2016

Medical Segment

Segment Reporting Information [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.3	%	94.4	%	96.2	%	94.7	%
Workers compensation	3.4	%	5.1	%	3.4	%	4.8	%
Medicare	0.3	%	0.5	%	0.4	%	0.5	%
Total	100	%	100	%	100	%	100	%

Marketing Segment

Segment Reporting Information [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	100.0	%	100.0	%	100.0	%	100.0	%
Workers compensation	0.0	%	0.0	%	0.0	%	0.0	%
Medicare	0.0	%	0.0	%	0.0	%	0.0	%
Total	100	%	100	%	100	%	100	%

Consolidated Segments

Segment Reporting Information [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

	Three Months Ended September 30,				Nine Months Ended September 30,
Payors	2016		2015		2016		2015
Private insurance and other private pay	96.8	%	95.1	%	96.7	%	95.2	%
Workers compensation	3.0	%	4.5	%	3.0	%	4.3	%
Medicare	0.2	%	0.4	%	0.3	%	0.5	%
Total	100	%	100	%	100	%	100	%

XML

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

The following table presents a summary of items comprising accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (in thousands):

	September 30, 2016		December 31, 2015
Accrued expenses:
Accrued salaries and related benefits	$	3,941	$	5,309
Other	16,720		11,339
Total accrued expenses	$	20,661	$	16,648
Other current liabilities:
Estimated amounts due to third party payors	$	6,348	$	3,795
Other	454		1,230
Total other current liabilities	$	6,802	$	5,025

XML

DEBT (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Debt at September 30, 2016 and December 31, 2015 consisted of the following (in thousands):

	September 30, 2016		December 31, 2015
Gross debt	$	24,687	$	23,275
Less: unamortized loan fees	855		563
Debt, net of unamortized loan fees	23,832		22,712
Less: current portion of term loan, net of unamortized loan fees	1,006		1,243
Long-term debt, net of unamortized loan fees	$	22,826	$	21,469

XML

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Schedule of Fair Value, by Balance Sheet Grouping

The following table summarizes our assets and liabilities measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands):

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
December 31, 2015:
Warrant and stock option derivative liabilities	$	—	$	—	$	2,951	$	2,951
Total	$	—	$	—	$	2,951	$	2,951
September 30, 2016:
Warrant and stock option derivative liabilities	$	—	$	—	$	1,917	$	1,917
Total	$	—	$	—	$	1,917	$	1,917

XML

SHARE BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes stock option activity for the nine months ended September 30, 2016 and 2015:

	Shares Underlying Options		Weighted- Average Exercise Price		Weighted-Average Remaining Life (years)
Outstanding at January 1, 2015	3,118,218		$	1.45	9.80
Granted	2,601,782		$	5.50	9.78
Exercised	(447,787	)	$	1.26	—
Forfeited	(372,213	)	$	1.11	—
Outstanding at September 30, 2015	4,900,000		$	3.65	9.47
Exercisable at
Exercisable at September 30, 2015	1,408,461		$	2.54	9.47
Exercisable at
Outstanding at January 1, 2016	5,465,000		$	2.97	9.20
Granted	2,457,075		$	2.14	9.40
Exercised	(1,083,750	)	$	1.91	—
Forfeited	(966,800	)	$	3.01	—
Outstanding at September 30, 2016	5,871,525		$	2.77	8.90
Outstanding at
Exercisable at September 30, 2016	2,234,025		$	2.32	8.50

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The table below shows the assumptions used in the model for options awarded during the nine months ended September 30, 2016 and 2015.

	Nine Months Ended September 30,
	2016		2015
Expected price volatility	114% - 117%		113% - 122%
Risk free interest rate	1.03% - 1.53%		1.34% - 1.87%
Expected annual dividend yield	0	%	0	%
Expected option term (years)	5 - 6		5 - 6
Expected forfeiture rate	0.5% - 11.6%		1.3% - 8.8%
Grant date fair value per share	$1.73 - $2.41		$2.97 - $6.31
Grant date exercise price per share	$1.99 - $2.82		$2.53 - $6.10

XML

WARRANTS AND OPTIONS LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2016

Warrants and Rights Note Disclosure [Abstract]

Schedule of Warrants or Rights, Valuation Assumptions

The estimated fair values of warrants and options accounted for as liabilities were determined on the date of the private placements and at each balance sheet date following using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	0.26% - 0.59%		0.11% - 0.64%
Expected life in years	0.25 - 1.15		0.25 - 2.0
Expected volatility	76% - 112%		71% - 89%
Expected dividend yield	0	%	0	%

Schedule of Warrants or Rights, Activity

The changes in fair value of the warrants and options (excluding non-employees) liability during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016			2015
Balance at beginning of year	$	2,109		$	6,657
Issuance of warrants and options	—			12,797
Transferred to equity upon exercise	—			(8,882		)
Change in fair value recorded in earnings	(1,729		)	(4,742		)
Balance as of September 30, 2016 and 2015	$	380		$	5,830

Schedule of Warrants or Rights

The following warrants and options were outstanding at September 30, 2016:

	Exercise price in Cdn$		Number of warrants and options	Remaining contractual life (years)
2015 Warrants	$	11.50	3,923,834	0.90
2015 Options	$	9.00	392,383	0.90
Outstanding and Exercisable as of September 30, 2016			4,316,217

Schedule of Option Awards, Valuation Assumptions

The estimated values of the option awards are determined using the Black Scholes pricing model with the following inputs:

	Nine Months Ended September 30,
	2016		2015
Risk free interest rate	1.01% - 1.14%		1.37% - 1.56%
Expected life in years	4 - 5		5 - 6
Expected volatility	103% - 114%		113% - 115%
Expected dividend yield	0	%	0	%

Schedule of Stockholders' Equity Note, Options to Non-employees

The changes in fair value of the liability related to vested yet un-exercised options issued to non-employees during the nine months ended September 30, 2016 and 2015 were as follows (in thousands):

	2016		2015
Balance at beginning of year	$	841	$	—
Vested during the period	533		1,531
Change in fair value recorded in earnings	163		65
Balance as of September 30, 2016 and 2015	$	1,537	$	1,596

XML

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

A detail of the Company’s earnings per share is as follows (in thousands except for share and per share amounts):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2016			2015		2016			2015
Basic:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Net (loss) income per common share	$	(0.04	)	$	0.15	$	(0.04	)	$	0.09
Diluted:
Net (loss) income attributable to Nobilis Health Corp.	$	(2,759	)	$	10,943	$	(2,918	)	$	6,038
Weighted average common shares outstanding	76,774,967			70,935,587		76,114,538			65,310,610
Dilutive effect of stock options, warrants, RSUs	—			6,720,676		—			6,720,676
Athas share consideration	—			—		—			3,036,337
Weighted average common shares outstanding assuming dilution	76,774,967			77,656,263		76,114,538			75,067,623
Net (loss) income per fully diluted share	$	(0.04	)	$	0.14	$	(0.04	)	$	0.08

XML

NONCONTROLLING INTERESTS (Tables)

9 Months Ended

Sep. 30, 2016

Noncontrolling Interest [Abstract]

Redeemable Noncontrolling Interest

Changes in contingently redeemable noncontrolling interests are as follows (in thousands):

	NHC - ASC Dallas			First Nobilis			Total
Balance at January 1, 2015	$	6,654		$	6,213		$	12,867
Distributions	(3,892		)	(7,617		)	(11,509		)
Net income attributable to noncontrolling interests	631			10,236			10,867
Total contingently redeemable noncontrolling interests at December 31, 2015	$	3,393		$	8,832		$	12,225
Balance at January 1, 2016	$	3,393		$	8,832		$	12,225
Distributions	(2,929		)	(600		)	(3,529		)
Net (loss) income attributable to noncontrolling interests	(210		)	2,081			1,871
Total contingently redeemable noncontrolling interests at September 30, 2016	$	254		$	10,313		$	10,567

Schedule of Variable Interest Entities

The following table summarizes the carrying amount of the assets and liabilities of our material VIE’s included in the Company’s Consolidated Balance Sheets (after elimination of intercompany transactions and balances) (in thousands):

	September 30, 2016			December 31, 2015
Total cash and short term investments	$	1,071		$	191
Total accounts receivable	8,638			8,660
Total other current assets	1,768			1,582
Total property and equipment	17,547			5,227
Total other assets	165			144
Total assets	$	29,189		$	15,804
Total accounts payable	$	3,847		$	2,286
Total other liabilities	5,924			7,059
Total accrued liabilities	4,242			2,664
Long term - capital lease	11,543			780
Noncontrolling interest	(8,547		)	(1,488		)
Total liabilities	$	17,009		$	11,301

XML

BUSINESS SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

A summary of the business segment information for the three months ended September 30, 2016 and 2015 is as follows (in thousands):

	Three months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	65,419		$	5,264		$	—		$	70,683
Operating expenses	60,871			2,958			—			63,829
Corporate costs	—			—			7,955			7,955
Income (loss) from operations	4,548			2,306			(7,955		)	(1,101		)
Change in fair value of warrant and option liabilities	—			—			133			133
Interest expense	329			1			414			744
Other (income) expense	(199		)	(57		)	58			(198		)
Income (loss) before income taxes	$	4,418		$	2,362		$	(8,560	)	$	(1,780	)
Other data:
Depreciation and amortization expense	$	1,564		$	388		$	79		$	2,031
Income tax expense	$	205		$	78		$	200		$	483
Capital expenditures	$	1,289		$	—		$	72		$	1,361

	Three months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	46,150		$	6,333		$	—		$	52,483
Operating expenses	36,466			5,670			—			42,136
Corporate costs	—			—			7,296			7,296
Income (loss) from operations	9,684			663			(7,296		)	3,051
Change in fair value of warrant and option liabilities	—			—			(6,381		)	(6,381		)
Interest expense (income)	169			(15		)	168			322
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,583			(205		)	(1,484		)	(106		)
Income before income taxes	$	12,290		$	883		$	401		$	13,574
Other data:
Depreciation and amortization expense	$	1,178		$	344		$	43		$	1,565
Income tax expense	$	176		$	80		$	—		$	256
Capital expenditures	$	1,041		$	—		$	—		$	1,041
Non-cash acquisition of property	$	10,485		$	—		$	—		$	10,485
Non-cash acquisition of intangibles and goodwill	$	1,534		$	—		$	—		$	1,534

A summary of the business segment information for the nine months ended September 30, 2016 and 2015 is as follows (in thousands):

	Nine months ended September 30, 2016
	Medical Services			Marketing			Corporate			Total
Revenues	$	166,922		$	16,905		$	—		$	183,827
Operating expenses	158,471			11,716			—			170,187
Corporate costs	—			—			24,380			24,380
Income (loss) from operations	8,451			5,189			(24,380		)	(10,740		)
Change in fair value of warrant and option liabilities	—			—			(1,566		)	(1,566		)
Interest expense	1,074			4			1,037			2,115
Other income	(1,682		)	(305		)	(1,024		)	(3,011		)
Income (loss) before income taxes	$	9,059		$	5,490		$	(22,827	)	$	(8,278	)
Other data:
Depreciation and amortization expense	$	5,026		$	1,436		$	209		$	6,671
Income tax expense (benefit)	$	662		$	149		$	(2,577	)	$	(1,766	)
Capital expenditures	$	4,000		$	—		$	388		$	4,388
Intangible assets	$	5,246		$	13,022		$	—		$	18,268
Goodwill	$	25,822		$	19,011		$	—		$	44,833
Total assets	$	175,279		$	44,413		$	21,291		$	240,983
Total liabilities	$	55,602		$	6,928		$	38,237		$	100,767

	Nine months ended September 30, 2015
	Medical Services			Marketing			Corporate			Total
Revenues	$	123,638		$	15,563		$	—		$	139,201
Operating expenses	94,589			13,471			—			108,060
Corporate costs	—			—			23,071			23,071
Income (loss) from operations	29,049			2,092			(23,071		)	8,070
Change in fair value of warrant and option liabilities	—			—			(4,677		)	(4,677		)
Interest expense	169			65			872			1,106
Bargain purchase	(4,358		)	—			—			(4,358		)
Other expense (income)	1,383			(446		)	(2,455		)	(1,518		)
Income (loss) before income taxes	$	31,855		$	2,473		$	(16,811	)	$	17,517
Other data:
Depreciation and amortization expense	$	2,079		$	1,035		$	99		$	3,213
Income tax expense	$	703		$	159		$	—		$	862
Capital expenditures	$	2,406		$	127		$	—		$	2,533
Intangible assets	$	5,734		$	14,172		$	—		$	19,906
Goodwill	$	14,163		$	19,011		$	—		$	33,174
Non-cash acquisition of property	$	15,345		$	—		$	—		$	15,345
Non-cash acquisition of intangibles and goodwill	$	13,532		$	—		$	—		$	13,532
Total assets	$	103,836		$	43,528		$	18,158		$	165,522
Total liabilities	$	38,360		$	3,909		$	22,831		$	65,100

XML

SUPPLEMENTAL CASH FLOWS - Supplemental Disclosures (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$ 2,052
Cash paid for interest		$ 1,129
Cash paid for taxes	2,279
Cash paid for taxes		633
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Non-cash acquisition of property and equipment	0
Non-cash acquisition of property and equipment		15,345
Non-cash acquisition of goodwill and intangibles	0
Non-cash acquisition of goodwill and intangibles		13,532
Non-cash deconsolidation of property and equipment	0
Non-cash deconsolidation of property and equipment		2,828
Non-cash deconsolidation of goodwill	0
Non-cash deconsolidation of goodwill		701
Athas settlement in lieu of contingent shares	$ 0
Athas settlement in lieu of contingent shares		$ 5,685

XML

ACQUISITIONS (Narrative) (Details)	1 Months Ended
	Nov. 30, 2015
Business Combinations [Abstract]
Acquisitions 1	60.00%

XML

ACQUISITIONS - Schedule of Fair Value of Identifiable Assets (Details) $ in Thousands	1 Months Ended
	Nov. 30, 2015 USD ($)
Net assets acquired:
Trade accounts receivable	$ 82
Prepaid expenses and other current assets	36
Inventory	69
Property and equipment	13,266
Other long-term assets	113
Goodwill	6,932
Tradename	160
Hospital license	12
Net assets acquired	20,670
Net liabilities assumed:
Trade accounts payable	2,668
Accrued liabilities	419
Current portion of capital leases	658
Long-term portion of capital leases	12,213
Total liabilities assumed	15,958
Consideration:
Cash, net of cash acquired	3,180
Noncontrolling Interest	1,532
Total consideration	$ 4,712

XML

ACQUISITIONS - Pro Forma Information (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($) $ / shares
Business Combinations [Abstract]
Revenue	$ 139,774
Income from operations	8,225
Net income attributable to noncontrolling interests	10,360
Net income attributable to common stockholders	$ 6,282
Net income per basic common share (in dollars per share) | $ / shares	$ 0.10

XML

TRADE ACCOUNTS RECEIVABLE, NET - Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Receivables [Abstract]
Trade accounts receivable	$ 84,573
Trade accounts receivable		$ 95,114
Allowance for doubtful accounts	(2,144)
Allowance for doubtful accounts		(5,165)
Receivables transferred	(357)
Receivables transferred		(298)
Receivables purchased	4,098
Receivables purchased		2,918
Trade accounts receivable, net	$ 86,170
Trade accounts receivable, net		$ 92,569

XML

TRADE ACCOUNTS RECEIVABLE, NET (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Receivables [Abstract]
Trade Accounts Receivable, Net 1	0		0
Trade Accounts Receivable, Net 2		$ 0.9		$ 1.1
Trade Accounts Receivable, Net 3			$ 0.4
Trade Accounts Receivable, Net 4					$ 0.3
Trade Accounts Receivable, Net 5	$ 0.1
Trade Accounts Receivable, Net 6		0.3
Trade Accounts Receivable, Net 7	0.8
Trade Accounts Receivable, Net 8		1.4
Trade Accounts Receivable, Net 9			0.6
Trade Accounts Receivable, Net 10				1.4
Trade Accounts Receivable, Net 11			$ 4.9
Trade Accounts Receivable, Net 12				5.2
Trade Accounts Receivable, Net 13			30 days
Trade Accounts Receivable, Net 14			45 days
Trade Accounts Receivable, Net 15			100.00%
Trade Accounts Receivable, Net 16	4.6
Trade Accounts Receivable, Net 17		3.2
Trade Accounts Receivable, Net 18			$ 11.2
Trade Accounts Receivable, Net 19				8.3
Trade Accounts Receivable, Net 20	$ 2.4
Trade Accounts Receivable, Net 21		$ 1.8
Trade Accounts Receivable, Net 22			5.9
Trade Accounts Receivable, Net 23				$ 4.5
Trade Accounts Receivable, Net 24			$ 4.1
Trade Accounts Receivable, Net 25					$ 2.9

XML

INVESTMENTS IN ASSOCIATES (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended	12 Months Ended
	Apr. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures [Abstract]
Investments In Associates 1			$ 0.7	$ 0.7
Investments In Associates 2		58.00%
Investments In Associates 3		70.00%
Investments In Associates 4	62.00%
Investments In Associates 5			$ 0.5

XML

FINANCIAL INSTRUMENTS AND CONCENTRATION - Schedule of Revenue by Major Customers by Reporting Segments (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Medical Segment
Segment Reporting Information [Line Items]
Private insurance and other private pay	96.30%
Private insurance and other private pay		94.40%
Private insurance and other private pay			96.20%
Private insurance and other private pay				94.70%
Workers compensation	3.40%
Workers compensation		5.10%
Workers compensation			3.40%
Workers compensation				4.80%
Medicare	0.30%
Medicare		0.50%
Medicare			0.40%
Medicare				0.50%
Total	100.00%
Total		100.00%
Total			100.00%
Total				100.00%
Marketing Segment
Segment Reporting Information [Line Items]
Private insurance and other private pay	100.00%
Private insurance and other private pay		100.00%
Private insurance and other private pay			100.00%
Private insurance and other private pay				100.00%
Workers compensation	0.00%
Workers compensation		0.00%
Workers compensation			0.00%
Workers compensation				0.00%
Medicare	0.00%
Medicare		0.00%
Medicare			0.00%
Medicare				0.00%
Total	100.00%
Total		100.00%
Total			100.00%
Total				100.00%
Consolidated Segments
Segment Reporting Information [Line Items]
Private insurance and other private pay	96.80%
Private insurance and other private pay		95.10%
Private insurance and other private pay			96.70%
Private insurance and other private pay				95.20%
Workers compensation	3.00%
Workers compensation		4.50%
Workers compensation			3.00%
Workers compensation				4.30%
Medicare	0.20%
Medicare		0.40%
Medicare			0.30%
Medicare				0.50%
Total	100.00%
Total		100.00%
Total			100.00%
Total				100.00%

XML

FINANCIAL INSTRUMENTS AND CONCENTRATION (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Investments, All Other Investments [Abstract]
Financial Instruments And Concentration 1	75.10%
Financial Instruments And Concentration 2		83.00%
Financial Instruments And Concentration 3		83.60%
Financial Instruments And Concentration 4		$ 0.2
Financial Instruments And Concentration 5			$ 0.3

XML

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES - Schedule of Accounts Payable and Accrued Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Accrued expenses:
Accrued salaries and related benefits	$ 3,941
Accrued salaries and related benefits	5,309
Other	16,720
Other	11,339
Total accrued expenses	20,661
Total accrued expenses	16,648
Other current liabilities:
Estimated amounts due to third party payors	6,348
Estimated amounts due to third party payors	3,795
Other	454
Other	1,230
Total other current liabilities	6,802
Total other current liabilities	$ 5,025

XML

OTHER LONG-TERM LIABILITIES (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other long-term liabilities	$ 3,523	$ 3,386
Unfavorable lease	3,200
Estimated amortization of unfavorable lease, remainder of 2016	100
Estimated amortization of unfavorable lease, 2017	500
Estimated amortization of unfavorable lease, 2018	300
Estimated amortization of unfavorable lease, 2019	300
Estimated amortization of unfavorable lease, 2020	300
Estimated amortization of unfavorable lease, thereafter	$ 2,200

XML

LINES OF CREDIT (Narrative) (Details) - USD ($)					9 Months Ended	12 Months Ended
	Aug. 19, 2016	May 18, 2016	Mar. 31, 2016	Jul. 30, 2015	Sep. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Abstract]
Lines Of Credit 1	$ 11,600,000.0		$ 5,000,000.0
Lines Of Credit 2			4.00%
Lines Of Credit 3					5.24%
Lines Of Credit 4					$ 8,100,000
Lines Of Credit 5						$ 3,000,000
Lines Of Credit 6				$ 1,500,000.0
Lines Of Credit 7				$ 5,000,000.0
Lines Of Credit 8		$ 3,000,000.0
Lines Of Credit 9		4.00%
Long-term Line of Credit					$ 0

XML

DEBT (Narrative) (Details)								9 Months Ended
	Aug. 19, 2016 USD ($)	Aug. 18, 2016 USD ($)	Aug. 01, 2016 USD ($)	Jul. 31, 2016	Mar. 31, 2016	Jul. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Sep. 30, 2016 USD ($)
Line of Credit Facility [Line Items]
Debt 1	$ 25,000,000.0						$ 20,000,000.0
Debt 2							4.00%
Debt 3								5.24%
Debt 4							0.70%
Debt 5							100.00%
Debt 6							$ 1,000,000
Debt 7								$ 24,700,000
Debt 8			$ 2,000,000.0
Debt 9			7.0
Debt 10				7.05
Debt 11	2.00				3.05
Fixed charge coverage ratio	3.00
Debt 14						$ 4,500,000.0
Debt 15						4.00%
Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 36,600,000.0	$ 30,600,000.0
Capital lease obligation limit	6,100,000.0	3,000,000.0
Credit Agreement | Term
Line of Credit Facility [Line Items]
Maximum borrowing capacity	25,000,000
Quarterly amortization payment	312,500	$ 250,000
Credit Agreement | Revolving
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 11,600,000.0

XML

DEBT - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Gross debt	$ 24,687
Gross debt		$ 23,275
Less: unamortized loan fees	855
Less: unamortized loan fees		563
Debt, net of unamortized loan fees	23,832
Debt, net of unamortized loan fees		22,712
Less: current portion of term loan, net of unamortized loan fees	1,006
Less: current portion of term loan, net of unamortized loan fees		1,243
Long-term debt, net of unamortized loan fees	$ 22,826
Long-term debt, net of unamortized loan fees		$ 21,469

XML

FAIR VALUE MEASUREMENTS - Schedule of Fair Value, by Balance Sheet Grouping (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Warrant and stock option derivative liabilities, Level 1		$ 0
Warrant and stock option derivative liabilities, Level 2		0
Warrant and stock option derivative liabilities, Level 3		2,951
Warrant and stock option derivative liabilities		2,951
Total, Level 1		0
Total, Level 2		0
Total, Level 3		2,951
Total		$ 2,951
Warrant and stock option derivative liabilities, Level 1	$ 0
Warrant and stock option derivative liabilities, Level 2	0
Warrant and stock option derivative liabilities, Level 3	1,917
Warrant and stock option derivative liabilities	1,917
Total, Level 1	0
Total, Level 2	0
Total, Level 3	1,917
Total	$ 1,917

XML

SHARE BASED COMPENSATION (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation 3			$ 0.0
Share Based Compensation 4				$ 5.4
Share Based Compensation 5	0	0	0	0
Stock compensation expense				$ 4.5
Share Based Compensation 6			0
Share Based Compensation 7				0
Share Based Compensation 8	350,000
Share Based Compensation 9			2,457,075
Share Based Compensation 10			297,075
Share Based Compensation 11			2,160,000
Share Based Compensation 12					3,166,782
Share Based Compensation 13					451,782
Share Based Compensation 17			650,000
Share Based Compensation 19			$ 1.3
Share Based Compensation 20				$ 2.9
Share Based Compensation 21			1.8
Share Based Compensation 22			4.2
Share Based Compensation 23	$ 1.6
Share Based Compensation 24		$ 1.3
Share Based Compensation 25			$ 5.0
Share Based Compensation 26				$ 4.3
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Stock options | Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					1 year
Share Based Compensation 14					450,000
Stock options | Share-based Compensation Award, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					3 years
Share Based Compensation 15					1,865,000
Stock options | Share-based Compensation Award, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					5 years
Share Based Compensation 16					400,000

XML

SHARE BASED COMPENSATION - Schedule of Stock Options, Activity (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Shares Underlying Options
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveQCBcSevenpThreeNinerNineFourx				3,118,218
Granted (in shares)		2,601,782
Exercised (in shares)		(447,787)
Forfeited (in shares)		(372,213)
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveMTzNineVHCFKTVM		4,900,000
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveOneThreeLsMGKxvSevenPc			5,465,000
Granted (in shares)	2,457,075
Exercised (in shares)	(1,083,750)
Forfeited (in shares)	(966,800)
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveFivelpGTbLSixfLJFive	5,871,525
Exercisable (in shares)		1,408,461
Exercisable (in shares)	2,234,025
Weighted- Average Exercise Price
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveNRtwMkTSixtkbN				$ 1.45
Granted (in dollars per share)		$ 5.50
Exercised (in dollars per share)		1.26
Forfeited (in dollars per share)		1.11
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveZFivetTWQmOneEightZeroDSeven		3.65
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveFourmSMHdcSixqsph			$ 2.97
Granted (in dollars per share)	$ 2.14
Exercised (in dollars per share)	1.91
Forfeited (in dollars per share)	3.01
ScheduleOfSharebasedCompensationStockOptionsActivityZeroThreeTwoSevenOneThreeSevenSixFiveOnePHvMGNineFourpPZv	2.77
Exercisable (in dollars per share)		$ 2.54
Exercisable (in dollars per share)	$ 2.32
Weighted-Average Remaining Life (years)
Outstanding				9 years 9 months 18 days
Granted		9 years 9 months 11 days
Outstanding		9 years 5 months 19 days
Exercisable		9 years 5 months 19 days
Outstanding			9 years 2 months 12 days
Granted	9 years 4 months 24 days
Outstanding	8 years 10 months 24 days
Exercisable	8 years 6 months

XML

SHARE BASED COMPENSATION - Schedule of Stock Options, Valuation Assumptions (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected price volatility Min	114.00%
Expected price volatility Max	117.00%
Expected price volatility Min		113.00%
Expected price volatility Max		122.00%
Risk free interest rate Min	1.03%
Risk free interest rate Max	1.53%
Risk free interest rate Min		1.34%
Risk free interest rate Max		1.87%
Expected annual dividend yield	0.00%
Expected annual dividend yield		0.00%
Expected option term Min	5 years
Expected option term Max	6 years
Expected option term Min		5 years
Expected option term Max		6 years
Expected forfeiture rate Min	0.50%
Expected forfeiture rate Max	11.60%
Expected forfeiture rate Min		1.30%
Expected forfeiture rate Max		8.80%
Grant date fair value Min (in dollars per share)	$ 1.73
Grant date fair value Max (in dollars per share)	2.41
Grant date fair value Min (in dollars per share)		$ 2.97
Grant date fair value Max (in dollars per share)		6.31
Grant date exercise price Min (in dollars per share)	1.99
Grant date exercise price Max (in dollars per share)	$ 2.82
Grant date exercise price Min (in dollars per share)		2.53
Grant date exercise price Max (in dollars per share)		$ 6.10

XML

WARRANTS AND OPTIONS LIABILITIES - Schedule of Warrants or Rights, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Warrants and Rights Note Disclosure [Abstract]
Risk free interest rate Min	0.26%
Risk free interest rate Max	0.59%
Risk free interest rate Min		0.11%
Risk free interest rate Max		0.64%
Expected life Min	3 months
Expected life Max	1 year 1 month 24 days
Expected life Min		3 months
Expected life Max		2 years
Expected volatility Min	76.00%
Expected volatility Max	112.00%
Expected volatility Min		71.00%
Expected volatility Max		89.00%
Expected dividend yield	0.00%
Expected dividend yield		0.00%

XML

WARRANTS AND OPTIONS LIABILITIES - Schedule of Warrants or Rights, Activity (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Warrant And Option Liability [Roll Forward]
ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroThreeTwoSevenOneThreeSevenSixFiveFvCffPsFivedxKOne			$ 2,109
ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroThreeTwoSevenOneThreeSevenSixFiveckFourkMPbFivecOneSixTwo				$ 6,657
Issuance of warrants and options	$ 0
Issuance of warrants and options		$ 12,797
Transferred to equity upon exercise	0
Transferred to equity upon exercise		(8,882)
Change in fair value recorded in earnings	(1,729)
Change in fair value recorded in earnings		(4,742)
ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroThreeTwoSevenOneThreeSevenSixFiveVBTmmThreeZeromttZeroX	$ 380
ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroThreeTwoSevenOneThreeSevenSixFivesFiveZeroBXhcNineSEightLh		$ 5,830

XML

WARRANTS AND OPTIONS LIABILITIES - Schedule of Warrants or Rights (Details)	9 Months Ended
	Sep. 30, 2016 CAD / shares shares
Exercise price
2015 Warrants (in Canadian dollars per share) | CAD / shares	CAD 11.50
2015 Options (in Canadian dollars per share) | CAD / shares	CAD 9.00
Number of warrants and options
2015 Warrants (in shares)	3,923,834
2015 Options (in shares)	392,383
Outstanding and Exercisable (in shares)	4,316,217
Remaining contractual life
2015 Warrants	10 months 24 days
2015 Options	10 months 24 days

XML

WARRANTS AND OPTIONS LIABILITIES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Nonemployee options outstanding (in shares)	600,000		600,000
Warrants And Options Liabilities 1			650,000
Warrants And Options Liabilities 2	$ 0.1	$ 0.2
Warrants And Options Liabilities 3			$ 0.2
Warrants And Options Liabilities 4				$ 2.8
2014 Warrant And Option Issuances
Class of Warrant or Right [Line Items]
Nonemployee options outstanding (in shares)	0		0

XML

WARRANTS AND OPTIONS LIABILITIES - Schedule of Option Awards, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Warrants and Rights Note Disclosure [Abstract]
Risk free interest rate Min	1.01%
Risk free interest rate Max	1.14%
Risk free interest rate Min		1.37%
Risk free interest rate Max		1.56%
Expected life Min	4 years
Expected life Max	5 years
Expected life Min		5 years
Expected life Max		6 years
Expected volatility Min	103.00%
Expected volatility Max	114.00%
Expected volatility Min		113.00%
Expected volatility Max		115.00%
Expected dividend yield	0.00%
Expected dividend yield		0.00%

XML

WARRANTS AND OPTIONS LIABILITIES - Schedule of Option Awards, Liability (Details) - Options To Non-employees - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Warrants and Rights Outstanding [Roll Forward]
Balance at beginning of year	$ 841	$ 0
Vested during the period	533	1,531
Change in fair value recorded in earnings	163	65
Ending balance	$ 1,537	$ 1,596

XML

EARNINGS PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Basic:
Net (loss) income attributable to Nobilis Health Corp.	$ (2,759)
Net (loss) income attributable to Nobilis Health Corp.		$ 10,943
Net (loss) income attributable to Nobilis Health Corp.			$ (2,918)
Net (loss) income attributable to Nobilis Health Corp.				$ 6,038
Weighted average common shares outstanding (in shares)	76,774,967
Weighted average common shares outstanding (in shares)		70,935,587
Weighted average common shares outstanding (in shares)			76,114,538
Weighted average common shares outstanding (in shares)				65,310,610
Net (loss) income per common share (in dollars per share)	$ (0.04)
Net (loss) income per common share (in dollars per share)		$ 0.15
Net (loss) income per common share (in dollars per share)			$ (0.04)
Net (loss) income per common share (in dollars per share)				$ 0.09
Diluted:
Net (loss) income attributable to Nobilis Health Corp.	$ (2,759)
Net (loss) income attributable to Nobilis Health Corp.		$ 10,943
Net (loss) income attributable to Nobilis Health Corp.			$ (2,918)
Net (loss) income attributable to Nobilis Health Corp.				$ 6,038
Weighted average common shares outstanding (in shares)	76,774,967
Weighted average common shares outstanding (in shares)		70,935,587
Weighted average common shares outstanding (in shares)			76,114,538
Weighted average common shares outstanding (in shares)				65,310,610
Dilutive effect of stock options, warrants, RSUs (in shares)	0
Dilutive effect of stock options, warrants, RSUs (in shares)		6,720,676
Dilutive effect of stock options, warrants, RSUs (in shares)			0
Dilutive effect of stock options, warrants, RSUs (in shares)				6,720,676
Athas share consideration (in shares)	0	0	0	3,036,337
Weighted average common shares outstanding assuming dilution (in shares)	76,774,967
Weighted average common shares outstanding assuming dilution (in shares)		77,656,263
Weighted average common shares outstanding assuming dilution (in shares)			76,114,538
Weighted average common shares outstanding assuming dilution (in shares)				75,067,623
Net (loss) income per fully diluted share (in dollars per share)	$ (0.04)
Net (loss) income per fully diluted share (in dollars per share)		$ 0.14
Net (loss) income per fully diluted share (in dollars per share)			$ (0.04)
Net (loss) income per fully diluted share (in dollars per share)				$ 0.08

XML

NONCONTROLLING INTERESTS (Narrative) (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interests 1	8.10%	8.10%
Noncontrolling Interests 2	75.00%	75.00%
Noncontrolling Interests 3	65.00%	65.00%
Noncontrolling Interests 4	2.30%	2.30%
Noncontrolling Interests 5	50.00%	50.00%
Noncontrolling Interests 6	65.00%	65.00%
Noncontrolling Interests 7	49.00%	49.00%
Noncontrolling Interests 8	40.00%	40.00%
Noncontrolling Interests 9	45.00%	45.00%
Noncontrolling Interests 10	40.00%	40.00%

XML

NONCONTROLLING INTERESTS - Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Increase (Decrease) in Temporary Equity [Roll Forward]
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFivewThreePDTVPPtNlThree			$ 6,654
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveOneSixBEightKZMTThreeFourySix			6,213
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveMzhcTSevenKbnfQB			$ 12,867
Distributions, NHC - ASC Dallas		$ (3,892)
Distributions, First Nobilis		(7,617)
Distributions, Total		(11,509)
Net income attributable to noncontrolling interests, NHC - ASC Dallas		631
Net income attributable to noncontrolling interests, First Nobilis		10,236
Net income attributable to noncontrolling interests, Total		10,867
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveSevenFKTmFSGQVNineV		3,393
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFivelrxSXFiveWLCGWw		8,832
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFivebqThreeEightByHvcKSOne		12,225
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveyEightSevenQBTBCgThreeVh		3,393
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveNinexwfFourDVrRLhv		8,832
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveSevenPSixFourcxftMGcg		$ 12,225
Distributions, NHC - ASC Dallas	$ (2,929)
Distributions, First Nobilis	(600)
Distributions, Total	(3,529)
Net (loss) income attributable to noncontrolling interests, NHC - ASC Dallas	(210)
Net (loss) income attributable to noncontrolling interests, First Nobilis	2,081
Net (loss) income attributable to noncontrolling interests, Total	1,871
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveyptnFrGxHhFourH	254
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveThreeqTMSBbFiveZeroHqR	10,313
RedeemableNoncontrollingInterestZeroThreeTwoSevenOneThreeSevenSixFiveVZTHsFivekksEightNThree	$ 10,567

XML

NONCONTROLLING INTERESTS - Schedule of Variable Interest Entities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Noncontrolling Interest [Abstract]
Total cash and short term investments	$ 1,071
Total cash and short term investments		$ 191
Total accounts receivable	8,638
Total accounts receivable		8,660
Total other current assets	1,768
Total other current assets		1,582
Total property and equipment	17,547
Total property and equipment		5,227
Total other assets	165
Total other assets		144
Total assets	29,189
Total assets		15,804
Total accounts payable	3,847
Total accounts payable		2,286
Total other liabilities	5,924
Total other liabilities		7,059
Total accrued liabilities	4,242
Total accrued liabilities		2,664
Long term - capital lease	11,543
Long term - capital lease		780
Noncontrolling interest	(8,547)
Noncontrolling interest		(1,488)
Total liabilities	$ 17,009
Total liabilities		$ 11,301

XML

INCOME TAXES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes 1			35.00%
Income Taxes 2			32.50%
Income Taxes 3			3.80%
Income Taxes 4			4.50%
Income Taxes 7			1.60%
Effective income tax rate reduction for discrete tax items			3.80%
Income Taxes 9	$ 0.5
Income Taxes 10			$ 1.7
Income Taxes 11	29.30%
Income Taxes 12			21.10%
Income Taxes 13	$ 0.3
Income Taxes 14			$ 0.8
Income Taxes 15		$ 0.3
Income Taxes 16				$ 0.9

XML

BUSINESS SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenues, Medical Services	$ 65,419
Revenues, Marketing	5,264
Revenues, Corporate	0
Revenues, Total	70,683
Operating expenses, Medical Services	60,871
Operating expenses, Marketing	2,958
Operating expenses, Corporate	0
Operating expenses, Total	63,829
Corporate costs, Medical Services	0
Corporate costs, Marketing	0
Corporate costs, Corporate	7,955
Corporate costs, Total	7,955
Income (loss) from operations, Medical Services	4,548
Income (loss) from operations, Marketing	2,306
Income (loss) from operations, Corporate	(7,955)
Income (loss) from operations, Total	(1,101)
Change in fair value of warrant and option liabilities, Medical Services	0
Change in fair value of warrant and option liabilities, Marketing	0
Change in fair value of warrant and option liabilities, Corporate	133
Change in fair value of warrant and option liabilities, Total	133
Interest expense, Medical Services	329
Interest expense, Marketing	1
Interest expense, Corporate	414
Interest expense, Total	744
Other (income) expense, Medical Services	(199)
Other (income) expense, Marketing	(57)
Other (income) expense, Corporate	58
Other (income) expense, Total	(198)
Income (loss) before income taxes, Medical Services	4,418
Income (loss) before income taxes, Marketing	2,362
Income (loss) before income taxes, Corporate	(8,560)
Income (loss) before income taxes, Total	(1,780)
Depreciation and amortization expense, Medical Services	1,564
Depreciation and amortization expense, Marketing	388
Depreciation and amortization expense, Corporate	79
Depreciation and amortization expense, Total	2,031
Income tax expense, Medical Services	205
Income tax expense, Marketing	78
Income tax expense, Corporate	200
Income tax expense, Total	483
Capital expenditures, Medical Services	1,289
Capital expenditures, Marketing	0
Capital expenditures, Corporate	72
Capital expenditures, Total	1,361
Revenues, Medical Services		$ 46,150
Revenues, Marketing		6,333
Revenues, Corporate		0
Revenues, Total		52,483
Operating expenses, Medical Services		36,466
Operating expenses, Marketing		5,670
Operating expenses, Corporate		0
Operating expenses, Total		42,136
Corporate costs, Medical Services		0
Corporate costs, Marketing		0
Corporate costs, Corporate		7,296
Corporate costs, Total		7,296
Income (loss) from operations, Medical Services		9,684
Income (loss) from operations, Marketing		663
Income (loss) from operations, Corporate		(7,296)
Income (loss) from operations, Total		3,051
Change in fair value of warrant and option liabilities, Medical Services		0
Change in fair value of warrant and option liabilities, Marketing		0
Change in fair value of warrant and option liabilities, Corporate		(6,381)
Change in fair value of warrant and option liabilities, Total		(6,381)
Interest expense (income), Medical Services		169
Interest expense (income), Marketing		(15)
Interest expense (income), Corporate		168
Interest expense (income), Total		322
Bargain purchase	$ 0	(4,358)	$ 0	$ (4,358)
Other expense (income), Medical Services		1,583
Other expense (income), Marketing		(205)
Other expense (income), Corporate		(1,484)
Other expense (income), Total		(106)
Income before income taxes, Medical Services		12,290
Income before income taxes, Marketing		883
Income before income taxes, Corporate		401
Income before income taxes, Total		13,574
Depreciation and amortization expense, Medical Services		1,178
Depreciation and amortization expense, Marketing		344
Depreciation and amortization expense, Corporate		43
Depreciation and amortization expense, Total		1,565
Income tax expense, Medical Services		176
Income tax expense, Marketing		80
Income tax expense, Corporate		0
Income tax expense, Total		256
Capital expenditures, Medical Services		1,041
Capital expenditures, Marketing		0
Capital expenditures, Corporate		0
Capital expenditures, Total		1,041
Non-cash acquisition of property, Medical Services		10,485
Non-cash acquisition of property, Marketing		0
Non-cash acquisition of property, Corporate		0
Non-cash acquisition of property, Total		10,485
Non-cash acquisition of intangibles and goodwill, Medical Services		1,534
Non-cash acquisition of intangibles and goodwill, Marketing		0
Non-cash acquisition of intangibles and goodwill, Corporate		0
Non-cash acquisition of intangibles and goodwill, Total		1,534
Revenues, Medical Services			166,922
Revenues, Marketing			16,905
Revenues, Corporate			0
Revenues, Total			183,827
Operating expenses, Medical Services			158,471
Operating expenses, Marketing			11,716
Operating expenses, Corporate			0
Operating expenses, Total			170,187
Corporate costs, Medical Services			0
Corporate costs, Marketing			0
Corporate costs, Corporate			24,380
Corporate costs, Total			24,380
Income (loss) from operations, Medical Services			8,451
Income (loss) from operations, Marketing			5,189
Income (loss) from operations, Corporate			(24,380)
Income (loss) from operations, Total			(10,740)
Change in fair value of warrant and option liabilities, Medical Services			0
Change in fair value of warrant and option liabilities, Marketing			0
Change in fair value of warrant and option liabilities, Corporate			(1,566)
Change in fair value of warrant and option liabilities, Total			(1,566)
Interest expense, Medical Services			1,074
Interest expense, Marketing			4
Interest expense, Corporate			1,037
Interest expense, Total			2,115
Other income, Medical Services			(1,682)
Other income, Marketing			(305)
Other income, Corporate			(1,024)
Other income, Total			(3,011)
Income (loss) before income taxes, Medical Services			9,059
Income (loss) before income taxes, Marketing			5,490
Income (loss) before income taxes, Corporate			(22,827)
Income (loss) before income taxes, Total			(8,278)
Depreciation and amortization expense, Medical Services			5,026
Depreciation and amortization expense, Marketing			1,436
Depreciation and amortization expense, Corporate			209
Depreciation and amortization expense, Total			6,671
Income tax expense (benefit), Medical Services			662
Income tax expense (benefit), Marketing			149
Income tax expense (benefit), Corporate			(2,577)
Income tax expense (benefit), Total			(1,766)
Capital expenditures, Medical Services			4,000
Capital expenditures, Marketing			0
Capital expenditures, Corporate			388
Capital expenditures, Total			4,388
Intangible assets, Medical Services			5,246
Intangible assets, Marketing			13,022
Intangible assets, Corporate			0
Intangible assets, Total			18,268
Goodwill, Medical Services			25,822
Goodwill, Marketing			19,011
Goodwill, Corporate			0
Goodwill, Total			44,833
Total assets, Medical Services			175,279
Total assets, Marketing			44,413
Total assets, Corporate			21,291
Total assets, Total			240,983
Total liabilities, Medical Services			55,602
Total liabilities, Marketing			6,928
Total liabilities, Corporate			38,237
Total liabilities, Total			$ 100,767
Revenues, Medical Services				123,638
Revenues, Marketing				15,563
Revenues, Corporate				0
Revenues, Total				139,201
Operating expenses, Medical Services				94,589
Operating expenses, Marketing				13,471
Operating expenses, Corporate				0
Operating expenses, Total				108,060
Corporate costs, Medical Services				0
Corporate costs, Marketing				0
Corporate costs, Corporate				23,071
Corporate costs, Total				23,071
Income (loss) from operations, Medical Services				29,049
Income (loss) from operations, Marketing				2,092
Income (loss) from operations, Corporate				(23,071)
Income (loss) from operations, Total				8,070
Change in fair value of warrant and option liabilities, Medical Services				0
Change in fair value of warrant and option liabilities, Marketing				0
Change in fair value of warrant and option liabilities, Corporate				(4,677)
Change in fair value of warrant and option liabilities, Total				(4,677)
Interest expense, Medical Services				169
Interest expense, Marketing				65
Interest expense, Corporate				872
Interest expense, Total				1,106
Other expense (income), Medical Services				1,383
Other expense (income), Marketing				(446)
Other expense (income), Corporate				(2,455)
Other expense (income), Total				(1,518)
Income (loss) before income taxes, Medical Services				31,855
Income (loss) before income taxes, Marketing				2,473
Income (loss) before income taxes, Corporate				(16,811)
Income (loss) before income taxes, Total				17,517
Depreciation and amortization expense, Medical Services				2,079
Depreciation and amortization expense, Marketing				1,035
Depreciation and amortization expense, Corporate				99
Depreciation and amortization expense, Total				3,213
Income tax expense, Medical Services				703
Income tax expense, Marketing				159
Income tax expense, Corporate				0
Income tax expense, Total				862
Capital expenditures, Medical Services				2,406
Capital expenditures, Marketing				127
Capital expenditures, Corporate				0
Capital expenditures, Total				2,533
Intangible assets, Medical Services				5,734
Intangible assets, Marketing				14,172
Intangible assets, Corporate				0
Intangible assets, Total				19,906
Goodwill, Medical Services				14,163
Goodwill, Marketing				19,011
Goodwill, Corporate				0
Goodwill, Total				33,174
Non-cash acquisition of property, Medical Services				15,345
Non-cash acquisition of property, Marketing				0
Non-cash acquisition of property, Corporate				0
Non-cash acquisition of property, Total				15,345
Non-cash acquisition of intangibles and goodwill, Medical Services				13,532
Non-cash acquisition of intangibles and goodwill, Marketing				0
Non-cash acquisition of intangibles and goodwill, Corporate				0
Non-cash acquisition of intangibles and goodwill, Total				13,532
Total assets, Medical Services				103,836
Total assets, Marketing				43,528
Total assets, Corporate				18,158
Total assets, Total				165,522
Total liabilities, Medical Services				38,360
Total liabilities, Marketing				3,909
Total liabilities, Corporate				22,831
Total liabilities, Total				65,100
Medical Services
Segment Reporting Information [Line Items]
Bargain purchase		(4,358)		(4,358)
Marketing
Segment Reporting Information [Line Items]
Bargain purchase		0		0
Corporate
Segment Reporting Information [Line Items]
Bargain purchase		$ 0		$ 0

XML

RELATED PARTY TRANSACTIONS (Narrative) (Details) number in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)
Related Party Transaction [Line Items]
Related Party Transactions 1			$ 1.4
Related Party Transactions 2	$ 0.5
Related Party Transactions 3		$ 0.6
Related Party Transactions 4	$ 0.4	$ 0.4
Related Party Transactions 5			1.6	$ 1.7
Related Party Transactions 6			1.3	1.3
Related Party Transactions 8			2.5
Related Party Transactions 9				$ 2.5
Related Party Transactions 10			1.9
Related Party Transactions 11				0.2
Related Party Transactions 12			1.0
Related Party Transactions 13				$ 0.3
Related Party Transactions 14			3.9
Related Party Transactions 15				$ 2.4
Affiliate | HOPD
Related Party Transaction [Line Items]
Related Party Transactions 7			3.6
Affiliate | Dallas Metro
Related Party Transaction [Line Items]
Related Party Transactions 7			$ 0.9

XML

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) CAD in Millions	9 Months Ended
	Sep. 30, 2016 CAD
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies 1	CAD 80

XML

SUBSEQUENT EVENTS (Narrative) (Details)			1 Months Ended	9 Months Ended
	Oct. 31, 2016 shares	Oct. 28, 2016 USD ($)	Nov. 30, 2015	Sep. 30, 2016 USD ($)
Subsequent Event [Line Items]
Outstanding balance				$ 24,700,000
Outstanding balance				$ 8,100,000
Ownership interest			60.00%
Subsequent Event
Subsequent Event [Line Items]
Ownership interest	75.00%
Subsequent Event | Arizona Center For Minimally Invasive Surgery, LLC, L. Philipp Wall, M.D., P.C., And Arizona Vein & Vascular Center, LLC
Subsequent Event [Line Items]
Purchase price		$ 22,000,000
Cash payments for business		17,000,000
Equity issued (value)		2,500,000
Debt incurred		$ 2,500,000
Earnout, measurement period		12 months
Earnout, percentage		50.00%
Indemnification value		$ 1,050,000
Indemnification period		24 months
Subsequent Event | SLH
Subsequent Event [Line Items]
Number of Class C Units acquired (in shares) | shares	60
Subsequent Event | Compass Bank Loans | Compass Bank
Subsequent Event [Line Items]
Face amount		$ 82,500,000.0
Consolidated fixed charge ratio		2.00
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 1.00 to 1.00
Subsequent Event [Line Items]
Commitment fee		0.375%
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 1.00 to 1.00 | Maximum
Subsequent Event [Line Items]
Consolidated leverage ratio		1.00
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00
Subsequent Event [Line Items]
Commitment fee		0.375%
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00 | Maximum
Subsequent Event [Line Items]
Consolidated leverage ratio		1.75
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00 | Minimum
Subsequent Event [Line Items]
Consolidated leverage ratio		1.00
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00
Subsequent Event [Line Items]
Commitment fee		0.45%
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00 | Maximum
Subsequent Event [Line Items]
Consolidated leverage ratio		2.50
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00 | Minimum
Subsequent Event [Line Items]
Consolidated leverage ratio		1.75
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of greater than or equal to 2.50 to 1.00
Subsequent Event [Line Items]
Commitment fee		0.50%
Subsequent Event | Compass Bank Loans | Compass Bank | Consolidate leverage ratio of greater than or equal to 2.50 to 1.00 | Minimum
Subsequent Event [Line Items]
Consolidated leverage ratio		2.50
Subsequent Event | Compass Bank Loans | Compass Bank | Base Rate | Consolidate leverage ratio of less than 1.00 to 1.00
Subsequent Event [Line Items]
Margin		2.00%
Subsequent Event | Compass Bank Loans | Compass Bank | Base Rate | Consolidate leverage ratio of less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00
Subsequent Event [Line Items]
Margin		2.25%
Subsequent Event | Compass Bank Loans | Compass Bank | Base Rate | Consolidate leverage ratio of less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00
Subsequent Event [Line Items]
Margin		2.50%
Subsequent Event | Compass Bank Loans | Compass Bank | Base Rate | Consolidate leverage ratio of greater than or equal to 2.50 to 1.00
Subsequent Event [Line Items]
Margin		2.75%
Subsequent Event | Compass Bank Loans | Compass Bank | London Interbank Offered Rate (LIBOR) | Consolidate leverage ratio of less than 1.00 to 1.00
Subsequent Event [Line Items]
Margin		3.00%
Subsequent Event | Compass Bank Loans | Compass Bank | London Interbank Offered Rate (LIBOR) | Consolidate leverage ratio of less than 1.75 to 1.00 but greater than or equal to 1.00 to 1.00
Subsequent Event [Line Items]
Margin		3.25%
Subsequent Event | Compass Bank Loans | Compass Bank | London Interbank Offered Rate (LIBOR) | Consolidate leverage ratio of less than 2.50 to 1.00 but greater than or equal to 1.75 to 1.00
Subsequent Event [Line Items]
Margin		3.50%
Subsequent Event | Compass Bank Loans | Compass Bank | London Interbank Offered Rate (LIBOR) | Consolidate leverage ratio of greater than or equal to 2.50 to 1.00
Subsequent Event [Line Items]
Margin		3.75%
Subsequent Event | Compass Bank Loans | Compass Bank | Through September 30, 2018
Subsequent Event [Line Items]
Consolidated leverage ratio		2.75
Subsequent Event | Compass Bank Loans | Compass Bank | December 31, 2018 to September 30, 2019
Subsequent Event [Line Items]
Consolidated leverage ratio		2.50
Subsequent Event | Compass Bank Loans | Compass Bank | December 31, 2019 to September 30, 2020
Subsequent Event [Line Items]
Consolidated leverage ratio		2.25
Subsequent Event | Compass Bank Loans | Compass Bank | Through December 31, 2020
Subsequent Event [Line Items]
Consolidated leverage ratio		2.00
Subsequent Event | Compass Bank Loans | Compass Bank | Fiscal quarter ending March 31, 2017
Subsequent Event [Line Items]
Line of credit fee		3.75%
Commitment fee		0.50%
Subsequent Event | Compass Bank Loans | Compass Bank | Fiscal quarter ending March 31, 2017 | Base Rate
Subsequent Event [Line Items]
Interest rate		2.75%
Subsequent Event | Compass Bank Loans | Compass Bank | Fiscal quarter ending March 31, 2017 | Eurodollar
Subsequent Event [Line Items]
Interest rate		3.75%
Subsequent Event | Compass Bank Loans | Compass Bank | Term
Subsequent Event [Line Items]
Face amount		$ 52,500,000.0
Subsequent Event | Compass Bank Loans | Compass Bank | Term | March 31, 2017 to December 31, 2018
Subsequent Event [Line Items]
Quarterly payment		700,000
Subsequent Event | Compass Bank Loans | Compass Bank | Term | March 31, 2019 to December 31, 2020
Subsequent Event [Line Items]
Quarterly payment		1,300,000
Subsequent Event | Compass Bank Loans | Compass Bank | Term | March 31, 2021 to September 30, 2021
Subsequent Event [Line Items]
Quarterly payment		2,000,000
Subsequent Event | Compass Bank Loans | Compass Bank | Revolving
Subsequent Event [Line Items]
Maximum borrowing capacity		$ 30,000,000.0